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A B S T R A C T
Background
This is an update of a Cochrane Review first published in 2015. The conclusions have not changed.
Hypodermic needles of different sizes (gauges and lengths) can be used for vaccination procedures. The gauge (G) refers to the outside
diameter of the needle tubing. The higher the gauge number, the smaller the diameter of the needle (e.g. a 23 G needle is 0.6 mm in
diameter, whereas a 25 G needle is 0.5 mm in diameter). Many vaccines are recommended for injection into muscle (intramuscularly),
although some are delivered subcutaneously (under the skin) and intradermally (into skin). Choosing an appropriate length and gauge
of a needle may be important to ensure that a vaccine is delivered to the appropriate site and produces the maximum immune response
while causing the least possible harm. Guidelines conflict regarding the sizes of needles that should be used for vaccinating children
and adolescents.
Objectives
To assess the effects of using needles of different sizes for administering vaccines to children and adolescents on vaccine immunogenicity
(the ability of the vaccine to elicit an immune response), procedural pain, and other reactogenicity events (adverse events following
vaccine administration).
Search methods
We updated our searches of CENTRAL, MEDLINE, Embase, and CINAHL to October 2017. We also searched proceedings of vaccine
conferences and two trials registers.
Selection criteria
Randomised controlled trials evaluating the effects of using hypodermic needles of any gauge or length to administer any type of vaccine
to people aged from birth to 24 years.
Data collection and analysis
Three review authors independently extracted trial data and assessed the risk of bias. We contacted trial authors for additional infor-
mation. We rated the quality of evidence using the GRADE system.
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Main results
We included five trials involving 1350 participants in the original review. The updated review identified no new trials. The evidence
from two small trials (one trial including infants and one including adolescents) was insufficient to allow any definitive statements to
be made about the effects of the needles evaluated in the trials on vaccine immunogenicity and reactogenicity.
The remaining three trials (1135 participants) contributed data to comparisons between 25 G 25 mm, 23 G 25 mm, and 25 G 16
mm needles. These trials included infants predominantly aged from two to six months undergoing intramuscular vaccination in the
anterolateral thigh using the World Health Organization (WHO) injection technique (skin stretched flat, needle inserted at a 90° angle
and up to the needle hub in healthy infants). The vaccines administered were combination vaccines containing diphtheria, tetanus,
and whole-cell pertussis antigens (DTwP). In some trials, the vaccines also contained Haemophilus influenzae type b (DTwP-Hib) and
hepatitis B (DTwP-Hib-Hep B) antigen components.
Primary outcomes
Incidence of vaccine-preventable diseases: No trials reported this outcome.
Procedural pain and crying: Using a wider gauge 23 G 25 mm needle may slightly reduce procedural pain (low-quality evidence) and
probably leads to a slight reduction in the duration of crying time immediately after vaccination (moderate-quality evidence) compared
with a narrower gauge 25 G 25 mm needle (one trial, 320 participants). The effects are probably not large enough to be clinically
relevant.
Secondary outcomes
Immune response: There is probably little or no difference in immune response, defined in terms of the proportion of seroprotected
infants, between use of 25 G 25 mm, 23 G 25 mm, or 25 G 16 mm needles to administer a series of three doses of a DTwP-Hib vaccine
at ages two, three, and four months (moderate-quality evidence, one trial, numbers of participants in analyses range from 309 to 402.
The immune response to the pertussis antigen was not measured).
Severe and non-severe local reactions: 25 mm needles (either 25 G or 23 G) probably lead to fewer severe and non-severe local reactions
after DTwP-Hib vaccination compared with 25 G 16 mm needles (moderate-quality evidence, one trial, 447 to 458 participants in
analyses). We estimate that one fewer infant will experience a severe local reaction (extensive redness and swelling) after the first vaccine
dose for every 25 infants vaccinated with the longer rather than the shorter needle (number needed to treat for an additional beneficial
outcome (NNTB) with a 25 G 25 mm needle: 25 (95% confidence interval (CI) 15 to 100); NNTB with a 23 G 25 mm needle: 25
(95% CI 17 to 100)). We estimate that one fewer infant will experience a non-severe local reaction (any redness, swelling, tenderness,
or hardness (composite outcome)) at 24 hours after the first vaccine dose for every 5 or 6 infants vaccinated with a 25 mm rather than
a 16 mm needle (NNTB with a 25 G 25 mm needle: 5 (95% CI 4 to 10); NNTB with a 23 G 25 mm needle: 6 (95% CI 4 to 13)).
The results are similar after the second and third vaccine doses.
Using a narrow gauge 25 G 25 mm needle may produce a small reduction in the incidence of local reactions after each dose of a DTwP
vaccine compared with a wider gauge 23 G 25 mm needle, but the effect estimates are imprecise (low-quality evidence, two trials, 100
to 459 participants in analyses).
Systemic reactions: The comparative effects of 23 G 25 mm, 25 G 25 mm, and 25 G 16 mm needles on the incidence of postvaccination
fever and other systemic events such as drowsiness, loss of appetite, and vomiting are uncertain due to the very low quality of the
evidence.
Authors’ conclusions
Using 25 mm needles (either 23 G or 25 G) for intramuscular vaccination procedures in the anterolateral thigh of infants using the
WHO injection technique probably reduces the occurrence of local reactions while achieving a comparable immune response to 25 G
16 mm needles. These findings are applicable to healthy infants aged two to six months receiving combination DTwP vaccines with a
reactogenic whole-cell pertussis antigen component. These vaccines are predominantly used in low- and middle-income countries. The
applicability of the findings to vaccines with acellular pertussis components and other vaccines with different reactogenicity profiles is
uncertain.
P L A I N L A N G U A G E S U M M A R Y
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Needle size for vaccination procedures in children and adolescents
Background
Vaccines contain antigens that make the body’s immune system produce antibodies that can protect against disease, which is known
as an immune response. Antigens are modified or partial forms of the virus, bacteria, or toxin that cause the disease that the vaccine
protects against. Because the antigen is altered from its original form, it cannot cause disease, but it can produce an immune response.
Vaccines can be injected using needles of different lengths and gauges. The needle gauge (G) refers to the width (diameter) of the
needle. The higher the gauge number, the narrower the needle. For example, a 25 G needle is approximately 0.5 mm in diameter and
is narrower than a 23 G needle, which has a diameter of 0.6 mm. Guidelines conflict regarding the lengths and gauges of needles that
should be used for vaccinating children and adolescents.
Review question
We wanted to find out if the length and gauge of needles used to vaccinate children and adolescents has an influence on the:
1) immune response to the injected vaccine;
2) pain experienced during the vaccination procedure;
3) occurrence of reactions such as swelling, tenderness, and redness at the site where the vaccine is given; fever (high temperature); and
other side effects that can occur after vaccination.
Quality of the evidence
We included five studies involving 1350 people. We rated the quality of the evidence from studies as very low, low, moderate, or high.
Very low-quality evidence means that we are very uncertain about the results. High-quality evidence means that we are very confident
in the results. There were problems with the design of some studies, and data were insufficient to answer some parts of our review
question. The quality of the evidence from two studies was too low to allow us to draw any conclusions about the effects of the needles
compared in the studies. However, there was sufficient evidence from the remaining three studies to allow us to reach conclusions.
Study characteristics
The three studies that allowed us to reach conclusions involved 1135 healthy infants aged mostly between two and six months. The
infants were vaccinated in the thigh with either 25 G 25 mm (narrow, long needles), 23 G 25 mm (wide, long needles), or 25 G 16
mm needles (narrow, short needles). The needles were inserted at right angles (90° angle) into the skin and pushed down into the
muscle of the thigh. The vaccines injected were combination vaccines designed to protect against several diseases including diphtheria
(D), tetanus (T), whooping cough (pertussis), and Haemophilus influenzae type b disease (Hib). The vaccines all contained whole-
cell pertussis (wP) vaccine antigens. These vaccines are commonly used in low- and middle-income countries but not in high-income
countries. Our review findings are therefore most relevant to low- and middle-income countries.
Key findings
We found moderate-quality evidence that infants vaccinated in the thigh with 25 mm needles probably have fewer severe reactions
(extensive redness and swelling in the thigh) after DTwP-Hib vaccination than infants vaccinated with 16 mm needles. We also found
that the longer needles probably lead to fewer non-severe reactions such as mild swelling, tenderness, and redness after vaccination.
The immune response to the vaccine is probably similar with the long and the short needles.
We found low-quality evidence that the wide, long needle may slightly reduce the pain of the vaccination procedure compared with the
narrow, long needle. We found moderate-quality evidence that the wide, long needle probably slightly reduces the duration of crying
immediately following vaccination compared with the narrow, long needle. The differences in pain and crying between use of the wide
and narrow needles are probably too small to be of any practical importance.
We found low-quality evidence that infants vaccinated with the narrow, long needle may have slightly fewer non-severe reactions than
infants vaccinated with the wide, long needle.
We do not know if needle size has an effect on fever or other reactions that sometimes occur after vaccination including drowsiness,
loss of appetite, and vomiting due to the very low quality of the evidence.
The evidence in our review is current to October 2017.
3Needle size for vaccination procedures in children and adolescents (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
25 G 25 mm needles compared with 25 G 16 mm needles for vaccination procedures
Patient or population: infants aged approximately 2 to 6 months undergoing vaccinat ion in the anterolateral thigh with a DTwP-Hib vaccine
Intervention: 25 G 25 mm needles; inject ion technique - skin stretched f lat between thumb and foref inger and needle inserted at a 90° angle to skin (WHO inject ion technique)
and up to the needle hub in healthy infants
Comparison: 25 G 16 mm needles; inject ion technique - same as above
Outcomes (1 to 7) Probable outcome with
25 G 16 mm needles*
Probable outcome with






Quality of the evidence
(GRADE)
Comments
1. Incidence of diph-
theria, tetanus, pertus-
sis,Haemophilus influen-
zae type b (Hib) (not
measured)
- - - - - Not measured
2a. Adequate immune
response (seroprotec-
t ion) against diphtheria
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against tetanus
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against pertussis
(not measured)2











































































































fluenzae type b disease
(surrogate outcome)2









3. Pain (not measured) - - - - - Not measured
4a. Procedural crying
(during and immedi-
ately af ter the vacci-
nat ion procedure) (not
measured)
- - - - - Not measured
4b. Persistent incon-
solable crying4









5. Severe local react ion
8








NNTB* * * 25 (95%CI 15
to 100)
6. Non-severe local re-
act ion10








NNTB* * * * 5 (95% CI 4
to 10)









* The basis for the assumed risk (i.e. the probable outcome with 25 G 16 mm needles) and the corresponding risk (ie the probable outcome with 25 G 25 mm needles) is
provided in footnote 1
* *Due to bounding the upper lim it of the conf idence interval for the absolute ef fect does not match exact ly the upper lim it of the conf idence interval for the relat ive ef fect
* * *NNTB = the expected number of infants who would need to be vaccinated with the 25 mm rather than the 16 mm needle for 1 addit ional infant to avoid a severe local
react ion event
* * * *NNTB = the expected number of infants who would need to be vaccinated with the 25 mm rather than the 16 mm needle for 1 addit ional infant to avoid a non-severe local
react ion event
CI: conf idence interval; DTwP-Hib vaccine: a combinat ion vaccine containing diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b vaccine ant igen







































































































GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality:We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
Please see the Data collect ion and analysis sect ion of the review for comprehensive details regarding the methods we used
to assess the quality of evidence for outcomes included in ’Summary of f indings’ tables. See the Ef fects of intervent ions
sect ion of the review for a full explanat ion of the rat ionale for our judgements regarding the quality of evidence for each
outcome.
1Only one trial provided data for the comparison between 25 G 25 mm and 25 G 16 mm needles (Diggle 2006). The assumed
and corresponding risks for all outcomes are based on the event rates in the needle size groups in this trial. In Diggle 2006, a
DTwP-Hib vaccine and a meningit is C conjugate (MenC) vaccine were concurrent ly administered in the right (DTwP-Hib) and
lef t (MenC) anterolateral thighs of infants aged 2 months (f irst vaccine dose), 3 months (second dose), and 4 months (third
dose). The MenC vaccine was administered in a schedule (t ime between vaccine doses) that is no longer recommended, and
the results pertaining to the ef fects of needle size on the immunogenicity and reactogenicity of this vaccine are not presented
in this ’Summary of f indings’ table or in the Abstract or Plain language summary for this Cochrane Review (the results are,
however, presented in the Ef fects of intervent ions sect ion).
2The term ’seroprotect ion’ refers to ant ibody t it re levels above a predef ined threshold level that correlates with protect ion
f rom disease (af ter complet ion of a series of 3 doses of a DTwP-Hib vaccine). The threshold levels used in this review were:
diphtheria ant itoxin levels ≥ 0.01 IU/ mL; tetanus ant itoxin levels ≥ 0.01 IU/ mL; Hib ant ibody t it re levels ≥ 1.0 µg/ mL. There
is no well-established immune correlate or surrogate of protect ion against pertussis.
3We downgraded the quality of evidence by one level for indirectness due to the use of a subst itute (surrogate) seroprotect ion
endpoint in place of the pat ient-important outcome of interest. Although the seroprotect ion endpoints were reported in only
one trial, thus precluding an evaluat ion of the consistency or inconsistency of results across trials, we did not downgrade the
quality of evidence. We considered the consistency of the results of the seroprotect ion analyses reported in the trial and the
results of the analyses of the rat ios of the ant ibody/ ant itoxin geometric mean concentrat ions (GMCs) between the needle
size groups. The GMC rat ios (25 mm versus 16 mm) were: diphtheria: 1.05 (95% CI 0.85 to 1.29); tetanus: 0.97 (95% CI 0.81
to 1.17); Hib: 1.35 (95%CI 1.02 to 1.79). (NOTE: a rat io > 1.0 indicates a higher ant ibody level (better immune response) af ter
vaccinat ion with the 25 mm compared with the 16 mm needle.)
4This term refers to a persistent inconsolable crying event last ing for ≥ 4 hours. The data presented in the table relate to
persistent inconsolable crying recorded at any t ime point (6 hours, day 1, day 2, or day 3) af ter concurrent administrat ion of
any dose (f irst , second, or third) of a DTwP-Hib vaccine and a MenC vaccine.
5We downgraded the quality of evidence by one level due to imprecision, taking into account the width of the 95% conf idence
interval accompanying the ef fect est imate.
6We downgraded the quality of evidence by one level for indirectness. The def init ion of persistent inconsolable crying (≥ 4






































































































The reported ef fect size may have dif fered if the latter def init ion had been used in the trial, and we considered that this
uncertainty merited downgrading the quality of evidence.
7We downgraded the quality of evidence by one level as this outcome was reported in only one trial, thus precluding any
evaluat ion of the consistency or inconsistency of results across trials.
8’Severe local react ion’ refers to redness and swelling covering more than two-thirds of the anterolateral thigh af ter the f irst
dose of a DTwP-Hib vaccine.
9Although blinding of outcome assessment was incomplete, we did not downgrade the quality of evidence for risk of bias. We
considered that the clinical severity of the react ion reduced the level of subject ivity in outcome assessment.
10’Non-severe local react ion’ refers to any redness, swelling, tenderness, or hardness (i.e. a composite outcome) at the
inject ion site on the day af ter the f irst dose of a DTwP-Hib vaccine.
11Similar ef fect sizes were observed in the trial af ter the second and third doses of the DTwP-Hib vaccine (second dose RR
0.67, 95% CI 0.54 to 0.83; third dose RR 0.65, 95% CI 0.52 to 0.80). The corresponding NNTBs were 6 (95% CI 4 to 12) for the
second dose and 5 (95% CI 4 to 10) for the third dose.
12We downgraded the quality of evidence by one level due to incomplete blinding of outcome assessment and the resultant
uncertainty over the potent ial for bias.
13Although this outcome was reported in only one trial, thus precluding an evaluat ion of the consistency or inconsistency of
results across trials, we did not downgrade the quality of evidence, taking into account the consistency of the ef fect sizes
af ter the f irst , second, and third doses of the DTwP-Hib vaccine (see footnote 11).
14The data presented in the table relate to fever (temperature ≥ 38 °C) experienced at any t ime point (6 hours, day 1, day 2, or







































































































B A C K G R O U N D
This is the first update of the original Cochrane Review published
in 2015.
An estimated 16 billion injections are administered by healthcare
practitioners worldwide every year, with immunisations account-
ing for approximately 5% of all injections (WHO 2015a). In the
US, the Centers for Disease Control and Prevention (CDC) rec-
ommends routine vaccination to prevent 17 vaccine-preventable
diseases (Kroger 2017). Children fully adhering to the US immu-
nisation schedule may receive up to 24 skin-puncturing injections
by the age of two years and up to five injections in a single visit
(IOM 2013). In many other high-income countries, the average
child who adheres to recommended immunisation schedules re-
ceives at least 18 injections before the age of 16 years, the ma-
jority of which are administered during the first six years of life
(Curtis 2012). The aim of administering any vaccine should be
to ensure the attainment of maximum immunity, with the least
possible harm (RCPCH 2002). Important harms are the pain and
distress associated with vaccination procedures and other common
reactogenicity events that can occur postvaccination such as local
reactions (e.g. redness, swelling, and tenderness at the injection
site) and systemic reactions (e.g. fever, malaise, irritability, and loss
of appetite).
Pain has been defined as “an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or de-
scribed in terms of such damage” (IASP 2004). Acute pain during
a vaccination procedure results from the stimulation of peripheral
nociceptive sensory neurons (pain sensors) during two separate
events: 1) needle puncture of the skin and underlying tissues; and
2) injection and deposition of the vaccine constituents into the
tissue (Taddio 2009a). Delayed pain following a vaccination pro-
cedure may arise due to an inflammatory process in damaged tis-
sue (Gidudu 2012). Pain can be experienced irrespective of the age
at which vaccines are administered because the physiological and
biochemical prerequisites for nociception are developed in utero,
and neonates and infants are able to demonstrate physiological
and behavioural pain responses (RCN 2009).
Most vaccines are administered during the developmentally criti-
cal first six years of life (Curtis 2012), and pain associated with the
procedure may have significant physiological, psychological, and
behavioural sequelae. The immediate physical effects of pain are
related to the stress response and can affect cardiopulmonary func-
tion, metabolic and inflammatory response, and immune com-
petence (Czarnecki 2011). Exposure to painful stimuli in infancy
has also been associated with anticipatory fear of future medical
procedures, increased sensitivity to pain and heightened respon-
siveness to painful stimuli, pain avoidance in later life, and nega-
tive effects on healthcare behaviour and attitudes (Johnston 1996;
Taddio 1997; Andrews 1999; Porter 1999; Taddio 2002; Young
2005; Taddio 2009a; Kassab 2011). In addition, negative expe-
riences with needle-related procedures, particularly in childhood,
can contribute to the development of needle phobias (Hamilton
1995; Wright 2009), which reduce compliance with future im-
munisation schedules and other preventive healthcare measures
(Hogan 2010; Gidudu 2012). Vaccination-related procedural pain
is also a source of anxiety and distress for the parents of children
undergoing vaccination and the healthcare workers who admin-
ister the injections (Schechter 2007; Taddio 2010; Kassab 2011).
Both parents and vaccinators have admitted to non-compliance
with childhood immunisation schedules to reduce pain and dis-
tress to children (Woodin 1995; Luthy 2009; Taddio 2012).
In light of the potential adverse short- and long-term consequences
of pain related to vaccination procedures, every conceivable effort
should be made by healthcare providers to minimise its occurrence.
It is also desirable to minimise the occurrence of postvaccination
local and systemic reactions. However, efforts to reduce reacto-
genicity events should not compromise vaccine immunogenicity,
that is the ability of the vaccine to elicit an immune response. One
aspect of vaccination procedures that has the potential to influence
both vaccine immunogenicity and reactogenicity is the size of the
needle used to administer the vaccine.
Description of the intervention
Hypodermic needles are available in a wide range of sizes for de-
livering drugs, vaccines, and other substances into the body or for
extracting fluids and tissue samples (Gill 2007). The term ’nee-
dle size’ is used to refer to two aspects of hypodermic needle ge-
ometry, namely gauge (diameter) and length. The gauge refers to
the nominal outside diameter of the needle tube, and the length
refers to the nominal length of the needle tube (ISO 1993). Both
dimensions are typically expressed in millimetres (mm), although
in some countries (e.g. the US and the UK) needle length is also
expressed in inches. The most commonly used system for describ-
ing the gauge of needles is the Stubs Iron Wire Gauge system,
developed in England in the early 19th century (Iserson 1987;
Ahn 2002). The gauge of a needle is often abbreviated as ’G’ or
’ga’; the higher the needle gauge number, the smaller the diameter
of the needle lumen (hole) (Pöll 1999). The International Orga-
nization for Standardization (ISO) has established ISO standards
for the inner and outer diameters of hypodermic medical needles
of a specified gauge number (ISO 2001). International standards
have also been developed for colour coding of needles to enable
rapid visual identification of the outside diameter of single-use hy-
podermic needles (ISO 1992). The standards for the most com-
monly recommended needle gauges for administering vaccines to
children and adolescents are presented below.
8Needle size for vaccination procedures in children and adolescents (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
International standards pertaining to the gauge and colour coding of hypodermic needles that are commonly recommended









Range of outside di-
ameters (mm)








22 G 0.70 Black 0.698 0.73 0.39 0.44 0.522
23 G 0.60 Deep blue 0.6 0.673 0.317 0.37 0.46
24 G 0.55 Medium pur-
ple
0.55 0.58 0.28 0.343 -
25 G 0.50 Orange 0.5 0.53 0.232 0.292 -
26 G 0.45 Brown 0.44 0.47 0.232 0.292 -
27 G 0.40 Medium grey 0.4 0.42 0.184 0.241 -
Max: maximum; min: minimum.
1Vaccinations typically require injection of less than 1 mL of fluid (Gill 2007), and the viscosity of most vaccines is such that 22 G
to 25 G needles are generally recommended for most vaccines that are administered intramuscularly and subcutaneously to children
and adolescents (Atkinson 2008; CDC 2011; DoH UK 2012a), and 25 G to 27 G for vaccines administered intradermally (ATAGI
2009; NIAC 2011).
Table adapted from the following sources: ISO 1992; ISO 1993; ISO 2001.
Different needle lengths are available for a given gauge number.
For example, in many countries 25 G (orange) needles are available
in lengths of 16 mm ( inch), 25 mm (1 inch), 32 mm (1¼
inches), and 38 mm (1½ inches) (Ajana 2008). Various needle
gauges are also available for a given needle length. For example,
25 mm needles are available in 22 G (black), 23 G (deep blue),
24 G (medium purple), and 25 G (orange).
Factors influencing needle size selection for
vaccination procedures
It is generally recommended that clinical decisions regarding the
choice of an appropriate needle size (gauge and length) for a par-
ticular vaccination procedure should take into account the age
and body mass of the person receiving the vaccine (see Appendix
1). Obesity increases the subcutaneous tissue thickness, and over-
weight and obese children and adolescents receiving intramuscular
injections may require longer needles to ensure that the vaccine
is administered into muscle (Koster 2009). Several other factors
influencing needle size selection include the prescribed route of
vaccine administration (intramuscular, subcutaneous, or intrader-
mal), the injection site, and the injection technique.
Route of administration and injection site
The recommended routes of administration (intramuscular, sub-
cutaneous, or intradermal) for injectable vaccines are specified in
manufacturers’ summaries of product characteristics (SPCs) and
in recommendations published by National Immunization Tech-
nical Advisory Groups (NITAGs) in different countries (Atkinson
2008). Injectable vaccines should be administered in sites where
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local, neural, vascular, or tissue injury is unlikely, and where they
will elicit the desired immune response (Atkinson 2008; CDC
2011).
The intramuscular route is recommended for most vaccines ad-
ministered to children and adolescents (CDC 2011; DoH UK
2012a). The vastus lateralis muscle in the anterolateral thigh (lo-
cated on the outside of the leg in the mid to upper thigh) is the
generally recommended site for infants under one year old, and the
deltoid muscle of the upper arm for older children and adolescents
(Diggle 2007). Many NITAGs have issued needle size recommen-
dations for intramuscular vaccinations that take into account the
age or size (body mass) of the vaccine recipient and the injection
site (see Appendix 1). However, these recommendations are not
consistent between countries. For example, in the UK, a needle
25 mm in length with a gauge of 23 G or 25 G is recommended
for intramuscular injections in the deltoid of children older than
one year of age (DoH UK 2012a). By contrast, in New Zealand,
23 G to 25 G 16 mm needles are recommended for deltoid site
injections in children aged 15 months to seven years (MoH NZ
2017). In the US, the recommended needle gauges and lengths for
intramuscular deltoid site injections in children and adolescents
aged three to 18 years range from 22 G to 25 G and from 16 to
25 mm, depending on injection technique (Kroger 2017).
Vaccines recommended for subcutaneous delivery include some
formulations of Japanese encephalitis vaccine (e.g. ’Green Cross’
vaccine, Imojev) and varicella vaccines (DoH UK 2012a; ATAGI
2013). Subcutaneous vaccine injections are usually administered
into the anterolateral thigh area of infants aged less than 12
months, and the upper, outer triceps area of people aged 12 months
or older (Atkinson 2008; CDC 2011). Some NITAGs have recom-
mended using needles 16 mm in length for administering vaccines
subcutaneously with gauges ranging from 23 G to 25 G (NIAC
2016; Kroger 2017), or from 25 G to 26 G (ATAGI 2016). By
contrast, the World Health Organization (WHO) has suggested
that 23 G 25 mm needles can be used for subcutaneous adminis-
tration of measles and yellow fever vaccines (WHO 2004).
Only a small number of vaccines are administered intrader-
mally using hypodermic needles. Bacille Calmette-Guérin (BCG)
vaccine against tuberculosis is administered using the Mantoux
method, and concentrated and purified cell-culture rabies vac-
cines can also be delivered intradermally using the same technique
(WHO 2010; Kim 2012). The preferred site for intradermal in-
jection of the BCG vaccine is over the insertion of the left deltoid
muscle, avoiding the tip of the shoulder due to an increased risk
of keloid scar formation at this site (DoH UK 2012a). Needles of
between 10 mm and 20 mm in length with gauges ranging from
25 G to 27 G have been advocated for administering intradermal
injections (Kroger 2013).
Injection technique for intramuscular vaccinations
For an intramuscular vaccination procedure, two aspects of injec-
tion technique may influence the length of needle chosen: 1) the
angle of needle insertion; and 2) whether the skin is bunched or
stretched before needle insertion.
Angle of insertion
National Immunization Technical Advisory Groups in several
countries (including Ireland, the UK, Australia, the US, and New
Zealand) recommend that intramuscular injections should be ad-
ministered at a 90° angle to the skin (NIAC 2011; DoH UK 2012a;
ATAGI 2013; Kroger 2017; MoH NZ 2017). However, recom-
mendations on injection angle have varied over time. For example,
before 2005, New Zealand endorsed a 45° angle and Australia a
45° to 60° angle (NHMRC 2000; NHMRC 2003; Petousis-Harris
2008). The angle of insertion will impact on the depth of needle
penetration, and an insertion angle that deviates from the perpen-
dicular may require the use of a longer needle to ensure that the
vaccine is administered into muscle (Petousis-Harris 2008).
Bunching or stretching
One technique for intramuscular injections entails gently bunching
the muscle using the free hand while inserting the needle perpen-
dicular to the skin. A second technique involves stretching the skin
flat over the injection site and then inserting the needle perpen-
dicular to the skin. A longer needle may be required to reach the
muscle with the bunching rather than the stretching technique.
Injection technique for subcutaneous vaccinations
For subcutaneous injections, it is generally recommended that the
needle be inserted into the subcutaneous tissues below the dermal
layer at a 45° angle to the skin (DoH UK 2012a; Kroger 2017). To
avoid administering the vaccine into muscle, some NITAGs rec-
ommend that the skin and subcutaneous tissue should be bunched
or pinched-up to raise these tissues from the muscle layer before
inserting the needle into the resulting skinfold (DoH UK 2012a;
NIAC 2016). Other NITAGs make no specific recommendation
in this regard (MoH NZ 2017).
Injection technique for intradermal vaccinations
Intradermal injection technique requires special training and
should only be administered by a trained provider (DoH UK
2012a; ATAGI 2016). It is generally recommended that the skin
should be stretched between the thumb and forefinger on one hand
and the needle inserted almost parallel to the skin surface with the
bevel facing upwards into the superficial layers of the dermis. The
recommended insertion depth varies from approximately 2 mm
to 5 mm (DoH UK 2012a; NIAC 2016).
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How the intervention might work
Unintentional deviation from the prescribed route of administra-
tion (intramuscular, subcutaneous, intradermal) for an injectable
vaccine can occur if a needle of an inappropriate length is used.
This can affect both vaccine immunogenicity (the ability of the
vaccine to elicit an immune response) and reactogenicity (adverse
events following vaccine administration). The majority of vaccines
administered to children and adolescents are given via the intra-
muscular route, and the needle used must be sufficiently long to
reach the muscle mass, but not excessively long as to involve un-
derlying nerves, blood vessels, or bone (Zimmerman 2006; CDC
2011; Kroger 2017). If the needle used is too short, the vaccine
may inadvertently be administered into the layer of subcutaneous
or deep fatty tissue rather than muscle, which may compromise
immune response and vaccine efficacy (Zuckerman 2000). Inad-
vertent subcutaneous or intradermal administration, particularly
of adjuvant-containing vaccines, can also increase the risk of reac-
togenicity events including pain, local irritation, induration (hard-
ening of the tissue at or near the injection site), skin discoloura-
tion, inflammation, and abscess formation (Atkinson 2008; CDC
2011). If the needle used is too long, there is a risk of overpene-
tration of the muscle, which can result in pain and damage to the
underlying bone or periosteum (a fibrous membrane covering the
surface of bones) (Lippert 2008).
Needle gauge may also influence the pain experienced during a
vaccination procedure. Progressive decreases in the frequency of
pain and bleeding on needle insertion into human skin have been
recorded when needles of successively smaller outer diameters (23
G, 27 G, 30 G, 32 G) were used in an automated needle injection
system where velocity, angle of insertion, and depth of injection
were controlled (Arendt-Nielsen 2006). However, any reduction
in insertion pain associated with using a higher gauge (narrow)
needle may potentially be offset during the subsequent injection
procedure. It has been hypothesised that the passage of the vaccine
through a narrow bore needle may produce an ’injection jet’ under
high pressure, thereby inducing more severe local reactions at the
injection site (Watson 2001). By contrast, although a wider-bore
needle may be associated with greater pain on needle insertion, the
vaccine may be dissipated over a wider area, potentially resulting in
less severe local reactions (Zuckerman 2000; RCN 2001). Needle
size (length and gauge) may therefore influence both vaccine im-
munogenicity and reactogenicity, and clinicians should endeavour
to select a needle for performing a specific vaccination procedure
that will ensure the attainment of maximum immunity with the
least possible harm.
Further indirect evidence to support the hypothesis that needle
size may have an impact on vaccination-related procedural pain
and the incidence of other reactogenicity events is provided by
trials that have reported differences in injection-related pain scores
and injection-related adverse effects (including bleeding and bruis-
ing) when using needles of different sizes to perform Mantoux
skin testing for tuberculosis (Flynn 1994), breast fine-needle aspi-
ration cytology (Daltrey 2000), and when administering insulin
subcutaneously (Schwartz 2004; Kreugel 2007; Hirsch 2010), on-
abotulinumtoxinA (Botox) intradermally into the axilla (Skiveren
2010), and lidocaine intradermally into the volar surface of the
forearm (Palmon 1998). Although the gauges and lengths of the
needles used for many of the aforementioned procedures are dif-
ferent to those typically recommended for vaccinations, it is rea-
sonable to postulate that similar effects may be observed when
needles of different sizes are used to administer vaccines via intra-
muscular, subcutaneous, and intradermal routes.
Why it is important to do this review
There are inconsistencies in the recommendations made by
NITAGs in different countries regarding the sizes of needles that
should be used when administering vaccines to children and ado-
lescents of specific ages or body masses at preferred injection sites
via intramuscular, subcutaneous, and intradermal routes. There
is also some evidence of variation in clinician adherence to these
recommendations. For example, surveys conducted in Australia,
Cook 2001, Scotland, McKinstry 2004, and the US, Schechter
2010, have documented that, contrary to guideline recommenda-
tions, some clinicians prefer to use a shorter (16 mm) rather than
a longer (25 mm) needle when administering intramuscular vac-
cinations to children. This reluctance to use longer needles may
be due to concerns about the possibility of damaging deep tissue
and bone and causing more discomfort to the child (Zuckerman
2000; McKinstry 2004).
The inconsistencies in NITAG recommendations, coupled with
the evidence of variable clinician compliance with these recom-
mendations, suggest medical uncertainty in this area. This review
may help to reduce uncertainty by providing a critical summary
and synthesis of the evidence from randomised controlled trials
(RCTs) on the beneficial and adverse effects of using needles of dif-
ferent sizes to administer vaccines to children and adolescents. The
review may also help to improve outcomes for people undergoing
vaccination, by assisting clinicians in making well-informed deci-
sions regarding the choice of needle size (gauge and length) for spe-
cific vaccination procedures that will minimise pain and discom-
fort while ensuring that an optimum immune response is attained.
Reducing the pain associated with vaccine injections has the po-
tential to improve parental, child, and adolescent satisfaction with
the vaccination experience, thereby enhancing vaccine uptake and
compliance with recommended immunisation schedules. This is
critically important in light of global concerns regarding subop-
timal vaccine uptake and outbreaks of vaccine-preventable dis-
eases in many countries (WHO 2009; Barret 2010; Roehr 2010;
WHO 2011; Diekema 2012; HPSC 2012; Kmietowicz 2012;
Wise 2013).
This review may also help to reduce international variations in
manufacturers’ packaging and presentation of vaccines, which may
influence clinicians’ decisions regarding the size of needle to use
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for specific vaccination procedures. For example, packages of the
human papillomavirus vaccine Gardasil currently supplied in Ire-
land include two needles: a 23 G 25 mm needle and a 25 G 16 mm
needle (Kiersey 2016). However, some presentations of Gardasil
available in other countries offer clinicians no choice when select-
ing a needle, as only one 25 G 25 mm needle is included in the
packaging (Merck 2007). Our review may help inform manufac-
turers’ decisions regarding the gauges and lengths of hypodermic
needles that are supplied with specific vaccines.
Finally, this review complements existing reviews published in the
Cochrane Library that have evaluated the effects of other inter-
ventions for needle-related procedural pain in children and ado-
lescents, including sweet-tasting solutions, Harrison 2015; Kassab
2012, and psychological interventions (Uman 2013).
O B J E C T I V E S
To assess the effects of using needles of different lengths and gauges
for administering vaccines to children and adolescents on vaccine
immunogenicity (the ability of the vaccine to elicit an immune re-
sponse), procedural pain, and other reactogenicity events (adverse
events following vaccine administration).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included RCTs in this review. We excluded quasi-ran-
domised trials due to the increased risk of systematic differences
between comparison groups (i.e. selection bias) if allocation is per-
formed on the basis of a pseudo-random sequence (e.g. odd/even
hospital number or date of birth, alternation).
Types of participants
We included trials involving children and adolescents, from birth
to 24 years of age, undergoing vaccination with any type of vac-
cine(s) administered via intramuscular, subcutaneous, or intrader-
mal routes using hypodermic needles in any setting (e.g. hospital
or community). For the purposes of this review, we defined a child
as a person aged less than 10 years and an adolescent as a person
aged 10 to 24 years. We chose the upper limit of 24 years because
“many researchers and developmental specialists in the U.S. use
the age span 10 - 24 years as a working definition of adolescence”
(Kaplan 2004; DHHS 2013).
Types of interventions
We included trials evaluating the effects of hypodermic needles of
any size (i.e. any gauge or length) used to administer any type of
injectable vaccine to children and adolescents.
We included trials making any of the following needle size com-
parisons:
1. needles with the same gauge but different lengths (e.g. 25 G
25 mm needle versus 25 G 16 mm needle);
2. needles with different gauges but the same length (e.g. 25 G
25 mm needle versus 23 G 25 mm needle);
3. needles with different gauges and different lengths (e.g. 23
G 25 mm needle versus 25 G 16 mm needle).
We excluded trials where the comparison arms of the trial inten-
tionally differed as part of the trial design with regard to factors
other than needle size that could influence immunogenicity and
reactogenicity outcomes. These factors included:
1. different vaccines administered to participants in the
comparison groups (e.g. one group was given an acellular
pertussis-containing vaccine and one group was given a whole-
cell pertussis-containing vaccine (these vaccines have different
reactogenicity profiles));
2. different volumes of vaccine administered to participants in
the comparison groups (e.g. one group was given 1.0 mL of a
vaccine and one group was given 0.5 mL);
3. vaccines administered by different routes (e.g. one group
was vaccinated by the subcutaneous route and one group was
vaccinated by the intramuscular route);
4. vaccines administered at different sites (e.g. one group was
vaccinated in the anterolateral thigh area and one group was
vaccinated in the deltoid region of the upper arm);
5. vaccines administered using different injection techniques
(e.g. one group was vaccinated using the WHO technique (skin
stretched flat and the needle inserted at a 90° angle), and one
group was vaccinated using a bunching technique whereby the
skin and subcutaneous tissue was bunched/pinched and the
needle inserted at a 45° angle).
We also excluded trials evaluating the effects of:
1. microneedle devices using solid or hollow, dissolvable or
non-dissolvable microneedles for intradermal vaccine delivery;
2. jet injectors;
3. devices for administering vaccines via intranasal injection;
4. bifurcated needles used to administer smallpox vaccine.
Types of outcome measures
We included all outcomes reported by trial authors that were
deemed likely to be meaningful to clinicians, patients (consumers),
parents, and policymakers. In the review protocol (Beirne 2013),
we prespecified the following primary and secondary outcomes
that we would consider in the review.
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Primary outcomes
1. Postvaccination incidence of vaccine-preventable diseases:
in the protocol, we stated that the diagnosis of these diseases
should be made using one or a combination of standard clinical
or bacteriological or serological criteria (e.g. a diagnosis of
pertussis (whooping cough) should be based on a characteristic
clinical history as well as isolation of Bordetella pertussis from a
clinical specimen or positive polymerase chain reaction (PCR)
assay for B pertussis. A diagnosis of hepatitis B infection should
be based on detection of the surface antigen of the hepatitis B
virus (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus
(HBV) DNA, or antibody to hepatitis B core (HBc) antigen in
serum (anti-HBc) with or without clinical or laboratory features
of hepatitis or its complications).
2. Pain, experienced during the vaccination procedure or at
any time point postvaccination measured via self report, observer
global reports, or behavioural measures using any age-
appropriate pain assessment tool with established validity and
reliability (see Appendix 2):
i) self report measures of pain:
a) visual analogue scales (VAS);
b) numerical rating scales (NRS);
c) verbal rating scales (VRS);
d) other scales with established validity and
reliability (see Appendix 2).
ii) observer global reports: observer versions of the self
report measures listed above, completed by parents, researchers,
healthcare professionals, or other observers (see Appendix 2).
iii) behavioural measures:
a) Face Legs Activity Crying Consolability scale
(FLACC) (Merkel 1997);
b) Children’s Hospital of Eastern Ontario Pain Scale
(CHEOPS) (McGrath 1985);
c) COMFORT scale (Ambuel 1992);
d) Neonatal Infant Pain Scale (NIPS) (Lawrence
1993);
e) Modified Behavioural Pain Scale (MBPS)
(Taddio 1995);
f ) other scales with established validity and
reliability (see Appendix 2).
3. Crying measures:
i) crying incidence following vaccination;
ii) persistent crying incidence following vaccination
(defined as the presence of crying that is continuous (not
episodic) and unaltered for three hours or more) (Bonhoeffer
2004);
iii) total cry duration (onset of first cry to cessation of all
crying (seconds));
iv) duration of crying (in seconds) during a specified time
period (e.g. three minutes) following vaccination;
v) percentage of time spent crying during a specified time
period (e.g. three minutes) following vaccination.
Secondary outcomes
1. Surrogate measures of vaccine efficacy or correlates of
vaccine-induced immunity including measures of serum
antibody responses to the administered vaccine such as geometric
mean concentration (GMC), geometric mean titre (GMT),
geometric mean fold increase (GMFI), or percentage of people
with a predefined antibody level (e.g. for yellow fever vaccine,
the proportion of people with a log neutralisation index (LNI) of
0.7 or higher). In the protocol for the review, we stated that
antibody responses to core vaccine antigens must be assessed
using standard tests, as described in Plotkin 2013. We have listed
thresholds of vaccine-induced correlates and surrogates of
protection for selected vaccines in Appendix 3.
2. Physiological measures including the following adverse
cardio-respiratory events measured by standard cardio-
respiratory monitors (e.g. monitors that detect central apnoea
using thoracic impedance and bradycardia employing
electrocardiography and beat-to-beat heart rate recording) or
observation by trained healthcare professionals or researchers or
other personnel or both standard monitoring and observation:
i) episodes of oxygen desaturation, defined as a
spontaneous fall in peripheral capillary oxygen saturation (SpO2)
of 85% for 10 seconds or longer in duration as measured with
pulse oximetry;
ii) episodes of bradycardia, defined as a fall in heart rate
of more than 30% below the baseline;
iii) episodes of apnoea, defined as a cessation of breathing
for more than 20 seconds or a shorter pause associated with
bradycardia or cyanosis.
3. Incidence of common adverse events following vaccine
administration: fever, erythema (redness), swelling, induration,
tenderness at the site of injection, local hypersensitivity reactions,
malaise, irritability, headache, and loss of appetite. In the
protocol for the review, we stated that we would include trials
reporting any of these adverse events, irrespective of how the
events had been defined and measured or recorded by the trial
authors. Where the information was available, we reported the
case definitions of adverse events used by trial authors and
explained how these events were measured by trial researchers in
the Characteristics of included studies table. We included trials
where data on common adverse events were reported separately
or combined as composite outcomes. Where trial authors
combined data on various adverse events, we reported precisely
what events (e.g. erythema, swelling, induration, etc.) were
included in the aggregated data.
4. Incidence of other local, systemic, or allergic adverse events
following vaccine administration reported by trial authors,
including:
i) local reactions: injection site nodule, granuloma, cyst,
haematoma, rash, abscess, cellulitis, ulceration (necrosis),
warmth, or any other reported morphological or physiological
change at or near the injection site;
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ii) other adverse events: disturbed sleeping, drowsiness/
tiredness, nausea, vomiting, diarrhoea, syncope (vasovagal or
vasodepressor reaction), anaphylaxis, febrile convulsions,
hypotonic-hyporesponsive episode (HHE), generalised rash,
paraesthesia, brachial neuritis (see Appendix 4 for explanations
of selected terms).
5. In the protocol for the review, we stated that we would also
report in our review any adverse events related to the equipment
used to deliver vaccines including, but not limited to, needle
bending, needle breakage, or detachment of the needle from the
syringe.
Search methods for identification of studies
Electronic searches
For this review update we searched the following databases, with
no language restrictions, using the search strategies in Appendix
5:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 9) via the Cochrane Register of Studies
Online (CRSO) (searched 24 October 2017);
• MEDLINE and MEDLINE in Progress via Ovid
(November 2014 to 23 October 2017);
• Embase via Ovid (November 2014 to 2017 week 43);
• CINAHL (Cumulative Index of Nursing and Allied Health
Literature) via EBSCOhost (November 2014 to 24 October
2017).
Details of the search strategy for the original review are available
in Beirne 2015.
Searching other resources
For this review update we searched the Annual Meeting Abstract
Archives of the Infectious Diseases Society of America (IDSA) (
2015), the proceedings of the 9th to the 11th Vaccine and Inter-
national Society for Vaccines ( ISV) congresses ( 2015 to 2017),
and the online library of the European Society of Clinical Micro-
biology and Infectious Diseases ( on 16 January 2018). In addi-
tion, we searched the US National Institutes of Health Ongoing
Trials Register ClinicalTrials.gov ( www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform ( ICTRP) (
apps.who.int/trialsearch/) to 17 January 2018.
Details of the search strategy for the original review are available
in Beirne 2015.
Data collection and analysis
Selection of studies
The PRISMA flow diagram in Figure 1 summarises the screening
and selection process for the updated review. Two review authors
(PB, SH) independently screened the titles and abstracts of the
search results.
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Figure 1. Study flow diagram.
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For the original review (Beirne 2015), three review authors (PB,
FS, SH) independently screened the titles and abstracts of the
search results to identify trials that met the selection criteria. We
retrieved the full texts of any potentially relevant papers and corre-
sponded with trial authors where necessary to clarify study eligibil-
ity. The PRISMA flow diagram for the original review is available
in Beirne 2015.
Data extraction and management
Three review authors (PB, SH, SC) independently extracted data
from the included trials using a predesigned data collection form
developed by one of the review authors (PB). The three review
authors independently piloted the data extraction form on one
of the included trials, Diggle 2006, before proceeding with data
extraction for the remaining included trials. Following comple-
tion of the data extraction process, the three review authors com-
pared the details recorded in the three independently completed
data collection forms for each trial. In instances where details were
missing from included trials (e.g. details regarding colour cod-
ing of needle hubs and the precise type and formulation of the
vaccines administered), we contacted the trial authors to obtain
the required information. Any disagreements regarding the details
recorded on the data extraction forms were resolved by discussion
and consensus.
The information recorded on the data extraction form included:
1. general trial information: trial ID, title of publication,
source of publication, year of publication, country where the
trial was conducted, details of trial authors, contact addresses, or
other contact details (e.g. email addresses) for trial authors;
2. characteristics of the study: trial design (e.g. parallel group),
trial setting (e.g. general practice), details necessary for assessing
the risk of bias as described in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions including
(Higgins 2011a):
i) methods used to generate a random allocation
sequence;
ii) methods used to conceal the allocation sequence;
iii) details of all measures used, if any, to blind
participants and personnel;
iv) details of all measures used, if any, to blind outcome
assessors;
v) details of the completeness of data for each outcome,
including attrition and exclusions from the analysis;
vi) details of any other concerns about bias.
3. characteristics of the trial participants: details of the
inclusion and exclusion criteria for the trial; baseline
characteristics of trial participants in the study groups including
age, gender, and weight; and the numbers randomised to each
group;
4. characteristics of the interventions: needle size (length and
gauge) used to administer the vaccine to different study groups;
details of any colour coding on the needle hubs; and details of
the needle composition, needle coating, needle bevel, and type of
needle hub. Type and formulation of vaccine administered,
including details of the ’biological’ characteristics of the vaccine
and the composition of the vaccine (e.g. presence or absence of
adjuvant). The volume of vaccine administered and details of the
vaccine manufacturer. Details of the personnel who administered
the vaccination. Details of the injection technique used including
bunching or stretching of skin and underlying tissues before needle
insertion, angle of needle insertion, depth of needle insertion
(e.g. needle inserted to full depth (i.e. to the needle hub), 2 mm
of needle exposed between the skin and needle hub). Several of
these issues were either not reported or were incompletely
reported in the included trials, and we corresponded with all trial
authors to obtain the missing information;
5. characteristics of the outcome measures: details of all
outcomes measured, definitions of outcomes, and time points of
measurements. Details of the outcome assessors and methods/
instruments used to measure outcomes. Units of measurement
(where relevant), upper and lower limits for any scales used;
6. trial results: for each outcome, we recorded details of the
numbers in each study group for whom outcome data were
available at each time point and details of, and reasons for, any
attrition or exclusions and any re-inclusions in analyses
performed by the trial authors. For dichotomous outcomes, we
recorded the numbers of participants experiencing the outcome
of interest in each study group at each time point. For
continuous outcomes, we recorded the mean value and standard
deviation of the outcome measurements in each study group at
each time point or the medians and interquartile ranges (IQR)
for skewed outcome distributions. Where trial authors log-
transformed the data for analysing antibody concentrations after
vaccination, we recorded geometric means and accompanying
95% confidence intervals (CI) and the standard deviations of
measurements on a natural log scale where reported;
7. miscellaneous information: source of funding for the trial,
key conclusions of the trial authors, miscellaneous comments
made by the trial authors, and references to other relevant studies.
One review author (PB) entered all relevant data into Review Man-
ager 5 (RevMan 2014); two review authors (SH, SC) checked data
entries. We considered contextual factors recorded in the data ex-
traction form for each trial (i.e. conditions and circumstances rel-
evant to the application of the intervention such as the country
(e.g. low- and middle-income, high-income) where the trial was
conducted and the trial setting (e.g. general practice, other set-
ting) when interpreting the overall results of the review. We also
considered the applicability, transferability, and external validity
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of findings for disadvantaged groups, as recommended in the “Eq-
uity checklist for systematic review authors” (Ueffing 2012).
Assessment of risk of bias in included studies
Three review authors (PB, SH, SC) independently assessed and
discussed the risk of bias in trials meeting the selection criteria.
Any disagreements were resolved by discussion and consensus.
The review authors were not blinded to the authors of each trial,
the trial location/setting, sources of funding for the trial, or trial
acknowledgements.
We assessed the following domains for each trial:
1. random sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
6. selective reporting (reporting bias);
7. other sources of bias (other bias).
For each domain, we reached a judgement of low risk of bias, high
risk of bias, or unclear risk of bias, and provided justification for
all judgements in the ’Risk of bias’ tables and in the Risk of bias in
included studies section of the review. In reaching our judgements,
we considered the risk of material bias, defined as “bias of sufficient
magnitude to have a notable impact on the results or conclusions
of the trial” (Higgins 2011a), rather than the risk of any bias. We
produced a separate ’Risk of bias’ table for each trial as described
in Section 8.6 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a).
Measures of treatment effect
The review team statistician (TF) monitored all statistical analyses
in our review.
Dichotomous data
We calculated risk ratios (RR), risk differences (RD), and numbers
needed to treat for an additional beneficial outcome (NNTB) as
effect measures for dichotomous outcomes. We performed any
meta-analyses of dichotomous data using RR (see Data synthesis).
None of the trials included in the review reported on the incidence
of vaccine-preventable diseases postvaccination, and we based our
analyses of the effects of needle size on vaccine immunogenicity
on differences in seroprotection rates between needle size groups.
The term ’seroprotection’ refers to antibody titre levels above a
predefined threshold level that correlates with protection from
disease. We used the following threshold levels for seroprotection
against diphtheria, tetanus, and Haemophilus influenzae type b
(Hib) disease: diphtheria antitoxin levels 0.01 IU/mL or greater,
tetanus antitoxin levels 0.01 IU/mL or greater, and Hib antibody
titre levels 1.0 µg/mL or greater (see Appendix 3).
Continuous data
We calculated mean differences (MD) with 95% CIs as effect
measures for continuous outcomes. Medians and ranges in needle
size groups were reported in tables. We did not perform any meta-
analyses of continuous data in this review.
In accordance with guidance proposed by the Cochrane Infec-
tious Diseases Group (Donegan 2010), where continuous data
(e.g. antibody titres) were summarised using geometric means, we
reported geometric mean ratios (GMRs) as effect measures. We
calculated the GMRs from the information provided in trial re-
ports as follows: the reported geometric means in the needle size
groups being compared were log-transformed to obtain the esti-
mated mean log concentrations. The standard errors (SE) on the
log scale were calculated from the quoted standard deviations on
the log scale and the sample size. We combined the mean log con-
centrations and corresponding SEs to obtain the difference in es-
timated log concentrations and the 95% CI for the difference in
mean log concentrations. Finally, the estimate of the difference in
the mean log concentrations and the corresponding 95% CI were
exponentiated to obtain the ratio of the geometric means and the
95% CI for the ratio of the geometric means.
Unit of analysis issues
All trials included in the review were parallel-group trials where
participants were individually randomised to the intervention
groups. Two trials had three groups and therefore contributed
multiple comparisons of relevance to the review (Diggle 2006;
Nirupam 2008). For example, Diggle 2006 contributed data for:
1. needles of the same lengths but different gauges (25 G 25
mm versus 23 G 25 mm);
2. needles with the same gauges but different lengths (25 G 25
mm versus 25 G 16 mm);
3. needles with different lengths and gauges (23 G 25 mm
versus 25 G 16 mm).
A unit of analysis error could have arisen if several comparisons
from this trial had been entered into a meta-analysis when these
comparisons had intervention groups and hence participants in
common. However, this issue did not arise as data from only one
comparison in Diggle 2006 (23 G 25 mm versus 25 G 16 mm)
were entered into the meta-analyses conducted as part of this re-
view (see Data synthesis). We did not include data from Nirupam
2008 in any meta-analyses.
Several trials included in the review presented multiple local reac-
tion outcomes at multiple time points raising a ’multiplicity’ is-
sue in the analysis (as described in Section 16.7.2 of the Cochrane
Handbook for Systematic Reviews of Interventions) (Higgins 2011b).
For example, in one trial each local reaction (swelling, tenderness,
redness, hardness) was measured at four time points (six hours,
days one, two, and three) after vaccination with each of three doses
of the two vaccines administered in the trial, giving a total of 96
separate analyses (4 outcomes x 4 time points x 3 doses x 2 vac-
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cines) (Diggle 2006). The existence of multiple analyses can be
a source of bias in systematic reviews if review authors selectively
highlight some analyses in the review (e.g. selective presentation
of results at time points where the analysis yielded statistically sig-
nificant findings). This issue of selectivity could have been prob-
lematic in our review as we did not identify in the review protocol
specific time points at which we would record and report local
reaction outcomes. We adopted two approaches to reduce the risk
of any potential bias arising from selectivity. First, we conducted
sensitivity analyses to investigate if the results of our review var-
ied according to time point selection. Second, when presenting
the results of analyses for local reaction outcomes in Effects of
interventions, we followed the advice specified in Section 16.7.2
of the Cochrane Handbook for Systematic Reviews of Interventions,
namely “If there is a choice of time-points for an outcome, at-
tempts should be made to present a summary effect over all time-
points, or to choose one time-point that is the most appropriate
one (although availability of suitable data from all trials may be a
problem)” (our emphasis) (Higgins 2011b). Where suitable data
were available from trials, we decided through discussion and con-
sensus to present the results of local reaction analyses at 24 hours
after vaccination or the nearest approximation to this time point
(e.g. day one postvaccination). There were several reasons for se-
lecting this time point. First, we considered that the most com-
mon local reactions after vaccination (redness, swelling, and ten-
derness) would have manifested by 24 hours with only a minority
appearing de novo after this time point. Second, we reasoned that
an analysis at an earlier time point (e.g. six hours postvaccination)
would undoubtedly capture numerous immediate but potentially
very transient local reactions (e.g. minor redness at the injection
site that could potentially dissipate shortly after the six-hour time
point). We considered that parents and clinicians would be less
concerned about such transient reactions and would be more con-
cerned about local reactions that persisted at 24 hours. Finally, one
previous systematic review and meta-analysis evaluating the effect
of needle size on vaccine reactogenicity also used the 24-hour time
point for analyses (Davenport 2003).
In instances where local reaction outcomes were not reported at
24 hours in a trial, we presented summary effects over all time
points. We also adopted this approach for analysing systemic reac-
tions (such as fever, irritability, and malaise) following vaccination.
These systemic reactions can appear at any time point postvacci-
nation, therefore we considered that it would be inappropriate to
use the 24-hour time point.
Dealing with missing data
We contacted the authors of all included trials to obtain missing
data or for data clarification. We recorded details of any discrep-
ancies between the numbers of participants randomised and the
numbers analysed in each treatment group for each outcome and
reported this information in the ’Risk of bias’ table for each trial.
If more than 20% of the data for a particular outcome were miss-
ing from a trial, we planned to exclude the trial from any meta-
analysis relating to that outcome. However, this issue did not arise
in relation to the meta-analyses we performed in the review (see
Data synthesis). In instances where missing outcome data could
reasonably be assumed to be missing at random, we analysed only
the available data (i.e. we conducted an available-case analysis).
We adopted this analysis strategy in our review for all missing out-
come data. Where appropriate, we explained the reasons why we
deemed it reasonable to assume that data were missing at random
in the ’Risk of bias’ table for each included trial (see Characteristics
of included studies).
Assessment of heterogeneity
We quantified inconsistency between the results of individual stud-
ies included in meta-analyses using the I2 statistic (Deeks 2011),
which describes the percentage of variability in effect estimates
that is due to heterogeneity rather than to chance. We interpreted
the values of the I2 statistic in accordance with the following ap-
proximate guide as specified in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011c):
1. 0% to 40%: might not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity;
4. 75% to 100%: considerable heterogeneity.
Where heterogeneity was present, we investigated the heterogene-
ity by performing further quality control checks of data extrac-
tion from included studies and data entry into Review Manager 5
(RevMan 2014). We had also planned to investigate heterogene-
ity by conducting the subgroup analyses specified in the review
protocol (Beirne 2013). However, the number of included trials
was insufficient to conduct these analyses (see Differences between
protocol and review).
Assessment of reporting biases
Publication bias
In the review protocol (Beirne 2013), we stated that we would
only conduct tests for funnel plot asymmetry if at least 10 studies
were included in the meta-analysis (Sterne 2011). As our review
included only five trials, we did not investigate the likelihood of
publication bias by producing a funnel plot.
Outcome reporting bias
Three review authors (PB, SH, SC) examined the reports of all
included trials for evidence of selective outcome reporting. We
contacted all trial authors for additional information. We judged
trials as having a low risk of bias due to selective outcome reporting
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if they fulfilled the following criteria specified in the Cochrane
’Risk of bias’ assessment tool (Higgins 2011c):
1. study protocol was available and all of the trial’s prespecified
outcomes (primary and secondary) that were of interest in our
review were reported in the prespecified way;
2. study protocol was not available, but we judged that the
published reports included all expected outcomes, including
those that were prespecified.
Data synthesis
We conducted all statistical analyses and data syntheses using Re-
view Manager 5 (RevMan 2014), in consultation with the review
team statistician (TF) where necessary. We only conducted statis-
tical syntheses of the results from individual trials if we deemed
the trials to be sufficiently similar in terms of the participants, in-
terventions, comparisons, and outcomes to render calculation of
a pooled estimate meaningful. In this context, we only included
two trials in the meta-analyses conducted in this review (Diggle
2000a; Diggle 2006). Both trials involved comparisons of the same
needle sizes (23 G 25 mm versus 25 G 16 mm), and similar doses
(third dose) of a DTwP-Hib vaccine were administered using sim-
ilar injection techniques. In addition, the trial participants were
of a similar age, and local reaction outcomes (redness, swelling,
and tenderness) were measured using similar techniques at sim-
ilar time points. Where we deemed meta-analysis inappropriate
or not feasible due to the heterogeneity of the included trials, we
presented a narrative summary of the results of individual trials at
appropriate time points as described in the Unit of analysis issues
section of the review.
In accordance with the review protocol (Beirne 2013), we used
the RR as the summary statistic in meta-analyses of dichotomous
outcomes and pooled the RRs using the random-effects Mantel-
Haenszel method (Higgins 2011c). We did not conduct any meta-
analyses of continuous outcomes in this review.
’Summary of findings’ tables
We used ’Summary of findings’ tables to summarise the results
for the main comparisons (Schünemann 2011a). We created these
tables by exporting data from Review Manager 5, RevMan 2014,
into GRADEprofiler (GRADE 2011). We then exported the tables
into Microsoft Word for additional editing before finally trans-
ferring the information into ’Summary of findings’ tables created
using the table editor in Review Manager 5.
We created three ’Summary of findings’ tables for comparisons be-
tween the following needles that were used to administer combi-
nation vaccines with diphtheria, tetanus, and whole-cell pertussis
(DTwP) vaccine antigen components to infants:
1. 25 G 25 mm versus 25 G 16 mm (comparison between
needles with different lengths but with the same gauge);
2. 25 G 25 mm versus 23 G 25 mm (comparison between
needles with different gauges but with the same length);
3. 23 G 25 mm versus 25 G 16 mm (comparison between
needles with different gauges and different lengths).
One trial evaluated the effects on vaccine immunogenicity and
reactogenicity of using these needle sizes to administer a meningitis
C conjugate (MenC) vaccine. We did not incorporate these results
into a ’Summary of findings’ table as the vaccine was administered
using a schedule (timing and spacing of vaccine doses) that is no
longer recommended. We summarised the results of any analyses
pertaining to the administration of the MenC vaccine in the main
text of the review.
Two small trials compared 38 mm versus 25 mm needles and 22
G 25 mm versus 23 G 25 mm versus 24 G 25 mm needles; we
did not construct separate ’Summary of findings’ tables for these
comparisons. We presented a narrative summary of the results of
these trials in the Effects of interventions section.
We included the following outcomes in the ’Summary of findings’
tables.
1. Immunogenicity outcomes
i) postvaccination incidence of vaccine-preventable
diseases
ii) proportion of seroprotected vaccine recipients: this
substitute (surrogate) immunogenicity outcome refers to the
proportion of vaccine recipients who responded in a prescribed
manner by reaching predefined antibody titre (or antitoxin)
’threshold levels’ of protection against disease (e.g. the
proportion of vaccine recipients with diphtheria antitoxin levels
0.01 IU/mL or greater) (see Appendix 3 for the threshold levels
used in this review)
2. Reactogenicity outcomes
i) pain: experienced during the vaccination procedure or
at any time point postvaccination measured using an age-
appropriate pain assessment tool with established validity and
reliability (see Appendix 2)
ii) crying: any measures of crying during and
immediately after the vaccination procedure or at any time point
postvaccination
iii) severe local reactions (redness and swelling covering
more than two-thirds of the anterolateral thigh)
iv) non-severe local reactions on the day after vaccination:
this composite outcome refers to any local reaction (e.g. any
redness, swelling, tenderness, or hardness/induration) at the
injection site
v) fever: experienced at any time point postvaccination
Not all of these outcomes were explicitly prespecified in our pro-
tocol for inclusion in ’Summary of findings’ tables. We have there-
fore explained (below) our rationale for selecting some entries in
the ’Summary of findings’ tables.
1. It is generally recommended that outcomes included in the
’Summary of findings’ tables should be those that are essential
for decision-making and that the emphasis should be on patient-
important outcomes (Guyatt 2013). In this context, our decision
to include a substitute (surrogate) immunogenicity outcome in
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the ’Summary of findings’ tables could be criticised. However, we
considered that the substitute outcome should be included
because no trials reported on the incidence of vaccine-
preventable diseases. This was not entirely unexpected given the
low incidence of many of these diseases, particularly in countries
with well-established vaccination programmes, which would
mean that trials with disease endpoints would require unfeasibly
large sample sizes and duration of follow-up. Under these
circumstances, the use of substitute outcomes was the only
realistic way of measuring the immune response to an
administered vaccine. In accordance with the recommendations
specified in GRADE guidelines (Guyatt 2013), we clearly
indicated in ’Summary of findings’ tables where inferences
regarding intervention effects were based on the results of
substitute endpoints, and we downgraded the quality of evidence
level for indirectness.
2. In the review protocol (Beirne 2013), we listed two
substitute immunogenicity endpoints that are commonly used in
vaccine trials: 1) the proportion of vaccine recipients who
reached a predefined antibody level following vaccination; this
endpoint specifies “a threshold level of an immune marker above
which subjects are assumed to be protected and below which they
are not” (WHO 2013a); and 2) GMC or GMT of antibody; this
endpoint uses antibody titres as continuous variables to predict
vaccine efficacy. In the review protocol, we did not specify which
of these substitute outcomes would be highlighted in ’Summary
of findings’ tables. We decided through discussion and consensus
to highlight the proportion of vaccine recipients who reached a
predefined threshold level of protection (as defined in Appendix
3). This decision took into account the use of this outcome in
other Cochrane Reviews (e.g. Bar-On 2012), and the fact that
threshold endpoints are considered to be particularly meaningful
when evaluating the immune response to specific components of
some combination vaccines (e.g. the Hib component of DTwP-
Hib vaccines) (Horne 2001). For completeness, we included the
results of analyses for GMCs and GMTs of antibodies in the
footnotes of the ’Summary of findings’ tables.
3. In the review protocol (Beirne 2013), we did not prespecify
that the outcome ’severe local reactions’ would be included in
’Summary of findings’ tables. However, there was unanimous
agreement within the review team that this outcome should be
included, considering the extent and clinical severity of these
reactions and their perceived importance to patients, their
parents, and clinicians.
4. In the review protocol (Beirne 2013), we did not specify
precisely what non-severe local reactions we would include in the
’Summary of findings’ tables and the time point(s) at which we
would report these outcomes. As previously described in the Unit
of analysis issues section, some of the included trials reported on
multiple individual local reactions at the injection sites (swelling,
tenderness, redness, and hardness) at multiple time points
postvaccination (six hours, days one, two, and three). In one
trial, these outcomes were also reported after each dose (first,
second, and third) of the vaccine series administered to trial
participants. This presentation of trial data posed a challenge in
terms of compiling user-friendly ’Summary of findings’ tables
that contained no more than the recommended seven outcomes
(Guyatt 2013). We decided through discussion and consensus
among the review team to include composite local reaction
outcomes (any redness, swelling, tenderness, or hardness/
induration at the vaccination site) experienced at 24 hours (day
one) after vaccination in the ’Summary of findings’ tables. The
reason for selecting the 24-hour (day one) time point is
explained in the Unit of analysis issues section. We also decided
to present in ’Summary of findings’ tables the findings for local
reactions after each dose of the vaccine(s) administered in the
trials because it is well established that the same vaccine given as
a primary dose (first dose) may have a different reactogenicity
profile than when it is given as a booster dose (WHO 2013b).
5. We based the inclusion of fever in the ’Summary of findings’
tables on a review of reports to the US Vaccine Adverse Events
Reporting System (VAERS) (CDC 2003). Postvaccination fever
and injection site (non-severe) local reactions such as skin
redness and oedema were the most frequently reported adverse
events. Reports to VAERS are typically submitted by all relevant
stakeholders in vaccination programmes, including healthcare
providers, vaccine recipients (or their parents/guardians), and
vaccine manufacturers. The Vaccine Adverse Events Reporting
System “encourages the reporting of any significant adverse event
occurring after the administration of any vaccine licensed in the
United States” (our emphasis). By implication, events reported to
this system could be deemed significant events for stakeholders,
thereby meriting inclusion in ’Summary of findings’ tables.
Methods used to assess the quality of the evidence for
outcomes included in ’Summary of findings’ tables
We assessed the quality of the evidence in relation to each outcome
included in the ’Summary of findings’ tables using the GRADE
evidence grading system (Schünemann 2009), as described in Sec-
tion 12.2 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Schünemann 2011b). One review author (PB) initially
applied the GRADE system and then discussed the quality of ev-
idence ratings for each outcome with two other members of the
review team (SH, SC). Final decisions on the ratings were reached
through discussion and consensus. We took the following factors
into account when deciding whether or not to downgrade the
quality of evidence in relation to each outcome:
1. risk of bias;
2. inconsistency of results;
3. indirectness of evidence;
4. imprecision of results;
5. publication bias.
Our review included only RCTs, and we downgraded the evidence
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for each outcome from high quality by one level if we considered
that there was a serious limitation in relation to a particular factor
or by two levels if we considered there was a very serious limitation.
We included footnotes in the ’Summary of findings’ tables to ex-
plain our reasons for downgrading the evidence. We also included
footnotes to justify some of our decisions not to downgrade the
quality of the evidence, particularly in instances where we consid-
ered that users of our review might reasonably disagree with our
decisions.
Some of the outcomes included in ’Summary of findings’ tables
were reported from a single trial, which created problems in terms
of evaluating the quality of the evidence as it related to the criterion
of consistency/inconsistency of results. The Agency for Healthcare
Research and Quality (AHRQ) in the US has noted that “evalu-
ation of consistency ideally requires an evidence-base with inde-
pendent replication of findings” and that we “cannot be certain
that a single trial, no matter how large or well-designed, presents
the definitive picture of any particular clinical benefit or harm
for a given treatment” (Owens 2009). The AHRQ has suggested
that consideration should be given to decreasing the strength of
evidence grade in instances where evidence is from a single study
and where consistency is therefore unknown (Owens 2010). We
adopted this approach of downgrading evidence for outcomes with
a single trial evidence base, with two exceptions.
1. Some trials reported two substitute endpoints for
immunogenicity: the proportion of vaccine recipients who
reached a predefined antibody level (seroprotection) following
vaccination, and the GMC or GMT of antibody. In evaluating
the immunogenicity evidence base for consistency, we considered
the consistency of the effect sizes for these different endpoints.
2. One included trial reported on some reactogenicity
outcomes (redness, swelling, tenderness, and hardness) after each
of three doses of the vaccines that were administered in the trial
using needles of different sizes. These doses of the vaccines were
administered to the same trial participants when they were aged
two months (first dose), three months (second dose), and four
months (third dose). In evaluating the evidence base for
consistency for these reactogenicity outcomes, we considered the
consistency of the effect sizes after each dose of the vaccine.
We acknowledge that neither point 1 nor 2 above represents truly
independent replication of findings. Nevertheless, we considered
that this was a reasonable approach to adopt when evaluating the
quality of evidence for some of the local reaction and immuno-
genicity outcomes reported in single trials in our review.
Identification and definitions of minimum important
differences
It has been recommended that systematic reviewers should en-
deavour to identify an appropriate minimum important differ-
ence (MID) for the outcomes of interest in the review (AHRQ
2012). The MID has been defined as “The smallest difference in
score of the outcome of interest that informed what patients or
proxies perceive as important and which would lead the patient or
clinician to consider a change in the management” (Schünemann
2005, cited in AHRQ 2012). The MID can facilitate the interpre-
tation of the results of a systematic review and the evaluation of
statistical significance in the context of clinical relevance (AHRQ
2012).
In order to determine and define MIDs for the immunogenicity
and pain outcomes reported in our review, we adopted approaches
suggested by the AHRQ including: reviews of the literature to lo-
cate already-conducted empirical studies to identify the smallest
change in a particular outcome that people perceive as important;
using MIDs specified by prominent authorities; and using MIDs
specified in the power calculations of relevant studies (AHRQ
2012). When reviewing the literature on MIDs in immune re-
sponses, we considered the power calculations in non-inferiority
trials of combination vaccines. The rationale for this approach
was that most of the trials included in our review involved using
needles of different sizes to administer combination vaccines, and
trials designed to evaluate combination vaccines are customarily
designed and analysed as non-inferiority studies (Horne 2001).
For differences in seroprotection rates between needle size groups,
we used an RD of 10% as the MID. We considered needle sizes
to have comparable effects on immune response if the 95% CI
accompanying the RD effect estimate was sufficiently narrow to
exclude a 10% difference in seroprotection rates in either direc-
tion. The selection of this MID was based on the recommended
non-inferiority 10% protection rate for vaccines specified by the
Committee for Proprietary Medicinal Products (CPMP 1999),
and cited in a systematic review of margins for equivalence and
non-inferiority in biomedical research (Lange 2005). This MID
was also used in several non-inferiority trials of combination vac-
cines (Guerra 2009; Kosalaraksa 2011; Thierry-Carstensen 2012;
EMA 2013).
When choosing an MID for the outcome of pain, we examined
the literature on pain scales for children and adolescents for in-
formation on differences in scores considered to be clinically sig-
nificant. In general, reported estimates of the minimum clinically
important difference ranged from 10% to 20% (e.g. a change of
one face on the Faces Pain Scale-Revised, or a change of 10 to 20
mm on a 100-millimetre VAS) (von Baeyer 2006). These MIDs
are commensurate with those specified in studies measuring pain
response to vaccinations using the 10-point MBPS. For example,
we identified one study that specified in a power calculation a
“clinically important difference in mean MBPS between groups of
2 units” (Ipp 2004). Another study specified that “only differences
greater than 1 point on the 10-point MBPS were considered clin-
ically significant” and that “this is in line with recently published
meta-analytic work determining the effect of a known analgesic
agent on immunization pain using MBPS” (Pillai Riddell 2013).
We selected as an MID the more conservative estimate of 1 point
on the 10-point MBPS scale or its equivalent on other scales.
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We did not specify MIDs for other reactogenicity outcomes (such
as local reactions, fever, irritability, etc.) reported in our review.
We could identify no consensus in the international literature on
differences in event rates for these outcomes that would be consid-
ered clinically important. Furthermore, MIDs for reactogenicity
events are rarely specified in power calculations in vaccine trials,
which are typically based on immunogenicity rather than reacto-
genicity endpoints. We therefore reported all observed differences
between needle size groups for these outcomes.
Subgroup analysis and investigation of heterogeneity
The number of trials included in the review was insufficient to
conduct subgroup analyses (see Differences between protocol and
review).
Sensitivity analysis
We performed meta-analyses using both fixed-effect and random-
effects models. Due to the small number of trials included in the
meta-analyses, we did not conduct any of the other sensitivity
analyses prespecified in our protocol (see Differences between
protocol and review) (Beirne 2013).
During the review process we made several post hoc decisions
including the time points at which we would analyse trial data,
the selection of MID in seroprotection rates between needle size
groups, and the presentation in ’Summary of findings’ tables of
the results pertaining to the effects of needle size on a composite
local reaction outcome rather than on the individual components
of the composite. We conducted sensitivity analyses to investigate
the impact of these decisions on the review findings. We presented
the results of these analyses in the Effects of interventions section.
R E S U L T S
Description of studies
Results of the search
As shown in Figure 1 and Appendix 6, our updated searches iden-
tified 2151 records. We screened out all 2151 records based on the
titles and abstracts and therefore identified no new studies for this
review update.
In the original review (Beirne 2015), our searches yielded 8058
records. We screened out 8013 references based on titles and ab-
stracts. We examined the remaining 45 records in full text, and ex-
cluded 33 records (see Excluded studies). We excluded for this re-
view update one trial originally assigned to ’studies awaiting classi-
fication’ (see Characteristics of excluded studies) (Ozdemir 2012).
Included studies
Five RCTs (reported in 11 articles) met the inclusion criteria of
the review and were included. Full details of the included trials are
provided in the Characteristics of included studies table.
Design and sample sizes
All of the trials were parallel-group trials. Three of the trials had
two groups (Diggle 2000a; Pathak 2007; Middleman 2010), and
two trials had three groups (Diggle 2006; Nirupam 2008). The
total number of randomised participants in the five trials was 1350,
with individual trial sample sizes ranging from 65, in Middleman
2010, to 696 participants, in Diggle 2006.
Settings
The vaccinations were administered in general medical practices
in England in two trials (Diggle 2000a; Diggle 2006); in tertiary
paediatric hospitals in India in two trials (Pathak 2007; Nirupam
2008); and at city clinics or in the participants’ homes in the USA
in one trial (Middleman 2010).
Participants
One trial involved obese adolescents aged 14 to 24 years (
Middleman 2010). All participants in the remaining trials were
infants under the age of six months and included:
1. healthy infants attending for routine vaccinations due at
four months of age (Diggle 2000a);
2. healthy infants attending for routine vaccinations due at
two, three, and four months of age (Diggle 2006);
3. infants up to 24 weeks of age attending for routine
vaccinations, 14% of whom were “malnourished”, with the
remainder being of “normal weight” (categorised as per WHO
growth standards) (WHO 2006; Pathak 2007);
4. healthy infants aged six to 10 weeks attending for
prescribed routine vaccinations (Nirupam 2008).
One trial included only two males (one in each of the comparison
groups) in the final data analysis (Middleman 2010). The propor-
tions of male participants in the remaining trials ranged from 51%
to 59%.
Interventions and comparisons
Needle sizes compared in the trials
Two trials compared needles with the same gauges but different
lengths:
1. 25 G 25 mm versus 25 G 16 mm (Diggle 2006);
2. 38 mm versus 25 mm (the precise gauge number is
unknown, but we received confirmation from the trial authors
that the needles had the same gauge) (Middleman 2010).
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Three trials compared needles with different gauges but the same
length:
1. 25 G 25 mm versus 23 G 25 mm (Diggle 2006; Pathak
2007);
2. 24 G 25 mm versus 23 G 25 mm versus 22 G 25 mm
(Nirupam 2008).
Two trials compared needles with different gauges and different
lengths:
1. 23 G 25 mm versus 25 G 16 mm (Diggle 2000a; Diggle
2006).
Vaccines used in the trials
The vaccines administered to trial participants were:
1. the first, second, and third doses of a recombinant hepatitis
B (Hep B) vaccine (Middleman 2010);
2. the third dose of a combined DTwP-Hib vaccine (Diggle
2000a);
3. the first, second, and third doses of a combined DTwP-Hib
vaccine and the first, second, and third doses of a MenC vaccine
(Diggle 2006);
4. either the first, second, or third doses of i) a combined
DTwP vaccine; ii) a combined DTwP-Hib vaccine; or iii) a
combined DTwP-Hib-Hep B vaccine (Pathak 2007);
5. the first dose of a combined DTwP vaccine and the first dose
of a recombinant hepatitis B (Hep B) vaccine (Nirupam 2008).
The volume of the vaccine(s) administered to trial participants
was:
1. 0.5 mL (Diggle 2006; Pathak 2007; Nirupam 2008);
2. 0.5 mL to 15% and 1 mL to 85% of the trial participants
(see Characteristics of included studies table for additional
details) (Diggle 2000a);
3. 0.5 mL to trial participants aged less than 19 years and 1 mL
to trial participants aged 19 years or greater (Middleman 2010).
The vaccination procedures were performed by general medical
practice nurses in one trial (Diggle 2000a); by paediatric research
nurses in one trial (Diggle 2006); by hospital nurses in two trials
(Pathak 2007; Nirupam 2008); and by a faculty paediatrician and
a trained medical student in one trial (Middleman 2010).
Route of administration, injection site, and injection
technique
The vaccines used in all trials were intended to be administered
via the intramuscular route. The injection site was the anterolat-
eral thigh in four trials (Diggle 2000a; Diggle 2006; Pathak 2007;
Nirupam 2008), and the deltoid region of the upper arm in one
trial (Middleman 2010). The skin was stretched flat and the nee-
dle was inserted into the skin at a 90° angle in all trials (WHO
injection technique). In three trials, the needle was inserted to
its full length up to the needle hub (Diggle 2000a; Diggle 2006;
Nirupam 2008). In one trial, some of the infants were malnour-
ished, and it is possible that the staff nurses may not have inserted
the full length of the needle when vaccinating these infants (per-
sonal communication with trial author) (Pathak 2007). In the trial
involving obese adolescents, 2 to 3 mm of needle was left visible
between the skin and the needle hub (Middleman 2010).
Outcomes
Details of the definitions of all outcomes (where provided by the
trial authors) and the time points at which the outcomes were
measured are provided in the Characteristics of included studies
tables.
Two trials reported immunogenicity outcomes:
1. failed immunogenicity (vaccine non-response): the
numbers of vaccinated participants who failed to reach a
predefined protective antibody concentration threshold (Diggle
2006; Middleman 2010). In this review, we reported the
numbers who reached (rather than failed to reach) predefined
thresholds, as specified in the review protocol (see Appendix 3
for details of the threshold levels used in this review);
2. antibody titres to HBsAg (Middleman 2010);
3. geometric mean concentrations (GMCs) of diphtheria,
tetanus, and Hib antibodies and geometric mean titres (GMTs)
of serogroup C meningococcal glycoconjugate antibodies
(Diggle 2006). The immune response to the pertussis (whooping
cough) component of the combined vaccine administered in the
trial was not measured as there is no well-established immune
correlate or surrogate of protection against pertussis.
Four trials reported reactogenicity outcomes:
1. pain (Pathak 2007);
2. crying:
i) procedural crying (Pathak 2007);
ii) persistent inconsolable crying (four hours or greater in
Diggle 2006; greater than three hours in Nirupam 2008).
3. severe local reaction (Diggle 2006);
4. common local reactions at the injection site:
i) redness (Diggle 2000a; Diggle 2006; Pathak 2007;
Nirupam 2008);
ii) swelling (Diggle 2000a; Diggle 2006; Pathak 2007;
Nirupam 2008);
iii) tenderness (Diggle 2000a; Diggle 2006; Pathak 2007;
Nirupam 2008);
iv) hardness (Diggle 2006).
5. common systemic reactions:
i) fever (Diggle 2006; Pathak 2007; Nirupam 2008);
ii) irritability (Nirupam 2008);
iii) eating less than usual/refusal to feed (Diggle 2006;
Nirupam 2008);
iv) sleepier than usual/drowsiness (Diggle 2006; Nirupam
2008).
6. other local, systemic, or allergic adverse events following
vaccine administration:
i) restricted movement (Pathak 2007);
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ii) vomiting (Diggle 2006; Nirupam 2008);
iii) use of analgesics (Diggle 2006; Pathak 2007);
iv) needle contact with bone Diggle 2006);
v) seizures (Nirupam 2008).
Three trials reported composite reactogenicity outcomes:
1. any local reaction (any redness, swelling, or tenderness)
after vaccination (Diggle 2000a);
2. any local reaction (any redness, swelling, hardness, or
tenderness) after vaccination (Diggle 2006);
3. any local reaction (any redness, swelling, tenderness, or
restricted movement) after vaccination (Pathak 2007).
Excluded studies
Of the 34 excluded full-text articles, seven articles reported the
results of studies comparing groups that had been vaccinated with
needles of different sizes on the rates of local and systemic reactions
(Ipp 1989; Cook 2005; Jackson 2008; Fateh 2014), or the immune
response (Shaw 1989; Johnsen 1995; Ozdemir 2012). Details of
these studies are provided in the Characteristics of excluded studies
table. Briefly, we excluded four of the studies because the partici-
pants were either not randomised to the comparison groups or in-
sufficient details were available about the precise method of alloca-
tion to study groups and insufficient outcome data were available
(Ipp 1989; Johnsen 1995; Jackson 2008; Ozdemir 2012). The re-
maining three studies were RCTs; we excluded one because the trial
participants were not children or adolescents (Shaw 1989), one
because the injection techniques used in the comparison groups
were different (Cook 2005), and one because different types of
syringe were used to administer the vaccine to participants in the
comparison groups (Fateh 2014).
We excluded the remaining 27 full-text articles for various reasons,
including that the article:
1. was a narrative review, an editorial, or opinion piece;
2. was a summary of, or commentary on, one of the trials that
met the selection criteria;
3. described a trial where there was no comparison of needle
size when administering vaccines;
4. described a trial where the injections administered were not
vaccinations;
5. described a trial comparing hypodermic needle versus jet
injector.
Risk of bias in included studies
We did not conduct formal assessments of interrater reliability be-
tween review authors for each domain in the Cochrane ’Risk of
bias’ tool. The three review authors (PB, SH, SC) were in complete
agreement for the domains of random sequence generation (selec-
tion bias) and allocation concealment (selection bias). Judgements
about all other domains, in particular regarding the risks of perfor-
mance bias and detection bias, were reached through discussion
and consensus. We have summarised the salient aspects of these
discussions in the relevant sections below. Figure 2 summarises
our decisions regarding the risk of bias for all included trials. The
empty fields in Figure 2 pertaining to detection bias and attrition
bias for specific outcomes indicate that these outcomes were not
measured in trials.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. Blank cells in the table indicate outcomes that were not measured in studies.
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Allocation
Random sequence generation
All trials described a random component in the sequence gen-
eration process. Four trials used computer-generated randomisa-
tion schemes (Diggle 2000a; Diggle 2006; Pathak 2007; Nirupam
2008), and one trial used random number tables (Middleman
2010).
Allocation concealment
In four trials, we considered that participants and investigators en-
rolling participants could not have foreseen needle size allocations
in advance of, or during, enrolment due to the use of sequentially
numbered, sealed, opaque envelopes to conceal allocation (Diggle
2000a; Diggle 2006; Pathak 2007; Nirupam 2008). We judged
one trial that did not conceal allocation as at high risk of bias for
this domain (Middleman 2010).
Blinding
As specified in the review protocol (Beirne 2013), when reaching
judgements about the risk of bias due to lack of blinding or in-
complete blinding we considered the risk of material bias rather
than the risk of any bias. The Cochrane Handbook for Systematic
Reviews of Interventions defines material bias as “bias of sufficient
magnitude to have a notable impact on the results or conclusions
of the trial, recognizing that subjectivity is involved in any such
judgement” (our emphasis) (Higgins 2011a). Overall, we were
less concerned about the potential for material bias due to lack of
blinding of participants and personnel in trials (performance bias),
and more concerned about the potential for material bias due to
lack of blinding of outcome assessors, particularly for subjective
outcomes. We have explained the reasons for this below.
Performance bias (blinding of participants, their parents,
and trial personnel)
One trial did not blind participants (obese adolescents) (
Middleman 2010). In the remaining trials, the participants were
all infants, and we deemed blinding of their parents or guardians
to be adequate if any one of the following conditions were fulfilled:
1. parents or guardians were not present when the child was
vaccinated, and they were not informed by trial personnel of the
needle size used to administer the vaccine;
2. parents or guardians were present when the child was
vaccinated but they did not view the procedure and were not
informed by trial personnel of the needle size used to administer
the vaccine;
3. in trials or trial comparisons where the effect of needle
gauge only was being assessed (i.e. the needles being compared
were of the same length), parents or guardians were present and
viewed the procedure, but the needle hubs were not colour-
coded, and they were not informed by trial personnel of the
gauge of needle used to administer the vaccine.
No trials completely fulfilled these conditions. In two trials, par-
ents or guardians were present and viewed the vaccination pro-
cedures (Diggle 2000a; Diggle 2006), with the exception of par-
ents known to be health professionals in the latter trial who were
specifically asked not to view the procedure. The needles were
colour-coded in both trials, but parents were not told by study
nurses which needle size was being used or how the different-
coloured hubs of the needles related to needle size. In the remain-
ing trials, parents or guardians were present during the vaccination
procedure, and the needle hubs were colour-coded (Pathak 2007;
Nirupam 2008). We therefore judged blinding of parents to be
either inadequate or incomplete in all trials.
Blinding of the personnel administering the vaccinations to trial
participants was not possible in the three trials that compared nee-
dles of different lengths (Diggle 2000a; Diggle 2006; Middleman
2010), as these differences would have been obvious to trial person-
nel experienced in performing vaccination procedures. In the three
trials that compared the effects of needles with the same lengths
but different gauges (Diggle 2006; Pathak 2007; Nirupam 2008),
the needle hubs were colour-coded, therefore the trial personnel
administering the vaccines were not blinded to needle gauge.
As recommended in Section 8.11.2 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a), when consid-
ering the risk of performance bias arising from lack of blinding
or incomplete blinding of participants and personnel, it is im-
portant to consider the “risk of bias in actual outcomes due to
lack of blinding during the study (e.g. due to co-intervention or
differential behaviour).” In this context, we had to consider the
likelihood that knowledge of needle size would have resulted in
trial personnel or parents differentially providing care or co-inter-
ventions to participants in the comparison groups and the like-
lihood that this would impact on immunogenicity and reacto-
genicity outcomes. We judged that such performance bias was un-
likely to have occurred for the following reasons. First, standard-
ised injection procedures were used by the trial personnel in all
trials, and the same injection procedures were reportedly used in
the comparison arms of the trials (see Characteristics of included
studies table). We considered it unlikely that knowledge of nee-
dle size would have resulted in trial personnel deviating from the
standardised injection technique or otherwise behaving in a man-
ner that could produce systematic differences between comparison
groups in terms of the care provided or in exposure to factors other
than the interventions of interest. We also deemed it unlikely that
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parental or guardian knowledge of needle size would have resulted
in systematic differences between study groups in terms of the care
provided to infants either during or following the vaccination pro-
cedure that would have materially influenced reactogenicity and
immunogenicity outcomes. We therefore assessed all trials as being
at low risk of performance bias. We acknowledge the subjectivity
inherent in this judgement.
Detection bias (blinding of outcome assessors)
In assessing the risk of bias from lack of blinding of outcome as-
sessment, we considered who was assessing the outcome and the
objectivity and subjectivity of the immunogenicity and reacto-
genicity outcomes.
Immunogenicity outcomes
Two trials reported immunogenicity outcomes (Diggle 2006;
Middleman 2010). In both trials, outcomes were assessed via as-
says of serum antibody concentrations performed by laboratory
staff who were unaware of the needle size group from which the
serum sample originated. We therefore judged that there was a low
risk of detection bias.
Reactogenicity outcomes
Four trials reported reactogenicity outcomes (Diggle 2000a;
Diggle 2006; Pathak 2007; Nirupam 2008).
Pain was assessed in only one trial using both a Modified Be-
havioural Pain Scale (MBPS) and a visual analogue scale (VAS)
(Pathak 2007). A researcher (nurse) viewed video clips of the vac-
cination procedure to assess infant pain response using the MBPS.
As the needle hubs were colour-coded and may have been visible
on the video recordings, we considered that the researcher was not
blinded. Two separate postvaccination pain assessments using the
VAS were conducted by a researcher and by parents or guardians.
The trial authors reported that the researcher was blinded. We
judged that blinding of parents was incomplete due to the colour-
coding of the needle hubs and parental presence during the vacci-
nation procedure. Overall, we considered the potential for detec-
tion bias for the pain outcomes reported in this trial to be uncer-
tain, and therefore judged this domain as at unclear risk of bias.
In the same trial, a researcher assessed crying time from digital
camera recordings. Although the researcher was reportedly blinded
to needle size, the colour-coded needle hubs may have been vis-
ible on the digital recordings, and we considered blinding to be
incomplete. Nevertheless, we judged that procedural crying was a
more objective outcome than pain and that assessment of crying
time was unlikely to be influenced by incomplete blinding, and
therefore considered there to be a low risk of detection bias for this
outcome. We reached a similar judgement with regard to the two
trials that reported persistent inconsolable crying (Diggle 2006;
Nirupam 2008), as we considered that outcome assessment was
unlikely to be influenced by knowledge of needle size.
The remaining reactogenicity outcomes in all trials (redness, ten-
derness, swelling, irritability, etc.) were assessed by the parents of
trial participants. We deemed blinding of parents as inadequate
or incomplete in all trials (see the above section on performance
bias), and there was considerable debate within the review team
about the potential for material bias arising from parental assess-
ment of subjective reactogenicity outcomes. Some members of the
review team noted that efforts were made in some trials to ensure
that parents were ’as blind as possible’ (e.g. in trials where par-
ents were not informed how the different-coloured hubs of the
needles related to needle size). Furthermore, they suggested that
knowledge of needle size allocation would be unlikely to influence
parental assessment of outcomes such as redness, particularly in
trials where a ruler was used to measure the diameter of any red-
ness, as this would have reduced the level of subjectivity inherent
in the assessment. Some review authors argued on these grounds
that a low risk of bias could be assigned in relation to the assess-
ment of some subjective reactogenicity outcomes. Other review
authors disagreed and suggested that complete blinding of out-
come assessors for all subjective outcomes should be ensured to
justify assigning a low risk of bias. These review authors also noted
that most of the trials included in the review reported binary sub-
jective outcomes (i.e. outcome present or absent), and that there
is empirical evidence from meta-epidemiological studies illustrat-
ing that randomised trials with non-blinded assessment of such
outcomes generate substantially biased estimates of treatment ef-
fects (Hróbjartsson 2012). There is also empirical evidence that
the failure to blind outcome assessors in randomised trials with
subjective measurement scale outcomes results in a high risk of
substantial bias (Hróbjartsson 2013). We ultimately considered
that this debate within the review team reflected uncertainty over
the potential for bias and agreed to assign an unclear risk of bias
in the detection bias domain for all subjective reactogenicity out-
comes assessed by parents. This is in accordance with recommen-
dations in the Cochrane Handbook for Systematic Reviews of Inter-
ventions, whereby the unclear risk category indicates “either lack
of information or uncertainty over the potential for bias” (Higgins
2011a).
Incomplete outcome data
Details regarding any disparities between the numbers of partici-
pants randomised and analysed in each trial can be found in the
Characteristics of included studies tables. We assessed the risk of
attrition bias separately for immunogenicity and reactogenicity
outcomes.
Immunogenicity outcomes
In one trial, missing immunogenicity outcome data were balanced
in numbers across intervention groups with similar reasons for
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missing data across groups, therefore we assigned a judgement of
low risk of bias (Diggle 2006). In another trial, there was a notable
disparity between the numbers of participants randomised (65)
and the number analysed for immunogenicity (24) (Middleman
2010). Due to the magnitude of this disparity, we considered that
there was uncertainty over the potential for bias, even though the
missing outcome data were balanced in numbers across the two
needle size groups with similar reasons for missing data across
groups. We therefore judged there to be an unclear risk of attrition
bias in this trial.
Reactogenicity outcomes
We judged that there was a low risk of attrition bias in all four
trials that reported reactogenicity outcomes (Diggle 2000a; Diggle
2006; Pathak 2007; Nirupam 2008). In Pathak 2007, follow-
up for pain and crying outcomes was 100% complete, as these
outcomes were assessed at the time of vaccination. For the re-
maining postvaccination reactogenicity outcomes assessed in this
trial, data were missing for 35% of the randomised participants,
but the missing data were balanced in numbers across the needle
size groups and there were similar reasons for missing data across
groups (see the Characteristics of included studies table for this
trial). In Nirupam 2008, only one trial participant was lost to fol-
low-up. In Diggle 2000a, outcome data were missing for 8% of the
randomised participants, and the numbers and reasons for missing
data were balanced across groups. In Diggle 2006, reactogenicity
outcome data were missing after the first, second, and third doses
of the vaccine for 2%, 6%, and 10% of the randomised partici-
pants, respectively. Missing outcome data were balanced in num-
bers across groups. There were also similar reasons for missing data
across groups, with the exception of trial withdrawals due to severe
local reactions. During the trial, 11 infants experienced redness
and swelling covering more than two-thirds of the anterolateral
thigh, contraindicating receipt of further whole-cell pertussis-con-
taining vaccine and, therefore, necessitating withdrawal of these
infants from the trial. Ten of the infants were vaccinated using the
narrow, short (25 G 16 mm) needle, and one was vaccinated using
the wide, long (23 G 25 mm) needle. Although these infants were
withdrawn from the trial, we did not treat the data for these 11
infants as missing outcome data. We analysed and reported severe
local reactions separately from other reactogenicity outcomes in
the Effects of interventions section of the review.
With regard to all trials, we judged that missing outcome data were
likely to be missing at random (i.e. the fact that these data were
missing was probably unrelated to actual values of the missing
data). The rationale for this judgement for each trial is provided
in the ’Risk of bias’ tables (see Characteristics of included studies
table). In the review protocol, we specified that where missing out-
come data could reasonably be assumed to be missing at random,
we would conduct available-case analyses of the trial data. The re-
sults of these analyses are presented in the Effects of interventions
section of the review.
Selective reporting
We reached a judgement of unclear risk of bias for four trials be-
cause we did not examine the trial protocols and were therefore
unable to confirm whether the trial reports contained all expected
outcomes, including those that were prespecified (Diggle 2000a;
Pathak 2007; Nirupam 2008; Middleman 2010). We did not ex-
amine the protocol for the remaining trial (Diggle 2006), but we
were given access by the principal trial author to all relevant orig-
inal trial data. We were confident that we had access to the trial
results for all of the prespecified primary and secondary outcomes
that were of interest in our review. We therefore judged that there
was a low risk of reporting bias for this trial.
Other potential sources of bias
We considered that all trials appeared to be free of other potential
sources of bias. In one trial, there was a potential source of bias
related to imbalances in the ages of the trial participants who were
analysed in the two groups, which resulted in differences between
the groups in the dose of the vaccine administered (Middleman
2010). In this trial, participants aged less than 19 years received
a 0.5 mL dose of the vaccine, whereas older participants received
1.0 mL. In the 38 mm (1.5 inch) needle group, 36% (5/14) of the
participants included in the final analysis were aged less than 19
years compared with 20% (2/10) of the participants analysed in
the 25 mm (1 inch) needle group. Due to the small sample size in
the trial, this imbalance may have occurred by chance rather than
failure of randomisation. One would anticipate lower antibody
titres to be recorded in participants receiving the smaller dose of the
vaccine and, therefore, the imbalance between the groups may have
biased the estimate of intervention effect (the difference between
the median titre levels in the groups). In the trial report, individual
participant titres were reported for each trial participant, but it was
unclear which titres corresponded to the individuals who received
0.5 mL of the vaccine. We obtained these details from the principal
trial author and reanalysed the data excluding the individuals from
each group who received 0.5 mL of the vaccine. The trial results
were essentially the same (albeit with reduced power due to the
exclusions). We therefore considered that a judgement of low risk
of bias was appropriate for this domain.
Effects of interventions
See: Summary of findings for the main comparison Comparison
between needles with different lengths but with the same gauge;
Summary of findings 2 Comparison between needles with
different gauges but with the same length; Summary of findings 3
Comparison between needles with different lengths and different
gauges
28Needle size for vaccination procedures in children and adolescents (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Comparisons between needles with different
lengths and the same gauge
Two trials provided data for this comparison (Diggle 2006;
Middleman 2010). One of the trials compared 25 G 25 mm and
25 G 16 mm needles (Diggle 2006), and one trial compared 38
mm and 25 mm needles (Middleman 2010). We were unable to
ascertain the precise gauge of the needles used in the Middleman
2010 trial, but the principal trial author confirmed that the nee-
dles had the same gauge. In Diggle 2006, a DTwP-Hib vaccine
and a MenC* vaccine were concurrently administered into the
right (DTwP-Hib vaccine) and left (MenC) anterolateral thighs
of infants when they were aged two months (first vaccine dose),
three months (second dose), and four months (third dose) using
the WHO injection technique, with the needle inserted to its full
length up to the needle hub. In Middleman 2010, the first, second,
and third doses of a hepatitis B vaccine were administered into the
deltoid region of the upper arm of obese adolescents aged 14 to
24 years. The skin was stretched flat before needle insertion and
injections were given at a 90° angle to the deltoid muscle, leaving
2 to 3 mm of needle visible between the arm and the needle hub.
*Note: the MenC vaccination schedule used in the trial is no longer
recommended. This is discussed in the Overall completeness and
applicability of evidence section.
25 G 25 mm versus 25 G 16 mm needles - effects on vaccine
immunogenicity
Seroprotection rates
In Diggle 2006, all infants for whom outcome data were avail-
able reached antibody titre level thresholds of protection against
diphtheria in both the 25 mm (155/155) and 16 mm (157/157)
needle groups. Similarly, the seroprotection rates against tetanus
were 100% in both the 25 mm (199/199) and 16 mm (191/191)
groups. Seroprotection rates against Hib disease were 88% (182/
206) in the 25 mm group and 80% (156/194) in the 16 mm group
(risk difference (RD) 8%, 95% confidence interval (CI) 1% to
15%). Seroprotection rates against MenC were 99% (188/189) in
the 25 mm group and 100% (179/179) in the 16 mm group (RD
-1%, 95% CI -2% to 1%).
Based on an MID in seroprotection rates of 10%, we judged the
immune response to the diphtheria, tetanus, and meningitis C
vaccine antigen components to be equivalent in the two needle
size groups. The longer needle may result in a superior immune
response to the Hib component of the combined vaccine, but
the evidence is inconclusive, as the lower boundary of the CI
accompanying the effect estimate is compatible with little or no
difference between the needle size groups.
We judged the quality of evidence for seroprotection to be mod-
erate, downgrading by one level for indirectness due to the use of
substitute endpoints in lieu of patient-important outcomes. Al-
though these endpoints were reported from a single trial without
independent replication of results in additional trials, we did not
downgrade the quality of evidence for consistency unknown. As
described in the Data collection and analysis section, we consid-
ered the consistency of the results from the antibody threshold
analyses and the results (reported below) of the ratios of the anti-
body GMCs or GMTs between the needle size groups.
Geometric mean antibody concentrations and geometric
mean antibody titres
The ratios (25 mm versus 16 mm) of the GMC of diphtheria and
tetanus antibodies were 1.05 (95% CI 0.85 to 1.29) for diph-
theria and 0.97 (95% CI 0.81 to 1.17) for tetanus. The GMC
of Hib antibodies was higher in the longer needle group than in
the shorter needle group (ratio of GMCs: 1.35, 95% CI 1.02 to
1.79). The GMT of serogroup C meningococcal glycoconjugate
antibodies was also higher in the longer needle group than in the
shorter needle group, although the lower boundary of the CI did
not exclude the absence of any difference between the needle size
groups (ratio of GMTs 1.20, 95% CI 0.92 to 1.57).
38 mm versus 25 mm needles - effects on vaccine
immunogenicity
In Middleman 2010, seroprotection rates against hepatitis B were
93% (14/15) in the 38 mm group and 91% (10/11) in the 25
mm group (RD 2%, 95% CI -19% to 24%). Median antibody
titres to hepatitis B surface antigen were higher in the 38 mm
compared with the 25 mm group (345.4 mIU/mL (interquartile
range (IQR) 243 to 464.2) in the 38 mm group versus 189.8
mIU/mL (IQR 143.6 to 324.7) in the 25 mm group; P = 0.03).
The latter analysis did not include the two trial participants (one
in each needle size group) who failed to reach antibody titre level
thresholds of protection against hepatitis B.
We judged the quality of evidence for these immunogenicity out-
comes to be very low, downgrading by one level for indirectness
due to use of a substitute endpoint in lieu of patient-important
outcomes, one level for imprecision due to the width of the CIs
around effect estimates, and one level for risk of bias taking into
account the absence of allocation concealment and the disparity
between the numbers of participants randomised and analysed in
the trial.
25 G 25 mm versus 25 G 16 mm needles - effects on pain,
crying, and other reactogenicity events
Only one trial reported data on reactogenicity outcomes, therefore
the results presented below are derived from this trial (Diggle
2006).
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Pain
The trial did not measure vaccination-related procedural pain.
Crying
After any dose of the two vaccines administered in the trial, per-
sistent inconsolable crying lasting for four or more hours was re-
ported in 2.2% (5/224) of infants in the 25 mm group and 0.9%
(2/223) of infants in the 16 mm group (risk ratio (RR) 2.49, 95%
CI 0.49 to 12.7). As the event rates were low in the two needle
size groups, the wide CI for the relative effect translated to a small
difference in absolute effect (RD 1.3%, 95% CI -1% to 4%). We
judged the quality of evidence for persistent inconsolable crying to
be very low; our reasons for downgrading the quality of evidence
are summarised below.
There was a debate within the review team about the GRADE
rating for this outcome with regard to the criterion of impreci-
sion. Some review authors considered that the CI accompanying
the RD effect estimate excluded important benefit and important
harm and that downgrading evidence quality for imprecision was
not justified. Other review authors noted that a potential 4% ab-
solute difference (i.e. the upper limit of the CI) for a distressing
persistent crying event could potentially be deemed important to
parents of infants undergoing vaccination. We decided by a con-
sensus borderline decision to downgrade the evidence rating for
this outcome by one level for imprecision. We also downgraded
the quality of evidence by one level because the outcome was re-
ported in only one trial, thus precluding any evaluation of the
consistency or inconsistency of results across trials. In addition,
the definition of persistent inconsolable crying used in the Diggle
2006 trial (four or more hours’ duration) differed from the case
definition proposed by Bonhoeffer 2004 as specified in the pro-
tocol for our review (three or more hours’ duration). The impact
of using the latter case definition on the effect size reported in the
Diggle 2006 trial is unknown. In light of this uncertainty, we also
downgraded the quality of evidence by one level for indirectness.
Severe local reaction after DTwP-Hib vaccination
Ten infants vaccinated with the 25 G 16 mm needle experienced
redness and swelling covering more than two-thirds of the an-
terolateral thigh necessitating withdrawal from the trial and con-
traindicating further receipt of DTwP-Hib vaccine. Nine of these
infants had a severe local reaction after the first dose of the vac-
cine, and the remaining infant experienced the reaction after the
second dose. No infants vaccinated with the 25 G 25 mm needle
experienced a severe local reaction (RD after first dose -4%, 95%
CI -7% to -1%). Based on these data, one additional infant would
be prevented from experiencing a severe local reaction after the
first dose of DTwP-Hib vaccine for every 25 infants vaccinated
with the longer rather than the shorter needle (number needed to
treat for an additional beneficial outcome (NNTB) 25, 95% CI
15 to 100).
We rated the quality of evidence for this outcome as moderate,
downgrading by one level because the results were from a single
trial; we were thus unable to reach a judgement regarding the con-
sistency or inconsistency of results across trials. We did not down-
grade the evidence for risk of bias despite incomplete blinding of
outcome assessment in the trial. We considered that the extent
and clinical severity of these severe reactions reduced the level of
subjectivity in outcome assessment.
Severe local reaction after meningitis C vaccination
No infants in either needle size group experienced a severe local
reaction after MenC vaccination.
Non-severe local reactions (composite outcome) after DTwP-
Hib vaccination
The incidence of any local reaction (composite outcome: any red-
ness, swelling, tenderness, or hardness) on the day after vaccina-
tion was consistently lower in the 25 G 25 mm group compared
with the 25 G 16 mm group:
1. after first dose: 36% (25 mm) versus 56% (16 mm):
i) RD -20% (95% CI -29% to -11%);
ii) NNTB 5 (95% CI 4 to 10).
2. after second dose: 37% (25 mm) versus 55% (16 mm):
i) RD -18% (95% CI -28% to -9%);
ii) NNTB 6 (95% CI 4 to 12).
3. after third dose: 37% (25 mm) versus 57% (16 mm):
i) RD -20% (95% CI -29% to -11%);
ii) NNTB 5 (95% CI 4 to 10).
We rated the quality of evidence to be moderate for these com-
posite outcomes, downgrading for risk of bias due to incomplete
blinding of outcome assessment and the resultant uncertainty over
the potential for bias. Although these results were from a single
trial, we did not downgrade the quality of evidence for this rea-
son. This decision took into account the consistency of the effect
estimates after each dose of the vaccine.
Non-severe local reactions (composite outcome) after
meningitis C vaccination
Data on the incidence of any local reaction (composite outcome:
any swelling, tenderness, redness, or hardness) were not available at
24 hours (day one). We have therefore presented below summary
effects across all time points measured in the trial.
After the first dose of the MenC vaccine, the incidence of any local
reaction was lower in the 25 mm group (41%) compared with
the 16 mm group (51%), although the upper boundary of the
CI accompanying the RD effect estimate was compatible with no
difference between the groups (RD -10%, 95% CI -19% to 0%).
The CIs accompanying the effect estimates after the second and
third doses of the vaccine were compatible with both reductions
and increases in the rates of local reactions after vaccination with
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the 25 mm compared with the 16 mm needle (second dose: RD
5%, 95% CI -5% to 14%; third dose: RD -2%, 95% CI -12%
to 7%). The MenC vaccine was less reactogenic than the DTwP-
Hib vaccine, which was reflected in the lower event rates for local
reactions in the needle size groups after each dose of the MenC
vaccine compared with the event rates after each dose of the DTwP-
Hib vaccine. For example, the incidence of any local reaction across
all time points in the 25 mm group after the first dose of the
DTwP-Hib vaccine was 62% compared with 41% after the first
dose of the MenC vaccine.
Fever, other systemic reactions, and use of paracetamol after
vaccination
The incidence of postvaccination fever at any time point after
concurrent administration of any dose of DTwP-Hib and MenC
vaccines was higher in infants vaccinated using the 25 mm (26%)
compared with the 16 mm (18%) needle, although the lower
boundary of the CI accompanying the effect estimate was com-
patible with no difference between the groups (RD 8%, 95% CI
0% to 16%).
There were no statistically significant differences in the incidence
of all other systemic outcomes between the needle length groups.
The RD effect estimates (25 mm versus 16 mm) were: -1% (95%
CI -9% to 7%) for paracetamol use; -3% (95% CI -10% to 4%)
for sleepier than usual; -1% (95% CI -9% to 6%) for vomiting
more than three times in 24 hours; and 0% (95% CI -9% to 9%)
for eating less than usual.
We assigned a very low quality of evidence rating for these out-
comes. We downgraded for imprecision, taking into account the
width of the CIs around the effect estimates; by one level for risk
of bias due to incomplete blinding of outcome assessment and
the resultant uncertainty over the potential for bias; and by one
level because these outcomes were reported in a single trial, thus
precluding any evaluation of the consistency or inconsistency of
results across trials.
Individual non-severe local reactions (swelling, tenderness,
redness, and hardness) after DTwP-Hib vaccination
The incidence of each individual local reaction on the day after
administration of the first dose of the vaccine was lower in infants
vaccinated with the 25 mm needle compared with the 16 mm
needle. Calculations of the NNTB indicated that the expected
number of infants who would need to be vaccinated with the
25 mm rather than the 16 mm needle in order to prevent an
additional local reaction at 24 hours were 13 (95% CI 7 to 100)
for swelling; 12 (95% CI 7 to 50) for tenderness; 13 (95% CI
7 to 100) for redness; and 7 (95% CI 4 to 13) for hardness.
After the second and third doses of the vaccine, the incidence
of redness, swelling, and hardness was also significantly lower in
infants vaccinated with the longer needle. The CIs accompanying
the RD point estimates for tenderness were compatible with both
reductions and small increases in incidence following vaccination
with the 25 mm compared with the 16 mm needle (after second
dose RD -4%, 95% CI -10% to 2%; after third dose RD -4%,
95% CI -11% to 3%).
Individual non-severe local reactions (swelling, tenderness,
redness, and hardness) after meningitis C vaccination
There were no statistically significant differences in the incidence
of each individual local reaction outcome between the needle size
groups on the day after vaccination with each dose of the MenC
vaccine. The RD effect estimates (25 mm versus 16 mm) ranged
from -6% (95% CI -13% to 1%) for redness after the third dose
of the vaccine to 1% (95% CI -4% to 6%) for tenderness after the
second dose.
Needle overpenetration (needle contacting bone)
The precise number of events in each needle size group was not
recorded. Diggle 2006 reported that approximately 4000 injec-
tions were administered during the trial and that each of the three
nurses who performed the vaccination procedures reported hitting
bone “less than five times in total.”
Serious adverse events after vaccination
Only one infant in the 25 G 25 mm group experienced a systemic
reaction requiring overnight hospital admission after the second
dose of concurrent DTwP-Hib and MenC vaccination. No other
infants participating in the trial were reported as having experi-
enced a serious adverse event.
2. Comparisons between needles with different
gauges and the same length
Comparison 2a: 25 G 25 mm versus 23 G 25 mm needles
Two trials provided data for this comparison (Diggle 2006; Pathak
2007). In both trials, 25 G 25 mm and 23 G 25 mm needles
were used to administer vaccines to infants using the WHO in-
jection technique. In Pathak 2007, the first, second, or third dose
of a combination vaccine with a whole-cell pertussis component
(DTwP or DTwP-Hib or DTwP-Hib-Hep B vaccine) was admin-
istered into the anterolateral thigh of infants aged approximately
one to six months. The vaccines administered in Diggle 2006 are
described under Comparison 1 (above).
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25 G (narrow-gauge) versus 23 G (wide-gauge) needles -
effect on vaccine immunogenicity
Pathak 2007 did not measure immunogenicity outcomes, there-
fore the results presented below are derived from the Diggle 2006
trial.
Seroprotection rates
All infants for whom outcome data were available reached antibody
titre level thresholds of protection against diphtheria in both the
25 G (157/157) and 23 G (154/154) needle groups. Similarly,
the seroprotection rates against tetanus were 100% in both the
25 G (199/199) and 23 G (203/203) groups. Seroprotection rates
against Hib disease were 88% (182/206) in the 25 G group and
85% (178/208) in the 23 G group (RD 3%, 95% CI -4% to 9%).
Seroprotection rates against MenC were 99% (188/189) in the 25
G group and 100% (196/196) in the 23 G group (RD -1%, 95%
CI -2% to 1%).
Based on an MID in seroprotection rates of 10%, we judged the
immune response to all four vaccine antigen components (diph-
theria, tetanus, Hib, and MenC) to be equivalent in the two needle
gauge groups.
We judged the quality of evidence for seroprotection to be mod-
erate, downgrading by one level for indirectness due to the use of
substitute endpoints in lieu of patient-important outcomes.
Geometric mean antibody concentrations and geometric
mean antibody titres
The ratio (25 G versus 23 G) of the GMCs of diphtheria antibodies
was 0.93 (95% CI 0.76 to 1.14) and of tetanus antibodies was
0.96 (95% CI 0.80 to 1.15). The GMC of Hib antibodies was
higher in the 25 G than in the 23 G group, but the lower limit
of the CI accompanying the effect estimate did not exclude the
absence of any difference between the groups (ratio of GMCs 1.29,
95% CI 0.98 to 1.69). The ratio of the GMT of serogroup C
meningococcal glycoconjugate antibodies was 0.93 (95% CI 0.72
to 1.2).
25 G (narrow-gauge) versus 23 G (wide-gauge) needles -
effects on pain, crying, and other reactogenicity events
Pain
Only one trial reported pain outcomes (Pathak 2007). The group
of infants vaccinated with the 25 G (narrow-gauge) needle had
higher mean net pain scores on an MBPS than the group vacci-
nated with the 23 G (wide-gauge) needle (6.6, standard deviation
(SD) 1.5 with 25 G needle versus 5.9, SD 1.3 with 23 G needle;
mean difference (MD) 0.70, 95% CI 0.39 to 1.01). Mean pain
scores were also higher in the 25 G group compared with the 23 G
group when pain was assessed by a researcher using a 100-millime-
tre VAS (67.2, SD 17.5 with 25 G needle versus 59.9, SD 16 with
23 G needle; MD 7.30, 95% CI 3.63 to 10.97). However, mean
pain scores were similar in the two groups when pain was assessed
by the mothers or guardians of infants using the VAS (52.2, SD
24.8 with 25 G needle versus 50.6, SD 26.3 with 23 G needle;
MD 1.60, 95% CI -4.0 to 7.2).
Based on an MID of 1 point on the 10-point MBPS scale (or
its equivalent on other scales, i.e. a 10-millimetre difference on a
100-millimetre VAS), all reported differences between the groups
in this trial may be clinically unimportant.
We judged the quality of evidence to be low, downgrading by one
level due to uncertainty over the potential for detection bias and
by one level for inconsistency taking into account 1) the difference
between the results of the parental and researcher pain assessments
using the VAS; and 2) the reporting of vaccination-related proce-
dural pain in only one trial, thus precluding an assessment of the
consistency or inconsistency of results across trials.
Crying
Two trials reported crying outcomes that were measured in dif-
ferent ways. Pathak 2007 measured procedural crying (i.e. cry-
ing during and immediately after the vaccination procedure), and
Diggle 2006 measured persistent inconsolable crying lasting for
four or more hours at any time point after vaccination. We rated
the quality of evidence separately for each outcome, as we did not
consider that an overall rating for crying was warranted given the
disparities in the outcome definitions.
In Pathak 2007, the group of infants vaccinated with the 25 G
(narrow-gauge) needle had a longer mean crying time than the
group vaccinated with the 23 G (wide-gauge) needle (45.4 sec-
onds, SD 27 with 25 G needle versus 37.4 seconds, SD 19.3 with
23 G needle; MD 8, 95% CI 2.86 to 13.14). The risk of an in-
fant still crying at 30, 60, and 90 seconds postvaccination was
also higher in the 25 G group than in the 23 G group (RR 1.43,
95% CI 1.18 to 1.73 at 30 seconds; RR 1.34, 95% CI 0.84 to
2.14 at 60 seconds; RR 30.62, 95% CI 1.85 to 507.37 at 90 sec-
onds). We judged the quality of evidence for “procedural crying”
to be moderate, downgrading by one level because the outcome
was reported in only one trial, thus precluding any evaluation of
the consistency or inconsistency of results across trials.
In Diggle 2006, after any dose of the two vaccines administered
in the trial, persistent inconsolable crying lasting for four or more
hours was reported in 2.2% (5/224) of infants in the 25 G group
and in 1.7% (4/235) of infants in the 23 G group (RD 0.5%,
95% CI -2% to 3%). We judged the quality of evidence for per-
sistent inconsolable crying to be very low. The rationale for our
judgement was identical to that described for this outcome under
Comparison 1 above.
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Severe local reaction after vaccination with a whole-cell
pertussis-containing combination vaccine
In Diggle 2006, after administration of the first dose of the vaccine,
no infants vaccinated with the 25 G 25 mm needle and only one
infant vaccinated with the 23 G 25 mm needle experienced redness
and swelling covering more than two-thirds of the anterolateral
thigh necessitating withdrawal from the trial (RD -0.4%, 95% CI
-2% to 1%). No infants in either needle gauge group experienced
a severe local reaction after the second and third doses of the
vaccine. In Pathak 2007, no infants in either needle gauge group
were reported to have experienced a severe local reaction.
We rated the quality of evidence to be high for this outcome. We
did not downgrade for imprecision, as there was only one event
in the Diggle 2006 trial, and hence the CI for the relative effect
translated to clinically small differences in absolute effects. We did
not downgrade the evidence for risk of bias despite incomplete
blinding of outcome assessment in the trials, as we considered that
the extent and clinical severity of these severe reactions reduced
the level of subjectivity in outcome assessment.
Severe local reaction after meningitis C vaccination
In Diggle 2006, no infants in either needle gauge group experi-
enced a severe local reaction after MenC vaccination.
Non-severe local reactions (composite outcome) after
vaccination with a whole-cell pertussis-containing
combination vaccine
Diggle 2006 and Pathak 2007 reported composite local reaction
outcomes postvaccination, but the components of the composite
differed between the trials. In Diggle 2006, any local reaction was
defined as any swelling, tenderness, redness, or hardness. In Pathak
2007, any local reaction was defined as any swelling, tenderness,
redness, or restriction of movement.
In Diggle 2006, the incidence of any local reaction on the day after
the first, second, and third doses of a DTwP-Hib vaccine was lower
in the group vaccinated with the narrower gauge needle, but the
CIs accompanying the RD effect estimates were compatible with
both reductions and increases in the incidence of local reactions
following vaccination with the 25 G needle compared with the 23
G needle (first dose: RD -3%, 95% CI -12% to 6%; second dose:
RD -5%, 95% CI -14% to 4%; third dose RD -7%, 95% CI -
16% to 2%).
In Pathak 2007, the incidence of any local reaction on the day
after vaccination was also lower in the group vaccinated with the
narrower gauge needle, but the effect estimate was accompanied
by a wide CI (RR 0.77, 95% CI 0.32 to 1.82). As restriction of
movement is not typically included as a component of composite
local reaction outcome measures in vaccine clinical trials, we used
the composite outcome reported in Diggle 2006 in Summary of
findings 2.
We judged the quality of evidence to be low for the composite
local reaction outcomes reported in Diggle 2006, downgrading
for risk of bias due to incomplete blinding of outcome assessment
and the resultant uncertainty over the potential for bias, and for
imprecision due to the width of the CIs accompanying the effect
estimates.
Non-severe local reactions (composite outcome) after
meningitis C vaccination
In Diggle 2006, data on the incidence of any local reaction (com-
posite outcome: any swelling, tenderness, redness, or hardness)
were not available at 24 hours (day one). We have therefore pre-
sented summary effects across all time points measured in the trial.
After each dose of the vaccine, the CIs accompanying the RD point
estimates were compatible with both reductions and increases in
the rates of local reactions following vaccination with the 25 G
needle compared with the 23 G needle (first dose: RD -6%, 95%
CI -15% to 3%; second dose: RD 4%, 95% CI -5% to 13%; third
dose: RD -5%, 95% CI -14% to 5%).
Fever, other systemic reactions, and use of paracetamol after
vaccination
Both trials reported the incidence of postvaccination fever (Diggle
2006; Pathak 2007). Summary effect data across all time points
were not available in Pathak 2007, therefore we have presented
the results for fever on day one after vaccination for this trial.
The direction of effect varied between the trials. In Diggle 2006,
fever incidence at any time point after any dose of the two vaccines
administered in the trial was higher in the group of infants vacci-
nated with the 25 G needle (26%) compared with the 23 G needle
(20%) (RD 6%, 95% CI -2% to 13%). By contrast, in Pathak
2007, fever incidence on the day after vaccination was lower in the
group vaccinated with the 25 G needle (62%) compared with the
23 G needle (78%) (RD -16%, 95% CI -34% to 1%). The CIs
accompanying the effect estimates in both trials did not rule out
the absence of any difference between the needle gauge groups.
The rates of fever were substantially higher in both needle size
groups in the Pathak 2007 trial than in the Diggle 2006 trial.
The reason for this disparity is unclear, but it may potentially
be due to differences in the definitions of fever used in the trials
(axillary temperature 38 °C or greater measured using a digital
thermometer in Diggle 2006; axillary temperature greater than
37.8 °C measured predominantly with a mercury thermometer in
Pathak 2007). The disparity may also be due to differences in the
vaccines administered in the trials, differences in the characteristics
of the study populations, and differences in the risk of bias between
the trials.
There were no statistically significant differences between the nee-
dle size groups in the incidence of all other systemic outcomes.
The RD effect estimates (25 G versus 23 G) were: -4% (95% CI
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-11% to 3%) in Diggle 2006 and -6% (95% CI -20% to 8%)
in Pathak 2007 for paracetamol use; -2% (95% CI -9% to 5%)
for sleepier than usual (Diggle 2006); -3% (95% CI -10% to 5%)
for vomiting more than three times in 24 hours (Diggle 2006);
and -6% (95% CI -15% to 3%) for eating less than usual (Diggle
2006).
We assigned a very low quality of evidence rating for these out-
comes. We downgraded for imprecision due to the width of the
CIs accompanying the effect estimates for some outcomes and for
inconsistency for the outcome of fever, taking into account the
variation in results between the trials and our inability to defini-
tively explain the reasons for this disparity. For outcomes reported
in a single trial, we downgraded by one level as we were unable
to evaluate the consistency or inconsistency of results across trials.
We also downgraded by one level for risk of bias due to incomplete
blinding of outcome assessment and the resultant uncertainty over
the potential for bias.
Individual non-severe local reactions (swelling, tenderness,
redness, hardness, restriction of movement) after vaccination
with a combination vaccine with a whole-cell pertussis
component
Both Diggle 2006 and Pathak 2007 reported on swelling, ten-
derness, and redness after vaccination. Diggle 2006 also reported
hardness at the injection site, and Pathak 2007 reported postvacci-
nation restriction of movement. There were no statistically signifi-
cant differences in the incidence of any of these reactions between
the 25 G and 23 G needle groups on the day after vaccination
with any dose of the vaccines administered in the trials. The RD
effect estimates (25 G versus 23 G) in the Diggle 2006 trial ranged
from -7% (95% CI -16% to 1%) for hardness after the third dose
of the vaccine to 2% (95% CI -3% to 8%) for swelling after the
first vaccine dose. In Pathak 2007, the RD effect estimates ranged
from -13% (95% CI -29% to 3%) for tenderness to -5% (95%
CI -17% to 7%) for redness.
Individual non-severe local reactions (swelling, tenderness,
redness, and hardness) after meningitis C vaccination
In Diggle 2006, there were no statistically significant differences
in the incidence of each local reaction between the 25 G and 23
G needle groups on the day after vaccination with each dose of
the MenC vaccine. The RD effect estimates (25 G versus 23 G)
ranged from -7% (95% CI -14% to 0%) for redness after the third
dose of the vaccine to 4% (0% to 7%) for swelling after the second
dose of the vaccine.
Needle overpenetration (needle contacting bone)
Diggle 2006 did not report the precise number of events in each
needle size group (see entry under this heading in Comparison 1
for additional details). Needle contact with bone was not recorded
in Pathak 2007.
Serious adverse events after vaccination
In Diggle 2006, only one infant in the 25 G group experienced
a systemic reaction requiring overnight hospital admission after
the second dose of concurrent DTwP-Hib and MenC vaccination.
No other infants in the Diggle 2006 or Pathak 2007 trials were
reported as having experienced a severe adverse event.
Comparison 2b: 24 G versus 23 G; 24 G versus 22 G; 23 G
versus 22 G needles
Only one trial compared the effects of 24 G 25 mm, 23 G 25
mm, and 22 G 25 mm needles (Nirupam 2008). In this trial, the
first dose of a DTwP vaccine and the first dose of a Hep B vaccine
were administered concurrently into the left (DTwP vaccine) and
right (Hep B vaccine) anterolateral thighs of infants aged six to 10
weeks using the WHO injection technique. We did not complete
’Summary of findings’ tables for the comparisons between 24 G,
23 G, and 22 G needles, and have not provided in the sections
below our rating of the quality of evidence for each individual out-
come reported in the trial for each comparison. Overall, we judged
the quality of the evidence to be very low for the reactogenicity
outcomes reported in the trial. Event rates were low in the trial for
several outcomes, and there were only 50 participants in each of
the three needle size groups, hence there were wide CIs accompa-
nying many of the effect measures necessitating downgrading ev-
idence quality for imprecision. We also downgraded the evidence
quality for incomplete blinding of outcome assessment and the
resultant uncertainty over the potential for bias. In addition, we
downgraded for ’consistency unknown’, as all outcomes for these
comparisons were reported in only a single trial, thus precluding
any evaluation of the consistency of results across trials. We have
presented the number of events that occurred in each needle size
group or the event rates in each group for all of the reactogenicity
outcomes reported in this trial. We have not presented effect sizes
for the differences between the groups.
Immunogenicity and pain
The trial did not measure or report immunogenicity outcomes
and vaccination-related procedural pain.
Crying
Only one infant in the 22 G group experienced persistent incon-
solable crying for more than three hours postvaccination. Persis-
tent inconsolable crying was not reported in any infants in the 24
G and 23 G groups.
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Severe local reaction after vaccination
No infants in any of the needle gauge groups were reported as
having experienced severe local reactions (redness and swelling
covering more than two-thirds of the anterolateral thigh) after
vaccination.
Fever, other systemic reactions, and use of paracetamol after
vaccination
The incidence of postvaccination fever at any time point after
concurrent vaccination with the DTwP and Hep B vaccines in
the 24 G group was 24% (12/50), in the 23 G group 24.5%
(12/49), and in the 22 G group 30% (15/50). Other systemic
reactions were infrequently reported in the needle gauge groups.
No infants in the 24 G and 22 G groups and only one infant in the
23 G group experienced vomiting postvaccination. Drowsiness
postvaccination was reported in only one infant in the 24 G group
and in no infants in the 23 G and 22 G groups. Refusal to feed was
reported in one infant in the 22 G and 23 G groups and no infants
in the 24 G group. Irritability was reported in two infants in the
22 G group and one infant in the 23 G and 24 G groups. The
incidence of postvaccination paracetamol use in the 24 G group
was 24% (12/50), the 23 G group 22.4% (11/49), and the 22 G
group 30% (15/50).
Non-severe local reactions after vaccination
The trial did not report composite local reaction outcomes. Indi-
vidual local reaction outcomes (swelling, tenderness, and redness)
were reported at six hours and on days one, two, and three after
vaccination with the DTwP (left thigh) and Hep B (right thigh)
vaccines. We have presented the results at day one postvaccination
below.
Swelling, tenderness, and redness after DTwP vaccination
The incidence of swelling on the day after vaccination in the 24
G group was 4% (2/50), the 23 G group 6.3% (8/49), and the
22 G group 14% (7/50). The incidence of tenderness on the day
after vaccination was also lower in the 24 G group (2%) compared
with the 23 G (6.1%) and 22 G (12%) groups. Redness on the
day after vaccination was infrequently reported in all needle gauge
groups (24 G (0%), 23 G (4%), 22 G (2%)).
Swelling, tenderness, and redness after hepatitis B
vaccination
The incidence of swelling on the day after vaccination in the 24
G group was 0% (0/50), the 23 G group 0% (0/49), and the 22
G group 4% (2/50). The incidence of tenderness on the day after
vaccination in the needle size groups was: 0% (24 G), 8.2% (23
G), and 8% (22 G). No redness was reported in any infant in any
of the needle gauge groups on the day after Hep B vaccination.
Serious adverse events after vaccination
Only one infant in the 22 G group experienced seizures requiring
hospital admission. No other serious adverse events were reported.
3. Comparison between needles with different
lengths and different gauges
Two trials provided data for this comparison (Diggle 2000a; Diggle
2006). Both trials compared 23 G 25 mm and 25 G 16 mm nee-
dles for administering vaccines using the WHO injection tech-
nique with the needle inserted to its full length up to the nee-
dle hub. In Diggle 2000a, the third dose of a DTwP-Hib vaccine
was administered into the anterolateral thigh of four-month-old
infants. The vaccines administered in Diggle 2006 are described
under Comparison 1 (above).
23 G 25 mm versus 25 G 16 mm needles - effects on vaccine
immunogenicity
Diggle 2000a did not measure immunogenicity outcomes, there-
fore the results presented below are derived from the Diggle 2006
trial. The numbers of infants in each needle size group for whom
immunogenicity data were available are described under Compar-
isons 1 and2 above.
Seroprotection rates
All infants for whom outcome data were available reached anti-
body titre level thresholds of protection (seroprotection) against
diphtheria, tetanus, and MenC in both the 23 G 25 mm and the
25 G 16 mm groups. Seroprotection rates against Hib disease were
85% (178/208) in the 23 G 25 mm group and 80% (156/194) in
the 25 G 16 mm group (RD 5%, 95% CI -2% to 13%).
Based on an MID in seroprotection rates of 10%, we judged the
immune response to the diphtheria, tetanus, and MenC vaccine
antigen components to be equivalent in the two needle size groups.
The longer needle may result in a superior immune response to
the Hib component of the combined vaccine, but the evidence is
inconclusive, as the lower boundary of the CI accompanying the
effect estimate is compatible with little or no difference between
the needle size groups.
We judged the quality of evidence for seroprotection to be mod-
erate, downgrading by one level for indirectness due to the use of
substitute endpoints in lieu of patient-important outcomes.
Geometric mean antibody concentrations and geometric
mean antibody titres
The ratios (23 G 25 mm versus 25 G 16 mm) of the GMCs
were: 1.13 (95% CI 0.91 to 1.40) for diphtheria antibodies; 1.01
(95% CI 0.84 to 1.22) for tetanus antibodies; and 1.05 (95%
CI 0.78 to 1.42) for Hib antibodies. The GMT of serogroup C
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meningococcal glycoconjugate antibodies was higher in the group
vaccinated with the 23 G 25 mm needle, but the lower limit of the
CI accompanying the effect estimate did not exclude the absence
of any difference between the needle size groups (ratio of GMTs
1.3, 95% CI 0.99 to 1.70).
23 G 25 mm versus 25 G 16 mm needles - effects on pain,
crying, and other reactogenicity events
Pain
Neither of the trials measured vaccination-related procedural pain
(Diggle 2000a; Diggle 2006).
Crying
Diggle 2000a did not measure crying. In Diggle 2006, after any
dose of the two vaccines administered in the trial, persistent in-
consolable crying lasting for four or more hours was reported in
1.7% (4/235) of infants in the 23 G 25 mm group and in 0.9%
(2/223) of infants in the 25 G 16 mm group (RR 1.9, 95% CI
0.35 to 10.26). As the event rates were low in the two needle size
groups, the wide CI for the relative effect translated to a small
difference in absolute effect (RD 0.8%, 95% CI -1% to 3%).
We judged the quality of evidence for persistent inconsolable cry-
ing to be very low. The rationale for our judgement is identical to
that described for this outcome under Comparison 1 above.
Severe local reaction after DTwP-Hib vaccination
In Diggle 2000a, no infants in either needle size group experienced
a severe local reaction after the third dose of the vaccine.
In Diggle 2006, 10 infants who were vaccinated with the 25 G
16 mm needle experienced redness and swelling covering more
than two-thirds of the anterolateral thigh necessitating withdrawal
from the trial and contraindicating further receipt of DTwP-Hib
vaccine. Nine of these infants had a severe reaction after the first
dose of the vaccine, and the remaining infant experienced the
reaction after the second dose. Only one infant vaccinated with
the 23 G 25 mm needle had a severe local reaction, which occurred
after the first dose of the vaccine (RD after first dose: -4%, 95% CI
-6% to -1%). Based on these data, one additional infant would be
prevented from experiencing a severe local reaction after the first
dose of a DTwP-Hib vaccine for every 25 infants vaccinated with
the 23 G 25 mm rather than the 25 G 16 mm needle (NNTB 25,
95% CI 17 to 100).
We rated the quality of evidence for this outcome to be moderate.
All of the severe reactions occurred in the Diggle 2006 trial, and
all but one of these reactions occurred after the first dose of the
vaccine. Severe local reactions may be more likely to occur after
the first vaccine dose, and this dose was not administered in the
Diggle 2000a trial, therefore we were unable to reach a judgement
regarding the consistency or inconsistency of results across trials
and downgraded the quality of evidence by one level on this basis.
We did not downgrade the quality of the evidence for risk of bias
despite incomplete blinding of outcome assessment in the trials.
We considered that the extent and clinical severity of these severe
reactions reduced the level of subjectivity in outcome assessment.
Severe local reaction after meningitis C vaccination
In Diggle 2006, no infants in either needle size group experienced
a severe local reaction after MenC vaccination.
Non-severe local reactions (composite outcome) after DTwP-
Hib vaccination
Diggle 2000a and Diggle 2006 reported composite local reaction
outcomes postvaccination, but the components of the composite
differed between the trials. In Diggle 2000a, any local reaction
was defined as any swelling, tenderness, or redness, whereas in
Diggle 2006, hardness was also included as a component of the
composite.
In Diggle 2000a, data were not available for the composite out-
come on the day after vaccination with the third dose of the vac-
cine. The incidence of any local reaction across all time points was
lower in the group vaccinated with the 23 G 25 mm needle (62%)
compared with the 25 G 16 mm group (84%) (RD -22%, 95%
CI -38% to -6%; NNTB 5, 95% CI 3 to 17).
In Diggle 2006, the incidence of any local reaction (any swelling,
tenderness, redness, or hardness) on the day after vaccination with
each dose of the vaccine was consistently lower in the 23 G 25
mm group compared with the 25 G 16 mm group:
1. after first dose: 39% (23 G 25 mm) versus 56% (25 G 16
mm):
i) RD -17% (95% CI -26% to -8%);
ii) NNTB 6 (95% CI 4 to 13).
2. after second dose: 41% (23 G 25 mm) versus 55% (25 G
16 mm):
i) RD -14% (95% CI -23% to -4%);
ii) NNTB 8 (95% CI 5 to 25).
3. after third dose: 44% (23 G 25 mm) versus 57% (25 G 16
mm):
i) RD -13% (95% CI -22% to -3%);
ii) NNTB 8 (95% CI 5 to 34).
We rated the quality of evidence to be moderate for these com-
posite outcomes, downgrading for risk of bias due to incomplete
blinding of outcome assessment and the resultant uncertainty over
the potential for bias.
Non-severe local reactions (composite outcome) after
meningitis C vaccination
In Diggle 2006, data on the incidence of any local reaction (com-
posite outcome: any swelling, tenderness, redness, or hardness)
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were not available at 24 hours (day one). We have therefore pre-
sented summary effects across all time points measured in the trial.
After each dose of the MenC vaccine, the CIs accompanying the
RD point estimates were compatible with both reductions and
increases in the rates of local reactions following vaccination with
the 23 G 25 mm needle compared with the 25 G 16 mm needle
(first dose: RD -4%, 95% CI -13% to 5%; second dose: RD 1%,
95% CI -8% to 10%; third dose: RD 2%, 95% CI -7% to 12%).
Fever, other systemic reactions, and use of paracetamol after
vaccination
Diggle 2000a did not report these outcomes.
In Diggle 2006, the incidence of postvaccination fever at any time
point after concurrent administration of any dose of DTwP-Hib
and MenC vaccines was 20% in the 23 G 25 mm group compared
with 18% in the 25 G 16 mm group (RD 2%, 95% CI -5% to
10%).
There were no statistically significant differences between the nee-
dle size groups in the incidence of all other systemic outcomes.
The RD effect estimates (23 G 25 mm versus 25 G 16 mm) were:
2% (95% CI -5% to 9%) for paracetamol use; -1% (95% CI -
8% to 6%) for sleepier than usual; 1% (95% CI -6% to 8%) for
vomiting more than three times in 24 hours; and 6% (95% CI -
3% to 15%) for eating less than usual.
We assigned a very low quality of evidence rating for these out-
comes. The rationale for our judgement is identical to that de-
scribed for these outcomes under Comparison 1 above.
Individual non-severe local reactions (swelling, tenderness,
redness, and hardness) after the first and second doses of a
DTwP-Hib vaccine
In Diggle 2006, the incidence of each individual local reaction
on the day after administration of the first dose of the vaccine
was lower in infants vaccinated with the 23 G 25 mm needle
compared with the 25 G 16 mm needle. Calculations of the NNTB
indicate that the expected number of infants who would need to
be vaccinated with the 23 G 25 mm rather than the 25 G 16
mm needle in order to prevent an additional postvaccination local
reaction at 24 hours were 10 (95% CI 6 to 25) for swelling; 12
(95% CI 7 to 50) for tenderness; 12 (95% CI 6 to 50) for redness;
and 8 (95% CI 5 to 20) for hardness.
Similar results for redness and hardness were observed after the
second dose of the vaccine. The CIs accompanying the effect es-
timates for swelling and tenderness after the second vaccine dose
were compatible with both reductions and increases in the rates of
these reactions following vaccination with the 23 G 25 mm needle
compared with the 25 G 16 mm needle (RD -5%, 95% CI -12%
to 2% for swelling; RD 1%, 95% CI -5% to 8% for tenderness).
Swelling, tenderness, redness, and hardness after the third
dose of a DTwP-Hib vaccine
Diggle 2000a and Diggle 2006 reported on swelling, redness, and
tenderness at six hours and on days one, two, and three after
the third dose of a DTwP-Hib vaccine. We performed a meta-
analysis (random effects) of the trial data for each outcome at day
one postvaccination. Vaccination with a 23 G 25 mm needle was
associated with a reduced incidence of swelling (RR 0.58, 95% CI
0.36 to 0.93; I2 = 54%), tenderness (RR 0.63, 95% CI 0.40 to
1.00; I2 = 0%), and redness (RR 0.61, 95% CI 0.36 to 1.01; I2 =
73%) on the day after vaccination compared with the use of a 25
G 16 mm needle. The upper limits of the CIs accompanying the
effect estimates for tenderness and redness were compatible with
no difference between the groups (Analysis 1.1; see Figure 3). As
specified in the review protocol (Beirne 2013), we repeated meta-
analyses using a fixed-effect model. The effect estimates obtained
were similar, although the CIs were narrower (see Appendix 7).
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Figure 3. Forest plot of comparison: 3 Comparisons between needles with different lengths and different
gauges, outcome: 3.1 Individual local reactions: swelling, tenderness, and redness on the day after vaccination
with the third dose of a DTwP-Hib vaccine.
Diggle 2000a did not report hardness at the injection site after
vaccination. In Diggle 2006, the incidence of hardness on the
day after vaccination was lower in the group vaccinated with the
23 G 25 mm needle (28%) compared with the 25 G 16 mm
needle (37%) (RR 0.76, 95% CI 0.57 to 1.00). The upper limit
of the CI accompanying the effect estimate was compatible with
no difference between the groups.
Swelling, tenderness, redness, and hardness after meningitis
C vaccination
In Diggle 2006, there were no statistically significant differences in
the incidence of each individual local reaction outcome between
the needle size groups on the day after vaccination with each dose
of the MenC vaccine. The RD effect estimates (23 G 25 mm
versus 25 G 16 mm) ranged from -4% (95% CI -9% to 1%) for
hardness after the second dose of the vaccine to 3% (95% CI -3%
to 9%) for redness after the second dose of the vaccine.
Needle overpenetration (needle contacting bone)
Diggle 2006 did not report the precise number of events in each
needle size group (see entry under this heading in Comparison 1
for additional details). Diggle 2000a did not report needle contact
with bone.
Serious adverse events after vaccination
In Diggle 2000a and Diggle 2006, no infants in either the 23
G 25 mm or the 25 G 16 mm group were reported as having
experienced a serious adverse event.
Sensitivity analyses
Apart from repeating meta-analyses using fixed-effect and random-
effects models, we did not conduct any of the other sensitivity
analyses prespecified in our protocol due to the small number of
trials (two) included in the meta-analyses (see Differences between
protocol and review).
During the review process, we made several post hoc decisions
with regard to the analysis of data that could have influenced the
main findings of the review. For example, we made a post hoc de-
cision to analyse trial data pertaining to local reactions at the 24-
hour time point, or the nearest approximation to this time point
(where these data were available from trials). We consider that the
time point selection was appropriate, and the rationale for this
decision is explained in the Unit of analysis issues section. Never-
theless, as local reaction outcomes were reported at several separate
time points (six hours, day one, day two, day three) and across
all time points in some trials, we conducted sensitivity analyses to
investigate if our overall findings regarding the effects of needle
size on local reactions were robust to decisions about time point
selection. These sensitivity analyses are reported in Appendix 7.
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The results of the analyses, particularly for the comparisons be-
tween needles of different lengths (25 mm versus 16 mm), illus-
trate that although the magnitude of the intervention effect var-
ied depending on time point selection, the direction of effect was
entirely consistent for all analyses. Furthermore, the differences in
effect sizes at different time points were between small and large
beneficial effects in favour of the longer needle. Our overall in-
terpretation of the evidence (that 23 G 25 mm needles and 25 G
25 mm needles probably reduce the incidence of local reactions
compared with 25 G 16 mm needles) would therefore not have
materially altered according to time point selection.
We also made a post hoc decision about the selection of a value
for MID in seroprotection rates (10%) between groups, and have
explained the rationale for this decision in the Data collection and
analysis section. We performed a sensitivity analysis using an MID
of 5% (see Appendix 7), and our conclusions about the effects
of needle size on DTwP-Hib vaccine immunogenicity would not
have materially altered if we had used the lower MID value.
We also performed a sensitivity analysis to investigate if our inter-
pretation of the evidence pertaining to the effects of needle size
on the immune response to the Hib component of the vaccine
would have varied depending on the choice of cut-off threshold
level for seroprotection (1.0 µg/mL or greater versus 0.15 µg/mL
or greater). Our overall conclusions were robust to threshold se-
lection (see Appendix 7).
Finally, we made a post hoc decision to highlight in the ’Summary
of findings’ tables the results pertaining to the effects of needle
size on a composite local reaction outcome rather than on the in-
dividual components of the composite. We conducted sensitivity
analyses to investigate if there were disparities between the esti-
mates of intervention effect on the composite outcome and the
estimates of intervention effect on individual components of the
composite (see Appendix 7). The analyses indicate that there were
some variations in the magnitude of the intervention effect on
individual components of the composite for all of the main com-
parisons made in the review. However, the direction of effect was
generally consistent across individual components, particularly for
the comparisons between the 25 mm and 16 mm needles, and
this direction of effect was accurately reflected in the effect size
for the composite outcome. We consider that the results of this
analysis justify our decision to present the composite outcome in
the ’Summary of findings’ tables.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
25 G 25 mm needles compared with 23 G 25 mm needles for vaccination procedures
Patient or population: infants aged approximately 2 to 6 months undergoing vaccinat ion in the anterolateral thigh with a DTwP combinat ion vaccine
Intervention: 25 G 25 mm needles; inject ion technique - skin stretched f lat between thumb and foref inger and needle inserted at a 90° angle to skin (WHO inject ion technique)
and up to the needle hub in healthy infants
Comparison: 23 G 25 mm needles; inject ion technique - same as above
Outcomes (1 to 7) Probable outcome with
23 G 25 mm needles*
Probable outcome with






Quality of the evidence
(GRADE)
Comments
1. Incidence of diph-
theria, tetanus, pertus-
sis,Haemophilus influen-
zae type b (Hib) (not
measured)
- - - - - Not measured
2a. Adequate immune
response (seroprotec-
t ion) against diphtheria
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against tetanus
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against pertussis
(not measured)2












































































































fluenzae type b disease
(surrogate outcome)2









3. Pain: 0 to 10 on
MBPS 0 = no pain; 10 =
worst possible pain4
Mean net pain score 5.
9 points
Mean net pain score 0.
7 points higher (0.39






groups of less than 1




ately af ter the vaccina-
t ion procedure)
Mean crying t ime 37
seconds
Mean crying t ime 8 sec-


















5. Severe local react ion
11
Estimates not available, but risk very low; see
footnote 12




Only 1 severe local
react ion event was
recorded in the 23 G 25
mm group in 1 trial
6. Non-severe local re-
act ion13


















* The basis for the assumed risk (i.e. the probable outcome with 23 G 25 mm needles) and the corresponding risk (i.e. the probable outcome with 25 G 25 mm needles) is
provided in footnote 1
* *Due to bounding the upper lim it of the conf idence interval for the absolute ef fect does not match exact ly the upper lim it of the conf idence interval for the relat ive ef fect
CI: conf idence interval; DTwP vaccine: a combinat ion vaccine containing diphtheria, tetanus, and whole-cell pertussis vaccine ant igen components. The vaccine may be
combined with other ant igen components including Haemophilus influenzae type b (DTwP-Hib vaccine) and hepat it is B (DTwP-Hib-Hep B vaccine); MBPS: Modif ied Behavioural






































































































GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality:We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
Please see the Data collect ion and analysis sect ion of the review for comprehensive details regarding the methods we used
to assess the quality of evidence for outcomes included in ’Summary of f indings’ tables. See the Ef fects of intervent ions
sect ion for a full explanat ion of the rat ionale for our judgements regarding the quality of evidence for each outcome.
1Two trials contributed data to this comparison (Diggle 2006; Pathak 2007). The assumed and corresponding risks for the
immune response outcomes, persistent inconsolable crying, and non-severe local react ions are based on the event rates in
the needle size groups in the Diggle 2006 trial. The entries in the table for pain and procedural crying are based on the results
of the Pathak 2007 trial. The entries for severe local react ions and fever are based on the results f rom both trials.
In Diggle 2006, a DTwP-Hib vaccine and a meningit is C conjugate (MenC) vaccine were concurrent ly administered in the right
(DTwP-Hib) and lef t (MenC) anterolateral thighs of infants aged 2 months (f irst vaccine dose), 3 months (second dose), and
4 months (third dose). The MenC vaccine was administered in a schedule (t ime between vaccine doses) that is no longer
recommended, and the results pertaining to the ef fects of needle size on the immunogenicity and reactogenicity of this
vaccine are not presented in this ’Summary of f indings’ table or in the Abstract or Plain language summary for this Cochrane
Review (the results are, however, presented in the Ef fects of intervent ions sect ion).
In Pathak 2007, the f irst , second, or third dose of 1) a DTwP vaccine or 2) a DTwP-Hib vaccine or 3) a DTwP-Hib-Hep B vaccine
was administered to infants aged up to 6 months.
2The term ’seroprotect ion’ refers to ant ibody t it re levels above a predef ined threshold that correlates with protect ion f rom
disease (af ter complet ion of a series of 3 doses of a DTwP-Hib vaccine). The threshold levels used in this review were:
diphtheria ant itoxin levels ≥ 0.01 IU/ mL; tetanus ant itoxin levels ≥ 0.01 IU/ mL; and Hib ant ibody t it re levels ≥ 1.0 µg/ mL.
There is no well-established immune correlate or surrogate of protect ion against pertussis.
3We downgraded the quality of evidence by one level for indirectness due to the use of a subst itute (surrogate) seroprotect ion
endpoint in place of the pat ient-important outcome of interest. Although the seroprotect ion endpoints were reported in only
one trial, thus precluding an evaluat ion of the consistency or inconsistency of results across trials, we did not downgrade the
quality of evidence. We considered the consistency of the results of the seroprotect ion analyses reported in the trial and the
results of the analyses of the rat ios of the ant ibody/ ant itoxin geometric mean concentrat ions (GMCs) between the needle
gauge groups. The GMC rat ios (25 G versus 23 G) were: diphtheria: 0.93 (95% CI 0.76 to 1.14); tetanus: 0.96 (95% CI 0.80 to
1.15); and Hib: 1.29 (95% CI 0.98 to 1.69). (NOTE: a rat io > 1.0 indicates a higher ant ibody level (better immune response)
af ter vaccinat ion with the 25 G compared with the 23 G needle.)
4The net pain score on the MBPS = postvaccinat ion MBPS score minus prevaccinat ion (baseline) MBPS score. Pain was also
assessed in the trial using a visual analogue scale (see footnote 6). We have highlighted the MBPS pain score in the table
because this pain scale was init ially developed for use with infants during medical procedures such as vaccinat ions.








































































































6In the trial, pain was also assessed by a researcher and by parents using a visual analogue scale (VAS) (0 to 100, 0 = no
pain; 100 = worst possible pain). In the 25 G group the researcher-assessed mean pain scores were 7.3 points higher (3.6
higher to 11 higher), and the parental-assessed mean pain scores were 1.6 points higher (4 points lower to 7 points higher)
compared with the 23 G group. Dif ferences of less than 10 points on the 100-millimetre VAS may not be clinically important.
We downgraded the quality of evidence by one level for inconsistency taking into considerat ion the dif ference between the
results of the parental and researcher pain assessments using the VAS and the report ing of procedural pain in only one trial,
thus precluding any evaluat ion of the consistency or inconsistency of results across trials.
7We downgraded the quality of evidence by one level because this outcome was reported in only one trial, thus precluding any
evaluat ion of the consistency or inconsistency of results across trials.
8This term refers to a persistent inconsolable crying event last ing for ≥ 4 hours. The data presented in the table are based on
the results of a single included trial (Diggle 2006), and relate to persistent inconsolable crying recorded at any t ime point (6
hours, day 1, day 2, or day 3) af ter concurrent administrat ion of any dose (f irst , second, or third) of a DTwP-Hib vaccine and a
MenC vaccine.
9We downgraded the quality of evidence by one level for imprecision taking into account the width of the conf idence interval(s)
around the ef fect est imate(s).
10We downgraded the quality evidence by one level for indirectness as the def init ion of persistent inconsolable crying (≥ 4
hours’ durat ion) used in the trial that reported this outcome dif fered f rom the def init ion specif ied in the protocol for our review
(≥ 3 hours’ durat ion). The reported ef fect size in the trial may have dif fered if the latter def init ion had been used in the trial,
and we considered that this uncertainty merited downgrading the quality of evidence.
11’Severe local react ion’ refers to redness and swelling covering more than two-thirds of the anterolateral thigh.
12In Diggle 2006, only one severe local react ion occurred in the 23 G group (1/ 235) and 0 were reported in the 25 G group (0/
224). In Pathak 2007, no severe local react ions were reported in either the 23 G (0/ 47) or the 25 G group (0/ 53). As there
was only one severe local react ion event, our judgement about the quality of evidence was based on the absolute rather than
the relat ive ef fect. The high quality rat ing ref lects the fact that a severe local react ion did not occur in 558 out of the 559
part icipants analysed for reactogenicity in the needle groups in the two trials. Although blinding of outcome assessment was
incomplete, we did not downgrade the quality of evidence for risk of bias. We considered that the clinical severity of the
react ion reduced the level of subject ivity in outcome assessment.
13’Non-severe local react ion’ refers to any redness, swelling, tenderness, or hardness (i.e. a composite outcome) at the
inject ion site on the day af ter the f irst dose of a DTwP-Hib vaccine.
14Similar ef fect sizes were observed in Diggle 2006 af ter the second and third doses of the DTwP-Hib vaccine (second dose
RR 0.89, 95% CI 0.70, 1.12; third dose RR 0.84, 95% CI 0.66 to 1.06).
15We downgraded the quality of evidence by one level due to incomplete blinding of outcome assessment and the resultant
uncertainty over the potent ial for bias.
16Although this outcome was reported in only one trial, thus precluding an evaluat ion of the consistency or inconsistency of
results across trials, we did not downgrade the quality of evidence, taking into account the consistency of the ef fect sizes
af ter the f irst , second, and third doses of the DTwP-Hib vaccine (see footnote 14).
17We downgraded the quality of evidence for inconsistency taking into account the variat ion between the results of the two
trials and our inability to def init ively explain the reason(s) for this heterogeneity. In Diggle 2006, fever incidence was higher
in the group of infants vaccinated with the 25 G needle (26%) versus the 23 G needle (20%) (RR 1.28, 95% CI 0.91 to 1.79).






































































































versus the 23 G needle (78%) (RR 0.79, 95% CI 0.61 to 1.02). The conf idence intervals accompanying the ef fect est imates in
both trials did not rule out the absence of any dif ference between the needle size groups. The rates of fever were substant ially
higher in both needle gauge groups in Pathak 2007 compared with Diggle 2006. The reason for the dif ference between the
results of the two trials is unclear, but it may be due to dif ferences in the def init ions of fever used in the two trials, in study
populat ions, in the vaccines administered, or in the risk of bias between the trials. See footnote 1 for details of the vaccines









































































































23 G 25 mm needles compared with 25 G 16 mm needles for vaccination procedures
Patient or population: infants aged approximately 2 to 6 months undergoing vaccinat ion in the anterolateral thigh with a DTwP-Hib vaccine
Intervention: 23 G 25 mm needles; inject ion technique - skin stretched f lat between thumb and foref inger and needle inserted at a 90° angle to skin (WHO inject ion technique)
and up to the needle hub in healthy infants
Comparison: 25 G 16 mm needles; inject ion technique - same as above
Outcomes (1 to 7) Probable outcome with
25 G 16 mm needles*
Probable outcome with






Quality of the evidence
(GRADE)
Comments
1. Incidence of diph-
theria, tetanus, pertus-
sis,Haemophilus influen-
zae type b (Hib) (not
measured)
- - - - - Not measured
2a. Adequate immune
response (seroprotec-
t ion) against diphtheria
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against tetanus
(surrogate outcome)2
1000 per 1000 1000 per 1000










t ion) against pertussis
(not measured)2





















































































































fluenzae type b disease
(surrogate outcome)2
3. Pain (not measured) - - - - - Not measured
4a. Procedural crying
(during and immedi-
ately af ter the vacci-
nat ion procedure) (not
measured)
- - - - - Not measured
4b. Persistent incon-
solable crying4









5. Severe local react ion
8








NNTB* * * 25 (95%CI 17
to 100)
6. Non-severe local re-
act ion11








NNTB* * * * 6 (95% CI 4
to 13)









* The basis for the assumed risk (i.e. the probable outcome with 25 G 16 mm needles) and the corresponding risk (i.e. the probable outcome with 23 G 25 mm needles) is
provided in footnote 1
* *Due to bounding the upper lim it of the conf idence interval for the absolute ef fect does not match exact ly the upper lim it of the conf idence interval for the relat ive ef fect
* * *NNTB = the expected number of infants who would need to be vaccinated with the 25 mm rather than the 16 mm needle for 1 addit ional infant to avoid a severe local
react ion event
* * * *NNTB = the expected number of infants who would need to be vaccinated with the 25 mm rather than the 16 mm needle for 1 addit ional infant to avoid a non-severe local
react ion event
CI: conf idence interval; DTwP-Hib vaccine: a combinat ion vaccine containing diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b vaccine ant igen
components; RR: risk rat io;WHO: World Health Organizat ion.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.








































































































Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
Please see the Data collect ion and analysis sect ion of the review for comprehensive details regarding the methods we used
to assess the quality of evidence for outcomes included in ’Summary of f indings’ tables. See the Ef fects of intervent ions
sect ion of the review for a full explanat ion of the rat ionale for our judgements regarding the quality of evidence for each
outcome.
1Two trials contributed data to this comparison (Diggle 2000a; Diggle 2006). In Diggle 2000a, the third dose of a DTwP-Hib
vaccine was administered into the anterolateral thigh of infants aged 4 months, and only non-severe local react ion outcomes
(redness, swelling, and tenderness) were reported postvaccinat ion. In Diggle 2006, a DTwP-Hib vaccine and a meningit is C
conjugate (MenC) vaccine were concurrent ly administered in the right (DTwP-Hib) and lef t (MenC) anterolateral thighs of
infants aged 2 months (f irst vaccine dose), 3 months (second dose), and 4 months (third dose). The MenC vaccine was
administered in a schedule (t ime between vaccine doses) that is no longer recommended, and the results pertaining to the
ef fects of needle size on the immunogenicity and reactogenicity of this vaccine are not presented in this ’Summary of f indings’
table. As the Diggle 2006 trial reported immunogenicity and reactogenicity outcomes af ter all three doses of the vaccine, the
assumed and corresponding risks for all outcomes presented in this table are based on the event rates in the needle size
groups in this trial.
2The term ’seroprotect ion’ refers to ant ibody t it re levels above a predef ined threshold level that correlates with protect ion
f rom disease (af ter complet ion of a series of three doses of a DTwP-Hib vaccine). The threshold levels used in this review
were: diphtheria ant itoxin levels ≥ 0.01 IU/ mL; tetanus ant itoxin levels ≥ 0.01 IU/ mL; and Hib ant ibody t it re levels ≥ 1.0 µg/
mL. There is no well-established immune correlate or surrogate of protect ion against pertussis.
3We downgraded the quality of evidence by one level for indirectness due to the use of a subst itute (surrogate) seroprotect ion
endpoint in place of the pat ient-important outcome of interest. Although the seroprotect ion endpoints were reported in only
one trial, thus precluding an evaluat ion of the consistency or inconsistency of results across trials, we did not downgrade the
quality of evidence. We considered the consistency of the results of the seroprotect ion analyses reported in the trial and the
results of the analyses of the rat ios of the ant ibody/ ant itoxin geometric mean concentrat ions (GMCs) between the needle
size groups. The GMC rat ios (23 G 25 mm versus 25 G 16 mm) were: diphtheria: 1.13 (95% CI 0.91 to 1.40); tetanus: 1.01
(95% CI 0.84 to 1.22); and Hib: 1.05 (95% CI 0.78 to 1.42). (NOTE: a rat io value > 1.0 indicates a higher ant ibody level (better
immune response) af ter vaccinat ion with the 23 G 25 mm compared with the 25 G 16 mm needle.)
4This term refers to a persistent inconsolable crying event last ing for ≥ 4 hours. The data presented in the table relate to
persistent inconsolable crying recorded at any t ime point (6 hours, day 1, day 2, or day 3) af ter concurrent administrat ion of
any dose (f irst , second, or third) of a DTwP-Hib vaccine and a MenC vaccine.
5We downgraded the quality of evidence by one level due to imprecision taking into account the width of the 95% conf idence
interval accompanying the ef fect est imate.
6We downgraded the quality of evidence by one level for indirectness. The def init ion of persistent inconsolable crying (≥ 4
hours’ durat ion) used in the trial dif f ered f rom the case def init ion specif ied in the protocol for our review (≥ 3 hours’ durat ion).
The reported ef fect size may have dif fered if the latter def init ion had been used in the trial, and we considered that this







































































































7We downgraded the quality of evidence by one level, as this outcome was reported in only one trial, thus precluding any
evaluat ion of the consistency or inconsistency of results across trials.
8’Severe local react ion’ refers to redness and swelling covering more than two-thirds of the anterolateral thigh af ter the f irst
dose of a DTwP-Hib vaccine.
9No severe local react ions were reported in Diggle 2000a, where all infants received the third dose of the vaccine only. Most
of the severe local react ions in Diggle 2006 occurred af ter the f irst dose of the vaccine. Severe local react ions may be more
likely to occur af ter the f irst vaccine dose, and as this dose was not administered in Diggle 2000a, we were unable to reach
a judgement regarding the consistency or inconsistency of results across trials. We therefore downgraded the quality of
evidence by one level.
10Although blinding of outcome assessment was incomplete, we did not downgrade the quality of evidence for risk of bias.
We considered that the clinical severity of the react ion reduced the level of subject ivity in outcome assessment.
11’Non-severe local react ion’ refers to any redness, swelling, tenderness, or hardness (i.e. a composite outcome) at the
inject ion site on the day af ter the f irst dose of a DTwP-Hib vaccine.
12Similar ef fect sizes were observed in Diggle 2006 on the day af ter the second and third doses of the DTwP-Hib vaccine
(second RR 0.76, 95% CI 0.62 to 0.92; third RR 0.77, 95% CI 0.64 to 0.94). The corresponding NNTBs were 8 (95% CI 5 to 25)
for the second dose and 8 (95%CI 5 to 34) for the third dose. In Diggle 2000a (n = 110), data on the day af ter vaccinat ion were
not available, but the incidence of any redness, swelling, or tenderness at any t ime point postvaccinat ion was signif icant ly
lower in infants vaccinated with the 23 G 25 mm versus the 25 G 16 mm needle (62%with 23 G 25 mm needle versus 84%with
25 G 16 mm needle; RR 0.74, 95%CI 0.58 to 0.94).
13We downgraded the quality of evidence by one level due to incomplete blinding of outcome assessment and the resultant
uncertainty over the potent ial for bias.
14Although this outcome was reported in only one trial, thus precluding an evaluat ion of the consistency or inconsistency of
results across trials, we did not downgrade the quality of evidence. This decision took into account the consistency of the
ef fect sizes af ter the f irst , second, and third doses of the DTwP-Hib vaccine (see footnote 12).
15The data presented in the table relate to fever (temperature ≥ 38 °C) experienced at any t ime point (6 hours, day 1, day 2, or








































































































D I S C U S S I O N
Summary of main results
Our review included five trials involving 1350 randomised par-
ticipants. Three of the trials (1135 participants) contributed data
to the comparisons between 25 G 25 mm, 23 G 25 mm, and 25
G 16 mm needles. These trials involved infants, predominantly
between the ages of two and six months, who were undergoing
intramuscular vaccination procedures with combination vaccines
containing DTwP antigens with or without other vaccine antigen
components including Hib (DTwP-Hib) and Hep B (DTwP-Hib-
Hep B). A MenC conjugate vaccine was administered concurrently
in one trial. The vaccines were administered in the anterolateral
thigh with the skin stretched flat and the needle inserted at a 90°
angle through the skin and up to the needle hub in healthy infants
(WHO injection technique). We have summarised the principal
findings from these trials in Summary of findings for the main
comparison; Summary of findings 2; and Summary of findings 3.
There is probably little or no difference in immune response be-
tween using 25 G 25 mm, 23 G 25 mm, and 25 G 16 mm needles
to administer a series of three doses of a DTwP-Hib vaccine to
infants aged two, three, and four months (moderate-quality evi-
dence). We identified no trials that measured the incidence of vac-
cine-preventable diseases, and our conclusions regarding the likely
effects of needle size on immune response are based on seropro-
tection rates to the diphtheria, tetanus, and Hib vaccine antigen
components. No trials measured the immune response to the per-
tussis component of the vaccine.
Using either 25 G 25 mm or 23 G 25 mm needles to administer a
DTwP-Hib vaccine probably leads to fewer severe local reactions
(extensive redness and swelling) after the first vaccine dose and
fewer non-severe local reactions (redness, swelling, tenderness, and
hardness) at 24 hours after the first, second, and third vaccine
doses compared with the use of a 25 G 16 mm needle (moderate-
quality evidence).
Using a wider gauge (23 G) 25 mm needle to administer a DTwP
combination vaccine may slightly reduce vaccination-related pro-
cedural pain (low-quality evidence) and probably leads to a slight
reduction in the duration of crying time immediately following
vaccination (moderate-quality evidence) compared with a nar-
rower gauge (25 G) 25 mm needle. However, the effects are prob-
ably not large enough to be of any practical or clinical importance
to patients, parents, and healthcare providers.
Use of the narrower gauge (25 G) 25 mm needle may result in a
small reduction in the incidence of local reactions at 24 hours after
DTwP vaccination compared with the wider gauge (23 G) 25 mm
needle. The effect estimates are imprecise, and further research is
very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate (low-quality
evidence).
The comparative effects of 23 G 25 mm, 25 G 25 mm, and 25 G 16
mm needles on the incidence of fever and persistent inconsolable
crying following DTwP vaccination are uncertain due to the very
low quality of the evidence. Similarly, there is insufficient evidence
to permit any definitive conclusions about the effects, if any, of
needle size on other systemic adverse events including drowsiness,
loss of appetite, and vomiting.
Only one trial compared the effects of using 23 G 25 mm, 25 G
25 mm, and 25 G 16 mm needles to administer a MenC vaccine
(a vaccine that has a better reactogenicity profile than DTwP vac-
cines) to infants aged two months (first vaccine dose), three months
(second dose), and four months (third dose). These needles proba-
bly produce a comparable immune response to the MenC vaccine
(moderate-quality evidence). However, the comparative effects of
the needles on postvaccination local and systemic reactions are un-
certain due to the imprecision of effect estimates. In addition, the
MenC vaccination schedule (timing between vaccine doses) used
in the trial is no longer recommended, and the applicability of the
trial results to contemporary schedules is uncertain. We have dis-
cussed this further in the Overall completeness and applicability
of evidence section.
One small trial compared the effects of using 38 mm versus 25
mm needles to administer a Hep B vaccine to obese adolescents.
Another trial compared the effects of using 22 G 25 mm, 23 G
25 mm, and 24 G 25 mm needles to administer a DTwP vaccine
and a Hep B vaccine to infants. The evidence from these trials was
of insufficient quality and the effect estimates were insufficiently
precise to allow any confident statements to be made about the
comparative effects of these needle sizes on vaccine immunogenic-
ity and reactogenicity.
Overall completeness and applicability of
evidence
The external validity of the evidence presented is constrained by
the small number of trials included in the review and the types
of participants, interventions, and outcomes investigated in the
trials.
Types of participants
Our review was confined to studies involving children (defined
as people aged less than 10 years) and adolescents (defined as
people aged 10 to 24 years), therefore no conclusions can be drawn
about the effects of using needles of different sizes for vaccination
procedures in adults. Only one trial included in the review involved
obese adolescents aged 14 to 24 years, but we judged the quality
of the evidence for the outcomes measured in the trial to be very
low, and hence the effects of using needles of different sizes for
vaccination procedures in this population group are uncertain. The
remaining four trials involved infants under the age of six months,
and the majority of trial participants were aged between six weeks
and four months. In addition, most of the trial participants were
healthy and generally of normal weight for their age, with the
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exception of a small proportion (14%) of the participants in one
trial, Pathak 2007, who were malnourished (weight categorised as
per WHO growth standards) (WHO 2006). There is a paucity
of evidence regarding the effects of using needles of different sizes
for vaccination procedures in children outside of these age groups,
in children who are overweight or obese, and in malnourished
children.
Types of interventions
The trials included in our review compared a limited range of
needle lengths and gauges, and our findings cannot be extrapolated
to needles of other sizes. However, the most robust evidence from
our review pertains to the comparative effects of 23 G 25 mm, 25 G
25 mm, and 25 G 16 mm needles, which are the most commonly
used needles sizes in clinical practice for intramuscular vaccination
procedures in children and adolescents (DoH UK 2012a).
All trials included in our review involved participants undergo-
ing intramuscular vaccination procedures. No conclusions can be
drawn about the effects of using needles of different sizes for ad-
ministering vaccines prescribed for delivery by subcutaneous or
intradermal routes.
In the four included trials that involved infants, the vaccines were
administered in the anterolateral thigh with the skin stretched flat
and the needle inserted at a 90° angle to the skin surface. There is
an absence of evidence from RCTs regarding the effects of using
needles of different sizes for administering vaccines intramuscu-
larly using other injection techniques, such as the bunching tech-
nique commonly used in the USA, and for angles of needle in-
sertion deviating from the perpendicular. Furthermore, no trials
evaluated the effects of using needles of different sizes for adminis-
tering vaccines to children in the deltoid muscle of the upper arm.
In four trials, combination vaccines were administered to trial par-
ticipants containing DTwP with or without other vaccine anti-
gen components including Hib (DTwP-Hib) and Hep B (DTwP-
Hib-Hep B). The whole-cell pertussis component of such com-
bination vaccines has been shown to be primarily, but not exclu-
sively, responsible for local and systemic reactions occurring af-
ter vaccination. This has been demonstrated in studies that have
compared reactogenicity event rates after DTwP versus DT vac-
cination and DTwP versus DTaP (acellular pertussis) vaccination
(WHO 2014a). In addition, combinations of DTwP and Hep B
with or without Hib do not result in adverse reactions that materi-
ally exceed in either frequency or severity those seen with the same
DTwP vaccine given alone (Decker 2013). The results of our re-
view are therefore likely to be most applicable in populations and
settings where combination DTwP vaccines are used either alone
or in combination with other vaccine antigens. In this context, the
review findings are of most relevance to low- and middle-income
countries, where combination vaccines with whole-cell pertussis
components are the vaccine of choice (Vashishtha 2013; WHO
2013c).
Due to their lower reactogenicity, acellular pertussis vaccines (aP)
containing purified, inactivated components of Bordetella pertussis
cells have replaced whole-cell pertussis vaccines in many high-in-
come countries (Sheridan 2012).* For example, in the UK a com-
bination vaccine (DTaP-IPV-Hib-Hep B) with an aP component
is currently (2017 to 2018) included in the routine vaccination
schedule (PHE 2017). In the USA, whole-cell pertussis vaccines
are no longer available, and only aP vaccines are currently licensed
for use (FDA 2018). Due to the different reactogenicity profiles
of vaccines with acellular and whole-cell pertussis components, it
cannot be assumed that similar effect sizes to those reported in
our review, particularly in relation to severe and non-severe local
reactions, would be observed in populations and settings where
aP-containing vaccines are predominantly or exclusively used.
Only one trial included in our review involved the administration
of a MenC vaccine (Diggle 2006). The vaccine schedule used in the
trial (first, second, and third doses of a Men C conjugate vaccine
at ages two, three, and four months) is no longer recommended
in the UK, where the trial was conducted. It has been replaced
by a schedule whereby a Hib-MenC vaccine dose is given at 12
months of age, and a MenACWY conjugate vaccine dose is given
at 14 years of age (PHE 2016). Furthermore, in Diggle 2006,
approximately 75% of the infants received Meningitec vaccine.
This particular vaccine is not recommended for use in the new
vaccination schedule. The applicability of the results presented in
our review to the current MenC vaccination schedule is therefore
uncertain.**
*NOTE: in July 2014, the WHO issued revised guidance on the
choice of pertussis vaccines based on evidence indicating that “li-
cenced aP vaccines have lower initial efficacy, faster waning of im-
munity and possibly a reduced impact on transmission relative to
currently internationally available wP vaccines” (WHO 2014b).
The WHO has advised that “countries currently using aP vaccine
may continue using this vaccine but should consider the need for
additional booster doses and strategies to prevent early childhood
mortality in case of resurgence of pertussis” (WHO 2014b). This
guidance was reinforced in a subsequent WHO position paper on
pertussis vaccines (WHO 2015b).
**NOTE: the current WHO immunisation schedule is that chil-
dren aged two to 11 months require two doses of a monovalent
MenC conjugate vaccine administered at an interval of at least two
months, and a booster about one year after (WHO 2017).
Types of outcomes
Our review was compromised by the absence of evidence per-
taining to the primary outcomes of interest. We identified no tri-
als that investigated the effect of needle size on the incidence of
vaccine-preventable diseases such as diphtheria, tetanus, pertussis,
Haemophilus influenzae type b disease, and hepatitis B. In many
countries, vaccination programmes have substantially reduced the
incidence of these diseases, thus trials addressing clinical outcomes
would require impractically large sample sizes and duration of
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follow-up. However, in some settings and for some diseases (e.g.
tetanus and Hib) trials reporting clinical outcomes could theoret-
ically be expected. The lack of clinical disease endpoints weakens
the conclusions that can be drawn from the small number of trials
included in the review (two) that evaluated the effects of needle
size on vaccine immunogenicity.
We identified no trials that evaluated the effect of needle length on
vaccination-related procedural pain and procedural crying (crying
during and immediately after the vaccination procedure), and we
located only one trial that evaluated the effect of needle gauge on
these outcomes. The paucity of trials reporting these outcomes is
particularly surprising given that the pain associated with vacci-
nation procedures is widely recognised as a source of anxiety and
distress for people receiving the vaccine injections, their parents/
guardians, and the healthcare providers who administer the injec-
tions (Schechter 2007).
How do the results of our review fit into the context of
current practice?
National Immunization Technical Advisory Groups in several
countries including the UK, Ireland, the USA, and Australia rec-
ommend the use of needles 25 mm in length for intramuscular
vaccination procedures in the anterolateral thigh of infants under
the age of 12 months (see Appendix 1). This recommendation is
supported by our review, which found that both severe and non-
severe local reactions probably occur less frequently when 25 mm
rather than 16 mm needles are used to administer DTwP combi-
nation vaccines to infants. National Immunization Technical Ad-
visory Groups have also made recommendations regarding appro-
priate needle sizes for vaccination procedures in preterm infants,
children over the age of 12 months, and adolescents. We are un-
able to comment on these recommendations, as the trials included
in our review either did not include these population groups, or
the quality of evidence was too low to allow any judgements to be
made.
Quality of the evidence
Our review included five trials involving 1350 randomised par-
ticipants. Overall, the quality of evidence was compromised, and
our confidence in effect estimates limited, by the use of substi-
tute (surrogate) immunogenicity outcomes in trials, incomplete
blinding of outcome assessment, small number of trials, hetero-
geneity of needle sizes compared in these trials, heterogeneity of
vaccines administered, and heterogeneity of outcomes (including
definitions of outcomes, methods used to measure outcomes, and
the time points for outcome measurement), which generally pre-
cluded meta-analysis. We formally rated the quality of the evidence
for outcomes included in ’Summary of findings’ tables using the
GRADE system. The ratings ranged from very low for some out-
comes such as fever and persistent inconsolable crying (indicating
considerable uncertainty regarding the estimates of effect) to mod-
erate for other outcomes such as non-severe local reactions after
DTwP-Hib vaccination (indicating that further research is likely
to have an important impact on our confidence in the estimate
of effect and may change the estimate). We have provided below
a synopsis of our decisions with regard to each of the five factors
that we considered when determining the quality of the evidence.
1. Risk of bias: in four of the trials included in our review we
judged that there was a low risk of selection bias because robust
sequence generation and allocation concealment methods were
used. In one trial, allocation was not concealed, and we assigned
a high risk of bias for this domain (Middleman 2010).
In all five trials, complete blinding of trial participants, their par-
ents or guardians, and personnel was not ensured because colour-
coded needles were used in all trials, and the lengths of the nee-
dles differed in three of the trials. Nevertheless, we judged that
there was a low risk of performance bias in all trials, and have
outlined the rationale for this decision in detail in the Risk of bias
in included studies section.
In reaching judgements regarding the risks of detection bias aris-
ing from lack of blinding of outcome assessors in trials, we took
into account the people assessing the outcome and the subjectiv-
ity and objectivity of the outcomes. In the two trials that assessed
immunogenicity outcomes using laboratory assays, we considered
that there was a low risk of detection bias. Only one trial assessed
the effects of needle gauge on vaccination-related procedural pain
and procedural crying. Due to the colour-coding of the needle
hubs, we considered that there was uncertainty over the potential
for detection bias for the subjective outcome of pain, and we as-
signed an unclear risk of bias judgement. However, we considered
that crying time (assessed from digital camera recordings) was a
more objective outcome, and we considered that there was a low
risk of detection bias for this outcome. We reached a similar de-
cision regarding the risk of detection bias in relation to the trials
that assessed persistent inconsolable crying.
Other local and systemic reactogenicity outcomes (including red-
ness, swelling, tenderness, and fever) were assessed by parents in a
number of trials. Due to lack of blinding or incomplete blinding of
parents in all trials that measured these outcomes, we considered
that the potential for bias was uncertain, and we assigned an un-
clear risk of bias judgement. We considered that this uncertainty
merited downgrading the quality of evidence for these outcomes.
We deemed attrition bias problematic in only one trial where there
was a notable disparity between the number of participants ran-
domised and the number analysed (Middleman 2010). We judged
that there was a low risk of attrition bias in the remaining trials
because there was either minimal loss to follow-up, or missing out-
come data were balanced in numbers across comparison groups
with similar reasons for missing data across groups.
We considered that there was a low risk of reporting bias in one
trial where we had access to all of the original trial data and we
were confident that we had access to the trial results for all of the
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prespecified primary and secondary outcomes that were of interest
to our review. For the remaining trials, we considered that there
was an unclear risk of reporting bias because we did not examine
the trial protocols, and it was unclear if the trial reports contained
all expected outcomes.
2. Indirectness: in the two trials that evaluated the effect of needle
size on vaccine immunogenicity, substitute outcomes were used
(seroprotection rates, geometric mean antibody concentrations, or
geometric mean antibody titres) instead of patient-important out-
comes (incidence of vaccine-preventable diseases). We therefore
downgraded the quality of evidence by one level.
3. Imprecision: most of the outcomes reported in our review were
dichotomous, and decisions on downgrading due to imprecision
were based on a consideration of the 95% CIs around relative risk
effect estimates. We downgraded for imprecision if the 95% CIs
included both ’no effect’ and the suggested GRADE threshold
for downgrading of a relative risk reduction (RRR) or relative
risk increase (RRI) greater than 25%. The only exception to this
occurred when event rates were very low for some outcomes and
where the 95% CIs around relative effect estimates were very wide,
but 95% CIs around absolute effect estimates were narrow. For
example, when comparing severe local reactions after vaccination
with 23 G 25 mm versus 25 G 25 mm needles, we considered the
results from two trials that involved 559 participants. Only one
severe local reaction occurred in people vaccinated with the 23 G
needle, and none occurred in people vaccinated with the 25 G
needle. We did not downgrade the quality of evidence pertaining
to this outcome for imprecision.
The results pertaining to most of the outcomes reported in the
only trial that compared 22 G, 23 G, and 24 G needles were im-
precise (Nirupam 2008). There were only 50 participants in each
group in the trial, and event rates were low for most outcomes,
inevitably resulting in wide CIs around effect estimates and down-
grading for imprecision. Consequently, we were unable to make
any confident statements regarding the comparative effects of these
needle gauges. Similarly, the only trial that compared 38 mm and
25 mm needles had a small sample size, and the width of the CI
around the effect estimate for the seroprotection endpoint in the
trial merited downgrading the quality of evidence for imprecision
(Middleman 2010).
4. Inconsistency: assessment of the degree of heterogeneity of re-
sults across trials was compromised by the small number of studies
included in our review. Some outcomes such as procedural pain
and crying were reported in only one trial, thus precluding an eval-
uation of the consistency or inconsistency of results across trials.
As explained in the Data collection and analysis section, we de-
creased the strength of evidence grade for specific outcomes where
there was only a single trial evidence base. An exception to this
occurred in relation to local reaction outcomes (redness, swelling,
tenderness, and hardness) in the Diggle 2006 trial, which were
recorded and analysed after each of the three doses of the two
vaccines administered in the trial. In this instance, we were able
to examine the consistency of effect estimates after each vaccine
dose. In the same trial, two substitute (surrogate) measures of im-
mune response were used, and we were able to compare the results
for these two substitute endpoints when evaluating the immuno-
genicity evidence base for consistency.
5. Publication bias: due to the small number of trials included
in the review, we did not conduct a formal assessment of the like-
lihood of publication bias via the construction and examination
of funnel plots. Our search for relevant trials was comprehensive
and included searches of electronic databases and clinical trial reg-
istries, and handsearching of reference lists of relevant narrative
and systematic reviews, evidence-based clinical practice guidelines,
key textbooks, and conference proceedings. In addition, we did
not impose any language restrictions on our searches. Although
we cannot entirely exclude the possibility of publication bias, we
consider that there is a low likelihood that we have overlooked rel-
evant trials. We decided not to downgrade the quality of evidence
for publication bias.
Potential biases in the review process
The strengths of the review process include the comprehensive
search of electronic databases, reference lists, conference proceed-
ings, and clinical trial registries to identify published and unpub-
lished trials. The robustness of the review process was further en-
hanced by the use of three review authors (PB, SH, SC) to inde-
pendently extract data from included trials and assess the risk of
bias. In addition, all relevant data entered into Review Manager
5 by PB was re-checked independently by SH and SC (RevMan
2014). We also contacted the authors of all included trials to ob-
tain missing data and for data clarification.
Our review has some potential limitations, particularly in relation
to a number of post hoc decisions about the analysis of data from
included trials and the presentation of results in ’Summary of
findings’ tables that we did not prespecify in the review protocol
(Beirne 2013). We have discussed the potential biases inherent
in these post hoc decisions below. We have also discussed some
of the challenges we encountered during the review process when
assessing risk of bias and when applying the GRADE system for
rating the quality of evidence.
Use of composite local reaction endpoints in ’Summary of
findings’ tables
In the three ’Summary of findings’ tables constructed for this re-
view we made a post hoc decision to present composite local re-
action outcomes (any redness, swelling, tenderness, or hardness)
rather than individual local reaction outcomes, and the ’illustra-
tive comparative risks’ for these composites were based on the data
obtained in the largest trial included in the review (Diggle 2006).
The use of composite outcomes in clinical trials can be misleading
if it is erroneously assumed that the intervention effect reported
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in the trial applies equally to all components of the composite,
whereas in reality the intervention effect may vary across com-
ponents of the composite that have different clinical importance
(Cordoba 2010). Of particular concern is a scenario where the in-
tervention effect on the composite outcome and the intervention
effect on one or more individual components of the composite
are in different directions. This issue did not arise in relation to
the main comparisons made in our review between 25 mm and
16 mm needles (25 G 25 mm versus 25 G 16 mm; 23 G 25 mm
versus 25 G 16 mm in infants undergoing DTwP vaccination). We
conducted sensitivity analyses to investigate the consistency of the
estimates of intervention effects on the composite outcome and on
the individual components of the composite in the Diggle 2006
trial. Although there were some variations in the magnitude of
intervention effects across individual local reaction outcomes, the
direction of effect was remarkably consistent across all outcomes,
and this direction of effect was accurately reflected in the com-
posite outcome measure. On balance, we consider that including
a composite outcome rather than individual local reaction out-
comes in the ’Summary of findings’ tables was the most efficient
way to summarise the effects of needle size on vaccine reactogenic-
ity without overwhelming the reader with information regarding
intervention effects on individual local reaction outcomes.
Time point selection
Another potential source of bias in the review was the selection
of the time point at which we analysed trial data relating to the
effects of needle size on the composite local reaction outcome in
the Diggle 2006 trial. We made a post hoc decision to use 24
hours postvaccination or the nearest approximation to this time
point. As explained in the Unit of analysis issues section, we con-
sider that this time point was the most appropriate at which to
analyse trial data. Nevertheless, this decision could have biased the
inferences drawn in our review regarding the effect of needle size
on local reactions if there were systematic differences in the re-
sults of analyses conducted at different time points (e.g. six hours,
day one, day two, and day three postvaccination). We explored
the potential for bias by performing sensitivity analyses to inves-
tigate how robust our conclusions were to decisions about time
point selection. These sensitivity analyses indicated that although
our estimates of the magnitude of the intervention effect would
have varied depending on time point selection (particularly for the
comparisons between 25 mm and 16 mm needles), the direction
of effect was overwhelmingly consistent across time points, and
our overall conclusions would not have materially altered accord-
ing to time point selection. We consider that the results of these
sensitivity analyses further enhance confidence in the findings of
our review.
Selection of minimum important differences
Our assessment of the effects of needle size on vaccine immuno-
genicity was based on differences in seroprotection rates between
groups, and we used as an MID an RD of 10%. For pain, we se-
lected an MID between groups of 1 point on the 10-point MBPS
scale or its equivalent on other scales. Although these MIDs were
not specified a priori in the review protocol, their selection was not
arbitrary, and they were identified using approaches suggested by
the Agency for Healthcare Research and Quality (AHRQ) (AHRQ
2012). Although there is obviously potential for debate over the
precise values of these MIDs, we consider that the methods used
to identify them were appropriate, and we have described these
methods in the Data collection and analysis section.
Use of the Cochrane ’Risk of bias’ tool and application of the
GRADE system
Our experiences during the review process were commensurate
with those highlighted in a number of studies that have demon-
strated poor reliability between review authors when applying the
Cochrane ’Risk of bias’ tool to assess the risk of bias in RCTs
(Hartling 2009; Hartling 2013; Armijo-Olivo 2014). In our re-
view, the three review authors (PB, SH, SC) who independently
assessed the risk of bias of included trials were in full agreement
only for the domains of sequence generation and allocation con-
cealment. There were some disagreements between review team
members with regard to all other domains, and thus the final
judgements presented in this review represent the outcome of a
process of discussion and consensus. In order to ensure complete
transparency in our review, we have explained the rationale for
our decisions both in the Risk of bias in included studies section
and in the ’Risk of bias’ table for each trial in the Characteristics
of included studies table. We have provided more detail in these
sections than would typically be presented in many systematic re-
views, as we consider that this additional detail will assist readers
in understanding the reasons for our judgements.
Similarly, all of the decisions reached in our review regarding the
quality of evidence ratings using the GRADE system represent the
outcome of a process of discussion and consensus between review
team members (PB, SH, SC) rather than unanimous agreement.
To ensure transparency in our review, and in accordance with best
practice, we have provided detailed footnotes in all ’Summary of
findings’ tables to explain our reasons for downgrading or not
downgrading the quality of the evidence.
We departed from formal guidance on using the GRADE system
with regard to the criterion of ’inconsistency’ for outcomes re-
ported in a single trial. Exponents of the GRADE approach have
suggested that reviewers should not downgrade for inconsistency
when there is only one study. For example, Schünemann 2011c
has stated that “... The obvious answer is that there is no incon-
sistency as there is only one study and therefore one would not
downgrade the quality of evidence on the basis of only one avail-
able study. Some of the reasons for this are that the one study can
be a very large study that evaluated all sorts of different popula-
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tions and provides information and estimates of effect that we can
be very confident in. Another reason is to ask where there would
be a threshold level for judging inconsistency, whether it be the
availability of two studies or three studies. Once again, the bottom
line is there is no downgrading for inconsistency when there is
only one study.” For some of the outcomes reported in single trials
in our review we did not deem it appropriate to follow this guid-
ance, as we did not consider that some of the relevant trials could
be deemed “very large [studies] that evaluated all sorts of different
populations and provides information and estimates of effect that
we can be very confident in.” We therefore adopted an approach
suggested by the AHRQ of downgrading evidence for outcomes
with a single trial evidence base on the grounds that consistency
is unknown (a full explanation is provided in the Data collection
and analysis section) (Owens 2009; Owens 2010). The only ex-
ceptions to this approach occurred where 1) trials reported two
substitute immunogenicity endpoints, and we were able to con-
sider the consistency of the effects sizes for the two endpoints; and
2) trials reported on local reactions after the first, second, and third
doses of a vaccine, and we were able to consider the consistency
of the effect sizes after each dose of the vaccine. Although there is
obviously potential for debate over the methods we adopted, we
consider that our approach has resulted in GRADE ratings that
accurately reflect our confidence in the estimates of effect.
Agreements and disagreements with other
studies or reviews
During the literature searches, we located six studies evaluating the
effects of needle size on vaccine immunogenicity and reactogenic-
ity that did not meet our selection criteria. We also identified a
number of systematic reviews and several studies that made recom-
mendations regarding the optimal needle length for intramuscular
vaccination procedures based on ultrasound, magnetic resonance
imaging (MRI), or computed tomography (CT) measurements
of the thickness of subcutaneous fat and muscle at recommended
vaccination sites in children and adolescents. We have summarised
the results of relevant studies under three separate headings below.
The evidence presented has not been systematically reviewed, and
a formal assessment of the risk of bias for each study has not been
conducted.
1. Agreements and disagreements with the results of excluded
studies that evaluated the effects of needle size on vaccine
immunogenicity and reactogenicity
We excluded two studies that involved adults (Shaw 1989; Johnsen
1995), one study where insufficient outcome data were available
(Ozdemir 2012), one randomised trial where different injection
techniques were used in the comparison groups (Cook 2005), and
one randomised trial where different syringes were used in the
comparison groups (Fateh 2014). We have not discussed the re-
sults from these studies because either the study populations were
not children or adolescents, the outcome data were considered in-
complete, or because the comparison groups intentionally differed
with regard to factors other than needle size that could influence
vaccine immunogenicity and reactogenicity. The principal results
from the remaining two excluded studies are summarised below
(Ipp 1989; Jackson 2008).
The participants in Ipp 1989 were healthy children aged 18
months attending private paediatric practices in Toronto, Canada
for routine well-child care. The children were sequentially assigned
to receive a combined diphtheria, tetanus, whole-cell pertussis,
and inactivated polio vaccine (DTwP-IPV) via intramuscular in-
jection into the deltoid muscle with a 25 G 16 mm needle (74
children) or into the anterolateral thigh with either a 25 G 25 mm
needle (67 children) or a 25 G 16 mm needle (64 children). The
injection technique used in the study was not specified. All local
and systemic postvaccination reactions were recorded by parents
at four and 24 hours postvaccination. As the injection sites dif-
fered in the comparison groups (deltoid in one group, anterolat-
eral thigh in two groups), we only considered the results relating to
the vaccination procedures performed in the anterolateral thigh.
The study authors reported no statistically significant differences
in fever, prolonged or unusual crying, and pain between the groups
vaccinated with 25 G 25 mm and 25 G 16 mm needles. However,
these outcomes were defined and measured in different ways to
the trials included in our review, and the study results cannot
be directly compared with our review findings. The incidence of
redness at the vaccination site was lower in children vaccinated
with the 25 G 25 mm needle (13.4%) compared with the 25 G 16
mm needle (40.6%) (P < 0.001). The incidence of swelling was
also lower in children vaccinated with the longer needle (13.4%
with 25 G 25 mm needle versus 32.8% with 25 G 16 mm needle; P
= 0.015). These results are commensurate with our review findings
of a reduced risk of local reactions associated with the use of 25 G
25 mm needles compared with 25 G 16 mm needles.
The participants in Jackson 2008 were children (median age 4.5
years) participating in a prospective postlicensure assessment of
the safety of the fifth consecutive dose of a combined diphtheria,
tetanus, and acellular pertussis vaccine (DTaP). The children were
vaccinated at a large health maintenance organisation in Wash-
ington state by clinical staff “according to their usual practice.”
The vaccination technique(s) used to administer the vaccine were
not described. Of the 1315 children included in the final analysis,
1174 were vaccinated in the upper arm (381 with a 16 mm needle
and 793 with a 25 mm needle), and 141 were vaccinated in the
thigh (49 with a 16 mm needle and 92 with a 25 mm needle).
The gauges of the 16 mm needles were 23 G (0.2% of needles),
25 G (49%), and 26 G (49%) (gauge unknown for 1.8% of the
needles). The gauges of the 25 mm needles were 22 G (0.3%), 23
G (8%), and 25 G (91%) (gauge unknown for 0.7% of needles).
All local and systemic postvaccination reactions were recorded by
parents on the evening of vaccination and for the next six days.
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The primary data analysis conducted by the study authors involved
comparisons of the risks of each outcome (across all time points)
between 25 mm and 16 mm needles, irrespective of needle gauge.
In a multivariate analysis, RRs were adjusted for age, gender, and
body mass index.
In the multivariate analyses of children vaccinated in the arm,
use of a 25 mm needle versus a 16 mm needle was associated
with a reduced incidence of any redness, swelling, and pain at the
injection site (redness: 65% with 25 mm needle versus 76% with
16 mm needle; RR 0.87, 95% CI 0.81 to 0.94; swelling: 55%
with 25 mm needle versus 67% with 16 mm needle; RR 0.83,
95% CI 0.75 to 0.91; pain: 53% with 25 mm needle versus 61%
with 16 mm needle; RR 0.86, 95% CI 0.77 to 0.96).
For vaccinations administered in the thigh, use of the longer needle
was associated with a reduced incidence of redness and swelling.
However, the CIs accompanying all multivariate adjusted RR ef-
fect estimates were compatible with both reductions and increases
in the incidence of reactions following vaccination with the 25
mm compared with the 16 mm needle (redness: 40% with 25
mm needle versus 49% with 16 mm needle; RR 0.81, 95% CI
0.56 to 1.16; swelling: 28% with 25 mm needle versus 35% with
16 mm needle; RR 0.90, 0.53 to 1.51; pain: 48% with 25 mm
needle versus 49% with 16 mm needle; RR 1.03, 95% CI 0.72 to
1.47). There were also no statistically significant differences in the
incidence of fever between needle size groups at either vaccination
site (arm or thigh).
Direct comparison between the results of this study and the find-
ings of our review is complicated by several factors including dif-
ferences in the types of populations, interventions, and outcomes
(including outcome definitions). Nevertheless, the overall results
pertaining to the effect of needle length on redness and swelling at
the injection site were consistent with the findings of our review:
the incidence of these reactions was lower in children vaccinated
with a 25 mm rather than a 16 mm needle.
2. Agreements and disagreements with the findings of other
systematic reviews
Davenport 2003 conducted a systematic review to determine the
effect of needle size on the incidence of local reactions following
immunisation. Two studies met the selection criteria for the review
(Ipp 1989; Diggle 2000a). Diggle 2000a compared 23 G 25 mm
versus 25 G 16 mm needles, and Ipp 1989 compared 25 G 25 mm
versus 25 G 16 mm needles for administering DTwP combination
vaccines into the anterolateral thigh.
Davenport 2003 only extracted data from the two studies for the
outcomes of redness and swelling at 24 hours postvaccination and
reported that “no other outcomes of local reaction measured in
the studies were used, as the data was not comparable” (Davenport
2003). A fixed-effect meta-analysis was conducted to pool the
results of the two studies. The pooled relative risks (16 mm versus
25 mm) at 24 hours were 2.52 (95% CI 1.70 to 3.72) for redness
and 2.31 (95% CI 1.55 to 3.43) for swelling. Davenport 2003
concluded that “use of the 25 mm needle to administer vaccines
in infants is favoured by both the individual studies and the meta-
analysis as being significantly less likely to produce redness and
swelling within 24 hours.”
There are several differences between this review and ours. First,
our review is more up-to-date and includes additional studies
that were not published at the time the Davenport 2003 review
was conducted. Second, Davenport 2003 included one study that
we excluded from our review because the participants were not
randomly allocated to the comparison groups (the results of this
study are summarised under heading 1. above) (Ipp 1989). Third,
Davenport 2003 combined the results of the two studies despite
the differences in the gauges of the longer needles used in the
studies (25 G 25 mm needles were used in Ipp 1989; 23 G 25
mm needles were used in Diggle 2000a). In our review, we only
combined the results of trials where the lengths and gauges of the
needles compared in each trial were the same.
Despite these differences, the overall conclusion reached by
Davenport 2003 is compatible with the findings of our review that
use of a 25 mm needle for administering childhood vaccines in
the anterolateral thigh reduces the risk of local reactions compared
with the use of a 16 mm needle.
Taddio 2009b conducted a systematic review to determine the ef-
fectiveness of physical interventions and injection techniques for
reducing pain during vaccine injection in children and adoles-
cents. The review included randomised and quasi-randomised tri-
als involving people up to 18 years of age who were undergoing
immunisation with a vaccine that required injection in any setting
and where pain or distress was measured within five minutes of
the vaccination procedure using validated techniques. A total of
19 trials were identified that met the selection criteria. However,
no trials were identified that evaluated the effects of needle size on
pain. A more recent review of the evidence on interventions for
the management of vaccination-related pain also identified this
research gap regarding the effect of needle size on pain and fear
(Noel 2015). This is commensurate with the findings of our re-
view that there is a dearth of research evaluating the effects of
needle size on the pain experienced during and immediately after
vaccination procedures; we found only one trial that investigated
the effect of needle gauge on vaccination-related procedural pain.
This paucity of research is equally applicable to vaccination proce-
dures performed on adults. In a systematic review of measures for
reducing injection pain during adult immunisation, Hogan 2010
reported that there were no studies evaluating the effect of needle
length or needle gauge on acute pain from vaccine injections.
3. Agreements and disagreements with the results of studies
measuring the thickness of subcutaneous tissue and muscle
at vaccination sites
Several researchers have conducted imaging studies using ultra-
sound or MRI and CT scans to measure the thickness of subcuta-
neous fat and muscle at recommended vaccination sites in children
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and adolescents. These measurements have been used to make rec-
ommendations regarding the optimal needle length for adminis-
tering vaccines intramuscularly. The recommendations emerging
from these studies are typically based on the estimated length of
needle that is considered sufficient, when used with a particular
vaccination technique and with a specific angle of needle insertion,
to penetrate the full thickness of subcutaneous tissues and enter
muscle but without overpenetrating the muscle thereby risking
needle contact with the underlying bone.
In order to compare and contrast the findings of our review with
the results of these studies, we examined only the results and rec-
ommendations from imaging studies pertaining to populations
and vaccination procedures that were similar to those involved
in the trials included in our review. In this context, we excluded
one study involving neonates (Lo 1992), and one study involv-
ing adults (Poland 1997), because no trials included in our re-
view involved these age groups. We also excluded one study that
involved early adolescents aged 11 years (mean body mass index
percentile 58th) to 15 years (median body mass index percentile
62nd) (Koster 2009). We deemed the participants in this study as
not sufficiently similar to the participants in the only trial included
in our review that involved obese adolescents aged 14 to 24 years
(Middleman 2010).
We identified six studies where imaging methods were used to
measure the thickness of subcutaneous tissue and muscle in the
anterolateral thigh of infants aged between two and six months
(Hick 1989; Chugh 1993; Groswasser 1997; Cook 2002; Lippert
2008; Nakayama 2016). These studies also included recommen-
dations regarding appropriate needle length for vaccination pro-
cedures using an injection technique with the needle inserted at
a 90° angle to the skin. We have summarised details of the mea-
surements obtained in these studies in Appendix 8. We have also
presented below a synopsis of the main recommendations emerg-
ing from the studies and have highlighted possible reasons for dis-
parities between the recommendations made in different studies.
In addition, we have outlined the reasons why caution should be
exercised when comparing the findings of the trials included in
our review with the results of these imaging studies.
Hick 1989 conducted ultrasound skin-to-muscle measurements
and skin-to-bone measurements of the anterolateral thigh of 24
infant girls and boys aged four months (16 weeks) at the Mayo
Clinic in the USA. Based on these measurements, it was estimated
that the muscle would not have been penetrated (and therefore
that the vaccine would not have been deposited intramuscularly)
in 25% of the study participants if a 16 mm needle was inserted at
a 90° angle to the longitudinal axis of the leg. In another study in
the USA, Lippert 2008 reviewed CT and MRI scans of 250 infants
who had attended a large children’s hospital in the midwestern US.
Only 12 of the CT and MRI scans reviewed were from infants
aged one year or under. Lippert 2008 recommended a 22 or 25
mm needle for intramuscular injections in the anterolateral thigh
of infants (see Appendix 8).
In contrast, in a study conducted in India, Chugh 1993 estimated
from ultrasound measurements that use of 15 mm needles inserted
at a 90° angle would have reached the anterolateral thigh muscle
layer in 100% of the study participants aged six to 12 weeks (52
infants); 97% of participants aged 13 to 18 weeks (58 infants);
and 100% of participants aged 19 to 24 weeks. The study authors
advocated the use of 15 mm needles with the WHO injection
technique for vaccination procedures in these age groups and esti-
mated that there was a significant risk of striking bone if a 25 mm
needle was used. Similarly, based on ultrasound measurements of
the thigh of 40 infants with a median age of 12 weeks in a chil-
dren’s hospital in Belgium, Groswasser 1997 reported that using
the WHO injection technique “should allow perfect intramuscu-
lar vaccine delivery using 16 mm needles.” Groswasser 1997 also
cautioned that using 25 mm needles with the WHO technique
“could present a real danger of damaging neurovascular structures
and bone.” In a study conducted in Australia, Cook 2002 per-
formed ultrasound measurements of the anterolateral thigh of 45
infants aged two to six months and concluded that a 16 mm needle
used with the WHO injection technique should be sufficient to
penetrate muscle and ensure intramuscular vaccine delivery. Sim-
ilar recommendations were made by Nakayama 2016 in a study
involving ultrasound thigh measurements of 154 infants aged two
to six months attending three paediatric hospitals in Japan. Based
on the measurements, the researchers estimated that a 16 mm nee-
dle inserted at a 90° angle would have penetrated to the muscle in
all age groups, while a 25 mm needle would have reached bone in
infants aged two months (see Appendix 8).
There are several possible explanations for the disparities between
some of the recommendations emerging from these imaging stud-
ies. First, there may have been differences in the weight of the
study participants conducted in different countries. Details of the
weights of infants in the two studies conducted in the USA were
not reported, but it is possible that they had better nutritional
status and higher mean weights than the participants in the stud-
ies conducted in India, Belgium, and Japan. Second, the results
of these studies may be sensitive to the methods used to obtain
the measurements. For example, the angle and positioning of the
ultrasound transducer on the anterolateral thigh vaccination site
differed in the studies conducted by Hick 1989 and Groswasser
1997, which may explain some of the disparity between the mea-
surements obtained in these studies (see Appendix 8). In addition,
pressure from the ultrasound transducer may compress the tissue
during measurement, thereby impacting on the readings obtained.
This may partially explain the differences in measurements ob-
tained in studies where ultrasound was used compared with non-
contact measurements obtained via CT and MRI scans in the study
conducted by Lippert 2008. The results of the Lippert 2008 study
were also subject to measurement error inherent in the computer
software used to measure the thickness of subcutaneous tissue and
muscle from CT and MRI scans. The measurement error was ±
one pixel, and the spacing of the pixels was not a standard size for
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all participants. These potential sources of measurement error in
studies are another reason why caution should be exercised when
interpreting the results.
Comparison between results of imaging studies and the
findings of our review
The results of the two imaging studies conducted in the USA sup-
port the contention that a 16 mm needle may not be sufficiently
long to consistently penetrate the muscle of the anterolateral thigh
of infants under the age of six months undergoing vaccination
procedures (Hick 1989; Lippert 2008). This may explain the find-
ings from the two trials included in our review of a decreased rate
of local reactions associated with the use of a 25 mm compared
with a 16 mm needle for vaccination procedures (Diggle 2000a;
Diggle 2006). Use of the shorter needle may result in the deposi-
tion of vaccine constituents, including adjuvants, subcutaneously
rather than intramuscularly, thereby resulting in an increased rate
of local reactions. However, as details of the weights of the study
populations in Hick 1989 and Lippert 2008 were not available, we
are unable to determine if the infants included in these studies are
truly comparable to the participants in Diggle 2000a and Diggle
2006.
The weights of the infants in the Diggle 2000a and Diggle 2006
studies were higher than the weights of infants in the imaging
studies conducted in India and Belgium. The warnings by Chugh
1993 and Groswasser 1997 of a significant risk of a 25 mm needle
overpenetrating muscle and striking bone may therefore not be
applicable to the study populations in Diggle 2000a and Diggle
2006. This is supported by the fact that needle contact with bone
was a rare occurrence in Diggle 2006 (see Effects of interventions).
Comparison between the findings of our review and the results
of these imaging studies is further complicated by the fact that
the study participants may not be representative of populations
undergoing vaccination procedures. Only two studies involved in-
fants attending for vaccinations (Chugh 1993; Cook 2002). In the
remaining studies, the participants were infants attending a “well
child clinic”, Hick 1989, and infants attending children’s hospitals
(Groswasser 1997; Lippert 2008; Nakayama 2016). The hospital
participants in these studies may have had systematically different
characteristics to healthy infants in the general population, thereby
compromising the external validity of the study results.
Finally, it should be noted that the ability of these imaging studies
to inform clinical practice is limited because images of the subcu-
taneous tissue and muscle were not taken while needles of different
sizes were actually inserted to confirm the subcutaneous or intra-
muscular location of the needle tips or their proximity to bone.
Such studies can therefore only provide indirect evidence regard-
ing appropriate needle length for intramuscular vaccination pro-
cedures. The only reliable way to investigate the effects of using
needles of different lengths on vaccine immunogenicity and reac-
togenicity is to conduct RCTs where actual vaccination procedures
are performed and clinically relevant outcomes are measured. In
this context, the results of the trials included in our review pro-
vide direct evidence that should be used to inform clinical decisions
regarding the choice of appropriate needle sizes for vaccination
procedures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review findings are most applicable to healthy infants between
the ages of approximately two and six months undergoing intra-
muscular vaccination in the anterolateral thigh with combined
vaccines containing diphtheria, tetanus, and whole-cell pertussis
antigens (DTwP vaccines) using an injection technique (WHO
technique) where the skin is stretched flat and the needle is in-
serted at a 90° angle through the skin and up to the needle hub:
1. using either a 25 G 25 mm or a 23 G 25 mm needle for the
vaccination procedure probably leads to fewer severe and non-
severe postvaccination local reactions while achieving a
comparable immune response to 25 G 16 mm needles
(moderate-quality evidence);
2. using a wider gauge 23 G 25 mm needle may slightly
reduce the pain associated with the vaccination procedure (low-
quality evidence) and probably leads to a slight reduction in the
duration of crying time immediately following vaccination
(moderate-quality evidence) compared with a narrower gauge 25
G 25 mm needle. The estimated effects are probably not large
enough to be of any practical importance to patients, parents,
and healthcare providers;
3. the narrower gauge 25 G 25 mm needle may result in a
small reduction in the incidence of local reactions compared with
the 23 G 25 mm needle. We are unable to make confident
statements about the precise magnitude of any reduction as the
trial estimates are imprecise (low-quality evidence);
4. we do not have sufficient evidence to determine if there are
any differences between 25 G 25 mm, 23 G 25 mm, and 25 G
16 mm needles in the incidence of systemic adverse events
following vaccination including fever, persistent inconsolable
crying, drowsiness, loss of appetite, and vomiting.
The main findings of our review were derived from a small num-
ber of trials that evaluated the effects of using needles of different
sizes to administer combination vaccines with a whole-cell pertus-
sis (wP) component. The review findings are therefore likely to
be most relevant in low- and middle-income countries, where wP
vaccines are predominantly used. These vaccines have a different
reactogenicity profile and cause more local and systemic reactions
than vaccines with an acellular pertussis (aP) component that are
used in most high-income countries. It cannot be assumed that
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similar results to those reported in our review, particularly in re-
lation to the effects of needle size on local reactions, would be
observed in populations and settings where aP vaccines are pre-
dominantly or exclusively used.
Implications for research
Our review included only a small number of randomised con-
trolled trials (RCTs) that evaluated the effects of a limited range of
needle sizes for administering vaccines to a restricted number of
populations (predominantly infants between the ages of two and
six months). As such, our review has identified several areas where
additional RCTs are required to inform healthcare decisions re-
garding the choice of appropriate needle sizes for vaccination pro-
cedures in children and adolescents. In formulating our research
recommendations, we have considered the types of interventions
and populations and the types of outcomes that should be con-
sidered in future trials. We have also included some recommenda-
tions regarding trial reporting.
Types of populations and interventions
As highlighted in the Background section of this review, there are
inconsistencies in the recommendations made by National Immu-
nization Technical Advisory Groups (NITAGs) in different coun-
tries regarding the sizes of needles that should be used when ad-
ministering vaccines to children and adolescents. These variations
are indicative of uncertainty regarding the optimal needle sizes that
should be used for vaccination procedures in people of specific
ages or body masses. Randomised controlled trials are required
to address these uncertainties, and we consider that the current
recommendations made by NITAGs can act as a useful template
to inform the interventions and populations that should be con-
sidered in future trials.
1. For intramuscular vaccination procedures in the
anterolateral thigh of infants under the age of 12 months, several
NITAGs recommend the use of 25 mm needles with needle
gauges ranging from 22 G to 25 G. The trials included in our
review provide some evidence that needle gauge may affect
vaccination-related procedural pain and the incidence of local
reactions. Additional RCTs are warranted to evaluate the effects
of 22 G, 23 G, 24 G, and 25 G 25 mm needles on pain
outcomes and other reactogenicity events.
2. For intramuscular vaccination procedures in the
anterolateral thigh of toddlers aged between approximately 12
months and three years, some NITAGs recommend the use of 25
to 32 mm needles with gauges ranging from 22 G to 25 G. Trials
should be conducted to identify the optimal needle length and
gauge for vaccination procedures in the anterolateral thigh in this
population group.
3. For intramuscular vaccination procedures in the deltoid
area of older children and adolescents, NITAG
recommendations regarding needle length vary from 16 mm to
25 mm with needle gauges ranging from 22 G to 25 G. Trials
should be conducted to identify the optimal needle length and
gauge for vaccination procedures in this population group.
4. Only one trial included in our review involved an obese
population. Obesity increases the subcutaneous tissue thickness,
and overweight and obese children and adolescents receiving
intramuscular injections may require longer needles to ensure
that the vaccine is administered into muscle. Given the rising
levels of obesity in many countries, trials are required to evaluate
the effects of using needles of different sizes for vaccination
procedures in overweight and obese individuals.
5. In all of the trials included in our review, the intramuscular
vaccination procedures involved stretching the skin flat before
needle insertion. We did not identify any trials where the
bunching technique was used to administer vaccines
intramuscularly (see Background for a description of this
technique). Randomised controlled trials comparing the effects
of using needles of different sizes with this vaccination technique
in various age groups are warranted. Longer needles are likely to
be required to reach the muscle with the bunching rather than
the stretching technique, and this should be taken into account
by researchers when deciding on the needle sizes to compare in
trials.
6. Our review identified no RCTs that evaluated the effects of
using needles of different sizes for administering vaccines
intended for delivery via intradermal and subcutaneous routes.
For intradermal vaccine administration, needles 10 mm to 20
mm in length with gauge sizes varying from 25 G to 27 G have
been recommended. For subcutaneous vaccinations, needles 16
mm to 25 mm in length with gauge sizes ranging from 23 G to
26 G have been recommended. Trials to identify the optimal
needle length and gauge for vaccines administered intradermally
and subcutaneously are warranted.
7. The effects of only two aspects of needle geometry (length
and gauge) were investigated in the trials included in our review.
Trials should be conducted to evaluate the effects, particularly on
vaccination-related procedural pain, of other needle
characteristics including needle bevel (e.g. three-bevel versus five-
bevel needle), needle coating (e.g. silicone versus no silicone),
and needle composition (e.g. stainless steel versus chrome nickel
steel).
8. The vaccines used in future trials should be those routinely
administered as part of national immunisation schedules. Several
of the trials included in our review involved the administration
of combination vaccines with reactogenic wP vaccine antigen
components; trials involving vaccines with different
reactogenicity profiles are required (e.g. acellular pertussis
vaccines).
Types of outcomes
The aim of any vaccination procedure should be to attain the max-
imum immunity with the least possible harm. Trials evaluating
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the effects of needle size for vaccination procedures should there-
fore ideally measure both immunogenicity and reactogenicity out-
comes.
Immunogenicity outcomes
We identified no trials that reported on the incidence of vaccine-
preventable diseases. Although these endpoints could not reason-
ably be expected in trials conducted in countries with low disease
incidence, in some settings and for some diseases (e.g. tetanus,
Haemophilus influenzae type b (Hib)) clinical disease endpoints
could potentially be used in trials. Where the use of clinical im-
munogenicity endpoints is neither practical nor feasible, two sub-
stitute immunogenicity outcomes should be used: 1) seroprotec-
tion (i.e. the proportion of vaccine recipients who responded in a
prescribed manner by reaching predefined threshold levels of pro-
tection against disease); and 2) geometric mean antibody concen-
trations or geometric mean antibody titres. We have summarised
generally accepted thresholds of vaccine-induced correlates and
surrogates of protection for selected vaccines in Appendix 3.
Reactogenicity outcomes
We identified only one trial that evaluated the effect of needle size
on vaccination-related procedural pain and procedural crying (cry-
ing with immediate onset after vaccination). Future trials should
use pain assessment tools with established validity and reliability
to measure the pain response to vaccination procedures using nee-
dles of differing lengths and gauges. We have listed several of these
tools in Appendix 2.
Some of the trials included in our review used different defi-
nitions of reactogenicity events, and some adverse events (e.g.
fever, swelling, and tenderness) were measured in different ways
in different trials. Future trials should use standardised case defi-
nitions for adverse events following immunisation (AEFI) to en-
sure comparability of results across clinical trials and to facilitate
meta-analysis of results from different trials. We suggest that re-
searchers should adopt the case definitions for AEFIs developed
by the Brighton Collaboration. Researchers should also consult
the detailed guidelines accompanying each case definition, which
are designed to facilitate the standardised collection, analysis, and
presentation of information about adverse events following im-
munisation (Brighton Collaboration 2014; see also Beigel 2007;
Gidudu 2008; Bonhoeffer 2009).
Trial reporting
Some adverse events (e.g. needle contact with bone) were not
reported in trial publications, and we were unable to determine
definitively if such events did not occur, or if such events may
have occurred but were simply not recorded and reported. We
recommend that trial authors should explicitly mention in trial
publications any adverse events that did not occur during the trial.
Our review identified several other deficiencies in trial reporting,
most notably in relation to the details provided regarding the nee-
dles, vaccines, and the vaccination procedures used in trials. At
a minimum, we would suggest that trial reports should provide
details on:
1. types of needles, including:
i) needle length and gauge;
ii) colour-coding of the needle hubs;
iii) needle composition (e.g. surgical-grade stainless steel,
chrome nickel steel);
iv) needle coating (e.g. silicone);
v) needle bevel (e.g. three-bevel needle, five-bevel needle);
vi) needle hub (e.g. luer lock plastic hub, luer lock
aluminium hub).
2. types of vaccines, including:
i) type and formulation of vaccine administered,
including details of the biological characteristics of the vaccine
(e.g. live attenuated or inactivated component vaccine, pH, and
osmolality of the vaccine) and the composition of the vaccine
(e.g. presence or absence of adjuvant);
ii) brand name of vaccine, manufacturer details, and
vaccine batch number;
iii) volume of vaccine administered.
3. vaccination technique, including:
i) details of the personnel who administered the
vaccination and any training provided;
ii) vaccination site;
iii) position of infant during vaccination procedure;
iv) bunching or stretching of skin and underlying tissues
before needle insertion;
v) angle of needle insertion;
vi) depth of needle insertion (e.g. needle inserted to full
depth (i.e. to the needle hub), 2 mm of needle exposed between
the skin and needle hub).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Diggle 2000a
Methods Randomised, controlled, parallel-group trial with 2 groups
Participants Trial setting: Buckinghamshire, England. 8 general medical practices (out of 12 general
practices approached). 2 practices were in semi-rural villages, 4 were situated near large
housing estates (1 with a high ethnic population), and 2 were in residential areas of the
town (described as “up-market areas”)
Participants: healthy infants (n = 119)* attending for third primary immunisation due
at 16 weeks of age in 1999 and spring 2000
Exclusion criteria: routine exclusion criteria for children receiving primary immunisa-
tions, as specified in national guidance at the time the trial was conducted (DoH 1996)
Of the 110 infants included in the final data analysis, 58% were male, 66% were 16 to
17 weeks of age at the time of vaccination, 24.5% were 18 to 19 weeks of age, and 9.
5% were ≥ 20 weeks of age. The mean (SD) weights were 6.7 kg (0.9) in the 23 G 25
mm group and 6.8 kg (0.9) in the 25 G 16 mm group
Interventions Needle sizes
23 G 25 mm, blue hub needle (n = 58)
25 G 16 mm, orange hub needle (n = 61)
Vaccine(s) administered
The third dose of DTwP-Hib vaccine. The vaccine contained an aluminium adjuvant
At the start of the trial all practices were using a 0.5 mL mix of Pasteur-Mérieux DTwP-
Hib vaccine. A change in national vaccine supply necessitated a change to a 1.0 mL mix
of Evans DTwP and Wyeth Lederle HibTiter
In the 23 G 25 mm group, 8/53 (15%) infants who completed the trial received the 0.
5 mL vaccine
In the 25 G 16 mm group, 8/57 (14%) infants who completed the trial received the 0.
5 mL vaccine
The 0.5 mL vaccine was presented in a uni-dose bypass syringe that allowed liquid DTwP
vaccine in the upper barrel to reconstitute dried Hib in the lower portion of the syringe
Injection technique
8 practice nurses administered the vaccines. The principal trial author (a paediatric re-
search nurse working with the Oxford Vaccine Group) recruited and trained the practice
nurses and instructed them verbally, by demonstration, and in writing to use the standard
intramuscular injection technique for infants advocated by the WHO (WHO 1998).
Practice nurses administered vaccines into the anterolateral thigh with the skin stretched
taut and the needle inserted at a 90° angle to the skin and up to the needle hub
75% of the infants who completed the trial in the 23 G 25 mm group were vaccinated
in the right leg compared with 79% in the 25 G 16 mm group
Outcomes Local reactions: erythema (redness), swelling, and tenderness at the injection site at 6
hours (on the evening after vaccination) and on the subsequent 3 evenings (day 1, day
2 and day 3)**
Composite local reaction: any local reaction (any redness, swelling, or tenderness) at
any time point after vaccination
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Diggle 2000a (Continued)
Methods used to measure the outcomes Parents were asked to examine their child’s leg each evening and to complete a “Local
Reaction Diary” on day 0 (6 hours after vaccination) and on days 1, 2, and 3 after
vaccination. If a reaction continued after day 3, parents were asked to record the date
that the reaction ended
Redness: using a ruler provided with the diary, parents measured and recorded the widest
part (in mm) of any visible redness at the injection site
Swelling: using the ruler, parents measured and recorded the widest part (in mm) of any
swelling that they could see or feel at the injection site, including any lump/hardness
that they could feel beneath the skin
Tenderness: parents gently moved their child’s leg and graded tenderness on a 0 to 3
scale:
Grade 3 = child cried when their leg was moved
Grade 2 = child cried or protested when the injection site was touched
Grade 1 = minor reaction when the injection site was touched
Grade 0 = no reaction present
When analysing the data, the trial authors used a dichotomous classification for each
reported outcome (i.e. outcome present/absent) and compared the incidence of each
local reaction between the groups at 6 hours and on days 1, 2, and 3 after vaccination.
Differences in the size of reaction between the groups were compared using a Chi2 test
for trend.
Missing outcome data In the 23 G 25 mm group, outcome data were missing for 5 (8.6%) of the randomised
trial participants. Parental diaries reporting local reactions were not returned for these 5
infants
In the 25 G 16 mm group, outcome data were missing for 4 (6.5%) of the randomised
trial participants. Parental diaries reporting local reactions were not returned for 3 infants,
and 1 infant was mistakenly included in the study at the second rather than the third
vaccination
Taking into account these reasons for missing outcome data, we judged that the data were
likely to be missing at random (i.e. the fact that these data were missing was probably
unrelated to actual values of the missing data)
Funding The trial was funded by the Smith and Nephew Foundation, London, through a nursing
research scholarship award 1998/1999
Notes *The original intention was to recruit 250 infants for the trial. However, the trial was
stopped early due to problems with the national vaccine supply when there was a nation-
wide replacement of the whole-cell pertussis component of the combined vaccine with
an acellular component that had a different reactogenicity profile. In accordance with the
guidance in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c), we did not include the early stopping of the trial in the ’Risk of bias’
assessment
**Immediate postvaccination reactions were also recorded by practice nurses. The stated
purpose of recording these reactions was to allow practice nurses to explain to the parent
how to measure any reactions; these data were not included in the final analysis
Risk of bias
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Diggle 2000a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors describe a random com-
ponent in the sequence generation process
(use of a computer-generated blocked ran-
domisation scheme stratified by practice)
Allocation concealment (selection bias) Low risk We judged that participants and investiga-
tors enrolling participants could not have
foreseen needle size allocations in advance
of, or during, enrolment due to the use of
sequentially numbered, sealed, opaque en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research nurses were not blinded, and
blinding of the parents of infants undergo-
ing vaccination was incomplete. However,
we judged that no trial outcomes were likely
to be influenced by this lack of blinding
(see Risk of bias in included studies for an
explanation of this judgement).
Blinding of outcome assessment (detection
bias)
Reactogenicity outcomes (other than pain,
crying)
Unclear risk Blinding of the outcome assessors (par-
ents) for reactogenicity outcomes was in-
complete, and we considered that there was
uncertainty over the potential for bias (see
Risk of bias in included studies for an ex-
planation of this judgement).
Incomplete outcome data (attrition bias)
Reactogenicity outcomes
Low risk Missing outcome data were reasonably
balanced in numbers across intervention
groups, with similar reasons for missing
data across groups
Selective reporting (reporting bias) Unclear risk We considered that there was insufficient
information to permit a judgement of low
risk or high risk (see Risk of bias in included
studies for an explanation of this judge-
ment).
Other bias Low risk This trial appeared to be free of other
sources of bias.
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Diggle 2006
Methods Randomised, controlled, parallel-group, non-inferiority trial with 3 groups
Participants Trial setting: 2 primary care trusts in England: 1. Vale of Aylesbury; 2. Buckinghamshire
and North East Oxfordshire. 18 general medical practices (out of 35 general practices
approached). The locations of practices ranged from affluent villages to council housing
estates, with 2 practices comprising a high proportion of ethnic minority families
Participants: healthy infants (n = 696) attending for routine vaccinations due at 2, 3,
and 4 months of age and where the first routine vaccination was due between February
2002 and January 2004
Exclusion criteria: < 37 weeks’ gestation, birth weight < 2500 g, had a severe chronic
disease, and were undergoing treatment likely to alter the immune response to vaccines
or had conditions that could bias the evaluation of an immune response (e.g. congenital
or acquired immunodeficiency)
Of the randomised infants (n = 696), 52% were male. At the time of the first, second,
and third vaccinations infants were aged: first: 7.8 to 11 weeks (mean about 8.8); second:
11.7 to 16 weeks (mean about 13); and third: 15.8 to 21 weeks (mean about 17.3)
The mean (SD) weights of the infants at the time of vaccination were:
23 G 25 mm: 5.2 kg (0.7); 25 G 16 mm: 5.3 kg (0.7); 25 G 25 mm: 5.3 kg (0.7), for
the first vaccination
23 G 25 mm: 6.0 kg (0.8); 25 G 16 mm: 6.0 kg (0.7); 25 G 25 mm: 6.1 kg (0.8), for
the second vaccination
23 G 25 mm: 6.6 kg (0.8); 25 G 16 mm: 6.8 kg (0.8); 25 G 25 mm: 6.8 kg (0.8), for
the third vaccination
Interventions Needle sizes
Group 1: 23 G 25 mm, blue hub needle (n = 240)
Group 2: 25 G 16 mm, orange hub needle (n = 230)
Group 3: 25 G 25 mm, orange hub needle (n = 226)
Vaccines administered
1. First, second, and third doses (0.5 mL)* of DTwP-Hib vaccine (ACT-Hib DTwP;
Pasteur-Mérieux-MSD, Berkshire). The vaccine contained an aluminium adjuvant
2. First, second, and third doses (0.5 mL)* of MenC vaccine. 72% of infants received
Meningitec (Wyeth Vaccines, Berkshire, UK) at the first and second doses and 76% at
the third dose, and the remainder received Menjugate (Chiron Vaccines, Liverpool, UK)
. Both of the MenC vaccines were conjugated to the CRM197 diphtheria-based protein,
and both contained an aluminium adjuvant
3. At each dose, all infants received the same brand of live oral polio vaccine (Poliomyelitis
Monodose vaccine, GlaxoSmithKline)
Injection technique
3 qualified and experienced paediatric nurses, who were appointed specifically for the
trial and who were trained by the principal trial author, administered the vaccines either
within the general practice setting or at the child’s home if parents were unable to attend
the general practice. The nurses used the standard intramuscular injection technique
for infants advocated by the WHO (WHO 2004). The vaccines were injected into the
anterolateral thigh with the skin stretched flat between the thumb and forefinger and
the needle inserted at a 90° angle into the skin up to the hub. The DTwP-Hib vaccine
was administered in the right thigh, and the MenC vaccine was given concurrently into
the left thigh
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Diggle 2006 (Continued)
Outcomes Immunogenicity outcomes
Vaccine non-response (immunogenicity failure): the number of participants who failed to
reach the following predefined protective antibody concentration thresholds:
1. diphtheria and tetanus antitoxin ≥ 0.01 µg/mL
2. MenC SBA titre > 8 using rabbit complement
3. Hib antibody level ≥ 0.15 µg/mL (correlate of short-term protection)
4. Hib antibody level ≥ 1.0 µg/mL (correlate of long-term protection)
Antibody concentrations: geometric mean concentrations of diphtheria, tetanus, and
Haemophilus influenzae type B antibodies and geometric mean titres of serogroup C
meningococcal glycoconjugate antibodies 28 to 42 days after the third vaccine dose
Local reactions: redness, swelling, hardness, and tenderness at both injection sites at 6
hours (on the evening after vaccination) and on the subsequent 3 evenings (day 1, day
2, and day 3) after vaccination with each vaccine dose
Severe local reaction: redness and swelling after vaccination covering more than two-
thirds of the anterolateral thigh
Composite local reactions: any local reaction (any redness, swelling, hardness, or ten-
derness) at any time point after vaccination
Systemic reactions and use of analgesics:
1. any pyrexia (axillary temperature ≥ 38 °C) at any time point (day 0, day 1, day 2,
day 3, or later) after the first, second, and third doses of the vaccines. Any pyrexia at
any time point after any dose of the vaccines
2. any paracetamol use at any time point after the first, second, and third doses of
the vaccines
3. any paracetamol use at any time point after any dose of the vaccines
4. sleepier than usual at any time point after any dose of the vaccines
5. vomited > 3 times in 24 hours at any time point after any dose of the vaccines
6. eating less than usual at any time point after any dose of the vaccines
7. persistent inconsolable crying (≥ 4 hours) at any time point after any dose of the
vaccines
Methods used to measure the outcomes Immunogenicity outcomes
Following application of a local anaesthetic cream (Ametop; Smith and Nephew Health-
care, Hull, UK), a 5 mL venous blood sample was taken by a research nurse at 28 to 42
days after administration of the third vaccine dose. All venepuncture procedures were
carried out in the family home. Analyses were conducted at 3 separate laboratories
1. serum immunoglobulin G against Hib was measured using ELISA, calibrated
against the US Food and Drug Administration 1983 international standard reference
serum (laboratory: Immunology Research Laboratory, Churchill Hospital, Oxford,
UK)
2. serum immunoglobulin G against tetanus was measured using ELISA, calibrated
against the WHO international standard anti-tetanus immunoglobulin (laboratory:
Immunology Research Laboratory, Churchill Hospital, Oxford, UK)
3. serogroup C meningococcal serum bactericidal assays were carried out against
strain C11 (phenotype C:16:P1.7-1,1) using baby rabbit serum (Pel-Freeze,
Rodgerson, AZ, USA) as an exogenous complement source. Serum bactericidal titres
were expressed as the reciprocal of the final serum dilution giving 50% killing at 60
minutes (laboratory: Health Protection Agency Meningococcal Reference Unit,
Manchester Royal Infirmary, Manchester, UK)
4. diphtheria antitoxin antibody levels were measured using a seroneutralisation
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assay with a micrometabolic inhibition test with reference standards (WHO
international standard for diphtheria antitoxin, first international standard
preparation) (laboratory: Sanofi Pasteur, USA)
It was not possible to allocate serum into the appropriate number of aliquots required to
go to the 3 separate laboratories. Priority for the serum analyses were therefore assigned
in the order of Hib, tetanus (for the local laboratory), MenC (for the Health Protection
Agency laboratory), and diphtheria Ags (for the US laboratory). Fewer serum samples
were therefore analysed for diphtheria antibody concentrations
No analysis of the immune response to the polio vaccine was conducted, as the vaccine
was administered orally. No analysis of the immune response to the pertussis component
of the combined vaccine was conducted due to the absence of a clear correlate of pertussis
protection
Local reactions
Parents were asked to examine the injection sites on their child’s legs (both right and left)
each evening and to complete a “Reaction Diary” on day 0 (6 hours after vaccination)
and on the subsequent 3 evenings (day 1, day 2, and day 3) after vaccination. If a reaction
continued after day 3, parents were asked to record the date that the reaction ended.
At the first vaccination visit, the research nurses instructed parents on how to complete
the reaction diary, and the demonstration was reinforced by written instructions in the
diary. If the nurse had concerns regarding parental understanding of the diary card, the
nurse contacted the parent by telephone on the first day postvaccination to offer further
clarification if necessary
The methods used to measure redness, swelling, and tenderness were identical to the
methods specified in the table above for Diggle 2000a.
Hardness: using a ruler provided with the diary, parents measured and recorded the
widest part (in mm) of any hardness or thickening of the skin at the injection sites
For the purposes of data analysis, a dichotomous classification was used for each reported
outcome (i.e. outcome present/absent)
Systemic reactions and use of analgesics
Parents were asked to answer the questions listed below and to record general reactions
in a diary at 6 hours (on the evening after the vaccination) and on the subsequent 3
evenings (day 1, day 2, and day 3). If a reaction continued after day 3, parents were asked
to record the date that the reaction ended
1. Has your child been sleepier than usual? Yes/No
2. Has your child vomited (been sick) more than 3 times in the last 24 hours? Yes/No
3. Has your child been eating less than usual? Yes/No
4. Has your child had any period of persistent crying that was not consolable by
comforting? Yes/No (parents who gave positive responses to this question were asked to
record when crying started and stopped)
Parents were also asked to record:
1. the child’s temperature at 6 hours and on the subsequent 3 evenings (day 1, day 2,
and day 3) using a digital thermometer placed in the armpit, ensuring skin-to-skin
contact. If a child’s temperature was more than 38 °C, parents were asked to take and
record temperatures morning and evening until it fell below 38 °C;
2. any paracetamol or other medication given on the first 3 days after vaccination
(including the name of medication, the date and time the medication was given, and
the reason for giving the medication).
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Missing outcome data Immunogenicity outcomes: of the 696 infants recruited to the study, a serum sample
was obtained from 614 (88%) infants. 2 samples were excluded from the immunogenicity
endpoints as the infants had been enrolled in error (infants had a birth weight < 2.
5 kg). In 120 (20%) of the samples taken, there was insufficient serum to perform
immunogenicity analyses for all 4 Ags. Serological analyses were prioritised in the order
Hib, tetanus, MenC, and diphtheria Ags; fewer samples were analysed for diphtheria
due to smaller amounts of serum obtained. The numbers of samples not analysed for
each Ag in each needle group are presented below
1. 23 G 25 mm: of the participants randomised to this group (n = 240), serum
samples were not analysed for: Hib (13%); tetanus (15%); MenC (18%); diphtheria
(36%).
2. 25 G 16 mm: of the participants randomised to this group (n = 230), serum
samples were not analysed for: Hib (16%); tetanus (17%); MenC (22%); diphtheria
(33%).
3. 25 G 25 mm: of the participants randomised to this group (n = 226), serum
samples were not analysed for: Hib (9%); tetanus (12%); MenC (16%); diphtheria
(31%).
The reasons for missing immunogenicity outcome data were similar across groups (see
notes above regarding serum aliquot assignment). On this basis, we judged that these data
were likely to be ’missing at random’ (i.e. the fact that they were missing was probably
unrelated to actual values of the missing data)
Reactogenicity outcomes: the proportions of randomised participants analysed for re-
actogenicity in the needle size groups after each dose of the vaccines were as follows
1. 23 G 25 mm: 98% after dose 1; 93% after dose 2; 90% after dose 3
2. 25 G 16 mm: 97% after dose 1; 93% after dose 2; 88% after dose 3
3. 25 G 25 mm: 99% after dose 1; 98% after dose 2; 93% after dose 3
During the trial, 11 infants experienced redness and swelling covering more than two-
thirds of the anterolateral thigh, contraindicating receipt of further whole-cell pertussis-
containing vaccine and therefore necessitating their withdrawal from the trial. 10 of the
infants were vaccinated using the narrow, short (25 G 16 mm) needle and 1 using the
wide, long (23 G 25 mm) needle. We did not treat the data for these 11 infants as missing
outcome data, and analysed and reported severe local reactions separately from other
reactogenicity outcomes in the Effects of interventions section.
Funding Funding for the trial was provided from 2 sources:
1. a competitive grant scheme, NHS Executive South East Region;
2. Becton Dickinson, a needle manufacturer.
The principal trial author described the funding arrangements as follows: “Funding for
the study (£137,000) was awarded through a competitive grant scheme administered by
the NHS executive South East Region and the study budget was formally administered
through the University of Oxford Department of Paediatrics [....] Additional support,
in the form of an unrestricted grant, was provided by Becton Dickinson, manufacturer
of injection needles. As each of the three needles were produced by this manufacturer,
this funding source did not compromise the integrity of the trial. Neither of the funding
sources had any role in study design and conduct; collection, management, analysis,
or interpretation of the data; or in preparation, review or approval of the publication
manuscript” (Diggle 2006).
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Notes *Information on the volume of vaccine administered at each dose was obtained from
Summary of Product Characteristics for each vaccine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors describe a random com-
ponent in the sequence generation process
(use of a computer-generated randomisa-
tion scheme stratified by general practice
with random variable block sizes)
Allocation concealment (selection bias) Low risk We judged that participants and investiga-
tors enrolling participants could not have
foreseen needle size allocations in advance
of, or during, enrolment due to the use of
sequentially numbered, sealed, opaque en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research nurses were not blinded, and
blinding of the parents of infants undergo-
ing vaccination was incomplete. However,
we judged that no trial outcomes were likely
to be influenced by this lack of blinding
(see Risk of bias in included studies for an
explanation of this judgement).
Blinding of outcome assessment (detection
bias)
Immunogenicity outcomes
Low risk We considered that blinding of outcome
assessment was ensured and that it was un-
likely that the blinding could have been
broken. Blood samples were analysed by
laboratory staff who were blinded to needle
size allocation
Blinding of outcome assessment (detection
bias)
Crying
Low risk Blinding of the outcome assessors (parents)
was incomplete. However, we considered
it unlikely that parental assessment and re-
porting of persistent inconsolable crying
for ≥ 4 hours would be influenced by
knowledge of needle size
Blinding of outcome assessment (detection
bias)
Reactogenicity outcomes (other than pain,
crying)
Unclear risk Blinding of the outcome assessors (parents)
was incomplete, and we considered that
there was uncertainty over the potential for
bias (see Risk of bias in included studies for
an explanation of this judgement).
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Incomplete outcome data (attrition bias)
Immunogenicity outcomes
Low risk Missing immunogenicity outcome data
were reasonably balanced in numbers
across the study groups, with similar rea-
sons for missing data across groups
Incomplete outcome data (attrition bias)
Reactogenicity outcomes
Low risk Missing reactogenicity outcome data were
balanced in numbers across the needle size
groups for all vaccine doses and at all time
points. There were similar reasons for miss-
ing data across groups, with the exception
of trial withdrawals due to severe local re-
actions (see Risk of bias in included studies
for an explanation of this judgement).
Selective reporting (reporting bias) Low risk Although we did not examine the trial pro-
tocol, the principal trial author gave us ac-
cess to all of the relevant original trial data.
We were confident that we had access to the
results for all of the prespecified primary
and secondary trial outcomes that were of
interest to our review
Other bias Low risk This trial appeared to be free of other
sources of bias.
Pathak 2007
Methods Randomised, controlled, parallel-group trial with 2 groups
Participants Trial setting: Chandigarh, India. The vaccination room of a tertiary paediatric hospital
(the Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Re-
search)
Participants: infants (n = 320) up to 24 weeks of age attending for routine primary
vaccines in January and February 2007
Exclusion criteria: preterm (gestational age < 37 weeks), chronic or acute illnesses
Of the randomised participants (n = 320), 59% were male, 43% were aged ≤ 6 weeks
at the time of vaccination, 29% were 7 to 12 weeks, and 28% were 13 to 24 weeks
In the 25 G 25 mm group (n = 161): 17.4% were classified as malnourished based on
WHO 2006 growth chart (11.9% Grade I malnutrition; 4.3% Grade II; 1.2% Grade
III)
In the 23 G 25 mm group (n = 159): 11.2% were classified as malnourished based on
WHO 2006 growth chart (6.3% Grade I malnutrition; 4.9% Grade II; 0% Grade III)
The mean weights (SD) of the 155 infants who were enrolled and randomised in February
2007 were 4.81 kg (1.05) in the 25 G 25 mm group (n = 82) and 5.13 kg (1.15) in the
23 G 25 mm group (n = 73).*
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Interventions Needle sizes
23 G 25 mm needle (n = 159)
25 G 25 mm needle (n = 161)
The needle hubs were colour coded (manufacturer: Becton, Dickinson and Company)
Vaccines administered
Infants received either the first, second, or third doses (0.5 mL) of either:
1. DTwP vaccine (Biological E. Limited (government supply), Azamabad,
Hyderabad, India);
2. DTwP-Hib vaccine (Easy Four, Panacea Biotech); or
3. DTwP-Hib-Hep B (Easy Five, Panacea Biotech or Tritanrix + Hiberix,
GlaxoSmithKline).
In the 23 G 25 mm group (n = 159):
1. 15.7% of infants received the DTwP vaccine, 13.2% the DTwP-Hib vaccine, 71.
1% the DTwP-Hib-Hep B vaccine;
2. 49% of infants received the first dose of the vaccine, 25% the second dose, and
26% the third dose.
In the 25 G 25 mm group (n = 161):
1. 13% of infants received the DTwP vaccine, 15% the DTwP-Hib vaccine, 72% the
DTwP-Hib-Hep B vaccine;
2. 51% of infants received the first dose of the vaccine, 27% the second dose, and
22% the third dose.
Injection technique
Trained staff nurses administered the vaccines using the standard intramuscular injection
technique for infants advocated by the WHO. Vaccines were administered into the
anterolateral thigh, with the skin stretched flat between the thumb and forefinger, the
needle inserted at a 90° angle and pushed down into the muscle. It is unclear if the needle
was inserted to its full length up to the hub for all infants; we were informed by 1 of the
trial authors that if an infant was malnourished, it is possible that the staff nurses may
not have inserted the full length of the needle in order to avoid injury to bone
Outcomes Pain: measured using the MBPS and a VAS
Crying: total crying duration (seconds). The proportions of infants still crying at 30,
60, and 90 seconds after vaccination
Local reactions: redness, swelling, tenderness, and restriction of movement on days 1,
2, and 3 after vaccination
Composite local reaction: any local reaction (any redness, swelling, tenderness, or
restricted movement) on day 1 after vaccination
Systemic reactions and medication use: fever and medication use on days 1, 2, and 3
after vaccination
Methods used to measure the outcomes Pain assessment using the MBPS: assessments were conducted by 2 researchers (a nurse
and a doctor). Infant behaviour was assessed at baseline using the MBPS around 5 seconds
to 1 minute before the vaccination procedure (information provided by trial author).
The vaccination procedure was recorded using a digital camera (Nikon Coolpix 7900)
5 seconds before the vaccine was administered and continued until the baby stopped
crying. The recordings were reviewed to score postvaccination behaviour of infants using
the MBPS. The researchers who conducted the baseline and postvaccination assessments
were reportedly blinded to needle gauge (information provided by trial author). Net pain
scores were calculated by subtracting prevaccination scores from postvaccination scores
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Pain assessment using the VAS: postvaccination pain was also scored by each infant’s
mother or guardian and by a researcher (nurse) using a VAS. The nurse was blinded to
needle gauge (information provided by trial author). The VAS consisted of a straight,
hatched horizontal line drawn on paper 100 mm in length and divided into 10 equal
parts. The researcher (nurse) explained to each infant’s mother that, on a scale of 0 to
100, 0 indicated no pain and 100 indicated maximum possible pain; mothers/guardians
were asked to rate their infant’s pain accordingly (information provided by trial author)
Crying duration: the total crying time (time to cessation of crying) in seconds was
measured by a researcher from the video recordings described above
Local reactions, systemic reactions, and medication use: these outcomes were only
measured for the 155 infants who were enrolled and randomised in February 2007. A
researcher (nurse) made daily telephone calls to parents on the 3 days following vacci-
nation. Parents were asked to report on the presence of redness, swelling, tenderness,
restriction of movement, fever, and the use of paracetamol. Study nurses instructed par-
ents on how to report these outcomes
Fever was defined as an axillary temperature of > 37.8 °C measured predominantly using
a mercury thermometer, although a few parents were reported to have used a digital
thermometer. Parents were asked to take the infant’s temperature morning and evening
and at any time when parents considered that the infant might be febrile (information
provided by trial author). Parents were asked to report any visible redness at the injection
site and their subjective perception of any restriction of movement experienced by their
infant. Parents were told to report tenderness if their infant cried when the injection site
was touched. For swelling, a graded scale (mild, moderate, or severe reaction) was initially
used, but the trial authors reported that parents had “difficulty in objectively measuring
the swelling as well as induration. Therefore we adopted a binary strategy (presence or
absence) of reporting all local and systemic reactions with clustering of mild, moderate
and severe reaction in a single group.”
Missing outcome data Data were available for all of the 320 participants who were enrolled and randomised in
January and February 2007 for the outcomes of pain and crying duration
Data on other reactogenicity outcomes were only available for 100/155 (64.5%) partici-
pants enrolled and randomised in February 2007. In the 23 G 25 mm group, 26/73 (35.
6%) were lost to follow-up, compared with 29/82 (35.4%) in the 25 G 25 mm group.
In both groups, all participants who were lost to follow-up did not have mobile or land-
line phones and could not be contacted to ascertain outcomes. Taking into account the
reason for missing outcome data, we judged that the data were likely to be missing at
random (i.e. the fact that these data were missing was probably unrelated to the actual
values of the missing data)
Funding The trial was not funded and was conducted as a thesis for an Master in Science degree
in Nursing
Notes *Details on mean weights were not available for the infants enrolled and randomised in
February 2007
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The trial authors describe a random com-
ponent in the sequence generation process
(use of a computer-generated randomisa-
tion scheme)
Allocation concealment (selection bias) Low risk We judged that participants and investiga-
tors enrolling participants could not have
foreseen needle size allocations in advance
of, or during, enrolment due to the use of
sequentially numbered, sealed, opaque en-
velopes to conceal allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trained staff nurses who adminis-
tered the injections were not blinded (nee-
dle hubs were colour coded). We deemed
blinding of the parents of infants undergo-
ing vaccination to be incomplete. However,
we judged that the trial outcomes were not
likely to be influenced by lack of blinding
(see Risk of bias in included studies for an
explanation of this judgement).
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk We considered that there was some uncer-
tainty over the potential for bias (see Risk
of bias in included studies for an explana-
tion of this judgement).
Blinding of outcome assessment (detection
bias)
Crying
Low risk Crying time was assessed from digital cam-
era recordings by a researcher who was re-
portedly blinded to needle size (see Risk of
bias in included studies for an explanation
of this judgement).
Blinding of outcome assessment (detection
bias)
Reactogenicity outcomes (other than pain,
crying)
Unclear risk Blinding of the outcome assessors (parents)
was incomplete, and we considered that
there was uncertainty over the potential for
bias (see Risk of bias in included studies for
an explanation of this judgement).
Incomplete outcome data (attrition bias)
Reactogenicity outcomes
Low risk There were no missing outcome data for
pain and crying duration. For other reacto-
genicity outcomes, missing data were rea-
sonably balanced in numbers across inter-
vention groups, with similar reasons for
missing data across groups
Selective reporting (reporting bias) Unclear risk We considered that there was insufficient
information to permit a judgement of low
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or high risk of bias (see Risk of bias in
included studies for an explanation of this
judgement).
Other bias Low risk This trial appeared to be free of other
sources of bias.
Nirupam 2008
Methods Randomised, controlled, parallel-group trial with 3 groups
Participants Trial setting: New Delhi, India. A child health promotion centre in a tertiary paediatric
hospital
Participants: infants (n = 150) aged 6 to 10 weeks attending between February 2008
and March 2009 for the first doses of a DTwP vaccine and a hepatitis B vaccine
Exclusion criteria: weight < 2.5 kg, progressive neurological disorders, major congenital
anomalies, “any illness and any skin disorder”
51% of the infants were male. The infants weighed 3.5 to 6.5 kg and were 50 to 66 cm
in length
In the 22 G 25 mm, 23 G 25 mm, and 24 G 25 mm groups the mean weights (SD)
were 4.8 kg (0.6) in 22 G 25 mm, 4.75 kg (0.48) in 23 G 25 mm, and 4.8 kg (0.49) in
24 G 25 mm, and mean lengths (SD) were 57 cm (2.9) 22 G 25 mm, 56.3 cm (2.3) in
23 G 25 mm, and 55.8 cm (2.1) in 24 G 25 mm
Interventions Needle sizes
22 G 25 mm (n = 50)
23 G 25 mm (n = 50)
24 G 25 mm (n = 50)
The needle hubs were colour coded (manufacturer: Becton, Dickinson and Company;
surgical grade stainless steel, regular bevel, regular wall type needles)
Vaccines administered
The first dose of DTwP (Triple Antigen, Serum Institute of India Ltd) and the first dose
of a hepatitis B vaccine (GeneVac-B, Serum Institute of India Ltd)
GeneVac-B consists of purified surface Ag of HBV obtained by culturing genetically
engineered Hansenula polymorpha yeast cells expressing the surface Ag gene of the virus.
There is no material of human or animal origin. Each paediatric dose of 0.5 mL contains
10 µg of surface Ag adsorbed on ≤ 1.25 mg of aluminium hydroxide, with ≤ 0.01%
thimerosal added as a preservative.*
Injection technique
2 nurses assisted with the vaccination procedure. 1 nurse injected the vaccine while the
other held the child’s lower limb steady. The vaccines were administered using the stan-
dard intramuscular injection technique for infants advocated by the WHO. The DTwP
vaccine was administered in the left and hepatitis B vaccines in the right anterolateral
aspects of the thigh with the skin stretched flat between the thumb and forefinger and
the needle inserted at a 90° angle into the skin up to the hub
Outcomes Crying: persistent inconsolable crying
Local reactions: redness, swelling, and tenderness at the injection site at 6 hours and on
the following 3 evenings (days 1, 2, and 3) after vaccination
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Systemic reactions and medication use: fever, vomiting, drowsiness, irritability and
refusal to feed, seizures. Use of analgesics (paracetamol), domperidone, or promethazine
for vomiting
Methods used to measure the outcomes Outcomes were recorded by parents using a diary card. Parents were contacted by tele-
phone daily by a doctor (paediatric resident) “to ensure proper observations and entries.
” The doctor making the phone calls was blinded to needle gauge. The infants were
examined in the hospital on day 4 after vaccination and the entries in the diary card were
verified by a researcher (1 of the trial authors) who was blinded to the needle group
Fever: defined as an axillary temperature > 37.4 °C as measured with a digital thermome-
ter. Parents were asked to take the infants temperature at 6 p.m. each evening and at any
time when parents considered that the infant might be febrile (information provided by
trial author)
Persistent inconsolable crying: defined as persistent crying for > 3 hours
Vomiting: defined as regurgitating a large amount of ingested milk 30 minutes after
ingestion
Drowsiness: graded by parents on a 1 to 4 scale:
1 = normal sleep duration; 2 = more sleepy than usual in terms of duration of sleep, but
arouses on own; 3 = more sleep duration but needs to be aroused; 4 = not arousable from
sleep
Irritability: graded by parents on a 1 to 4 scale:
1 = none; 2 = easily consolable; 3 = requiring increased attention but consolable; 4 =
inconsolable
Refusal to feed: recorded as either ’Yes’ or ’No’
Redness: parents were provided with a measuring tape and were asked to measure and
record the widest part of any visible redness at the injection site at 6 p.m. each evening.
Parents were instructed in the measurement technique “with the use of pictorial repre-
sentation and visual cues” (information provided by trial authors)
Swelling: parents used the measuring tape to record the circumferential diameter of
both thighs at the site of maximum swelling at 6 p.m. each evening. This measurement
was compared with the baseline measurement taken just prior to vaccination. Parents
were instructed in the measurement technique “with the use of pictorial representation
and visual cues” (information provided by trial authors). Any swelling was defined as an
increase in thigh circumference measurement of 5 to 20 mm from baseline; significant
swelling was defined as an increase in thigh circumference measurement of > 20 mm
from baseline
Tenderness: parents touched the vaccination site and graded tenderness on a 1 to 4 scale:
1 = no effect on infants activity on touching the site;
2 = makes non-specific grimace when vaccination site was touched;
3 = withdrew their legs on touching;
4 = cried when vaccination site was touched.
Each thigh was tested separately when the child was comfortable and awake prior to
touching the site. Parents were instructed that it should be a “gentle press” and that too
much force should not be applied at the vaccination site
When analysing the trial data, the trial authors used a dichotomous classification for each
reported outcome (i.e. outcome present/absent) and compared the incidence of each
local reaction between the groups at 6 hours and on days 1, 2, and 3 after vaccination
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Missing outcome data Only 1 trial participant was lost to follow-up (in the 23 G 25 mm group). The family
was reported as “having moved out of the city for personal reasons.”
Funding The trial authors state that “this study was not funded by any agency and the authors
did not take any grant from any agency.”
Notes *Details obtained from Shivananda 2006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors describe a random com-
ponent in the sequence generation process
(use of a computer-generated randomisa-
tion sequence)
Allocation concealment (selection bias) Low risk We judged that participants and investiga-
tors enrolling participants could not have
foreseen needle size allocations in advance
of, or during, enrolment due to the use of
sequentially numbered, sealed, opaque en-
velopes to conceal allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The nurses who administered the injections
were not blinded (needle hubs were colour
coded). We deemed blinding of the par-
ents of infants undergoing vaccination as
incomplete. However, we judged that the
trial outcomes were not likely to be influ-
enced by lack of blinding (see Risk of bias
in included studies for an explanation of
this judgement).
Blinding of outcome assessment (detection
bias)
Crying
Low risk We deemed blinding of the outcome as-
sessors (parents) as incomplete. However,
we considered it unlikely that parental as-
sessment and reporting of persistent incon-
solable crying for > 3 hours would be in-
fluenced by knowledge of needle size
Blinding of outcome assessment (detection
bias)
Reactogenicity outcomes (other than pain,
crying)
Unclear risk Parents recorded local reactions in a diary,
and the diary entries were “verified” by a
researcher blinded to needle gauge. As the
needle hubs were colour coded and as par-
ents were present during the vaccination
procedure, we considered that there was
uncertainty over the potential for detection
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bias for these outcomes (see Risk of bias in
included studies for an explanation of this
judgement).
Incomplete outcome data (attrition bias)
Reactogenicity outcomes
Low risk Outcome data were missing for only 1 trial
participant.
Selective reporting (reporting bias) Unclear risk We considered that there was insufficient
information to permit a judgement of low
risk or high risk (see Risk of bias in included
studies for an explanation of this judge-
ment).
Other bias Low risk This trial appeared to be free of other
sources of bias.
Middleman 2010
Methods Randomised, controlled, parallel-group trial with 2 groups
Participants Trial setting: Houston, TX. Participants enrolled between December 2001 and October
2004 at city clinics, a health fair, and a high school. Vaccinations performed either at a
clinic site or in participants’ homes if they were unable to attend the clinic
Participants: obese adolescents (n = 65) aged 14 to 24 years, weighing > 90 kg (females)
and > 120 kg (males) who reported that they had never received a hepatitis B vaccination
series
Exclusion criteria: immune system illness, chronic disease, long-term steroid use, preg-
nant, planned significant weight loss
Of the 24 adolescents included in the final data analysis 22 were female; age at enrolment
(range 14.1 to 24.7 years); BMI (range 31.1 to 49.5 kg/m2); deltoid skinfold thickness
(range 32.7 to 49.3 mm); triceps skinfold thickness (range 32 to 50 mm). The trial
participants were described as “predominantly Hispanic” and as of low socio-economic
status
Interventions Needle sizes
38 mm (n = 36)
25 mm (n = 29)
The needles had the same gauge, but the precise gauge number is unknown (personal
communication with trial authors). It is not known if the hubs of the needles were colour
coded
Vaccine(s) administered
3 doses of a recombinant hepatitis B vaccine (Engerix B, GlaxoSmithKline Biologicals,
Rixensart, Belgium) administered on a 0 (first dose), 1 month (second dose), 4 month
(third dose) schedule. Participants who were younger than 19 years received 0.5 mL of
the vaccine, and those aged 19 years or over received 1.0 mL
5 participants (out of the 14 analysed) in the 38 mm group and 2 participants (out of
the 10 analysed) in the 25 mm group received the vaccine series with a 0.5 mL dose
Each 0.5 mL dose of Engerix B contains 10 µg of hepatitis B surface Ag adsorbed on 0.
25 mg aluminium as aluminium hydroxide. Each 1 mL dose contains 20 µg of hepatitis
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B surface Ag adsorbed on 0.5 mg aluminium as aluminium hydroxide. Engerix B is
formulated without preservatives and contains trace amounts of thimerosal (< 1.0 µg
mercury), sodium chloride (9 mg/mL), and phosphate buffers (disodium phosphate
dihydrate, 0.98 mg/mL; sodium dihydrogen phosphate dihydrate, 0.71 mg/mL).*
The median time from the first to the third vaccinations was 136 days (range 119 to
177) in the 25 mm (1 inch) group and 130 days (range 123 to 156) in the 38 mm (1½
inch) group
Injection technique
The principal trial author (a faculty paediatrician (adolescent medicine subspeciality))
and a medical student (trained by the principal trial author) administered the vaccine
injections using the same standardised protocol. Injections were given at a 90° angle to
the deltoid muscle, leaving 2 to 3 mm of needle visible between the arm and the needle
hub. The skin was stretched before needle insertion (personal communication with trial
authors)
Outcomes Immunogenicity outcomes
Vaccine non-response (immunogenicity failure): the number of participants who received
all 3 doses of the vaccine but who failed to reach anti-HBs titre levels ≥ 1.5 mIU/mL.
NOTE: in our review we used the cut-off threshold value of ≥ 10 mIU/mL cited in
Appendix 3. Using this threshold value had no impact on the trial results pertaining to
seroprotection
Antibody concentrations: antibody titres to hepatitis B surface Ag (anti-HBs) 2 months
after the third vaccination
Methods used to measure the outcomes Blood was obtained at baseline and 2 months after the third vaccination. The time from
third vaccination to titre assessment was 64 days (range 57 to 72) in the 25 mm needle
group and 66 days (range 59 to 76) in the 38 mm needle group. Presence of antibody
to hepatitis B surface Ag (anti-HBs) was determined at baseline (to rule out previous
immunisation) and after completion of the vaccination series using the AUSAB kit
(Abbott Laboratories, North Chicago, IL). This kit uses a solid-phase ELISA technique
to detect anti-HBs levels in serum or plasma. Testing was carried out in a laboratory at
the Baylor College of Medicine by a laboratory technician who was blinded to group
allocation (personal communication with trial authors)
Missing outcome data In the 25 mm needle group, 19/29 (65.5%) randomised participants were not included
in the final data analysis. 10 were withdrawn for positive baseline anti-HBs (evidence
of previous immunisation), 8 moved or did not response to follow-up communication,
and 1 was a vaccine non-responder (and received a fourth dose of the vaccine as per the
study protocol)
In the 38 mm needle group, 22/36 (61%) randomised participants were not included
in the final data analysis. 7 were withdrawn for positive baseline anti-HBs, 1 was a
vaccine non-responder, and the remainder either moved, did not respond to follow-up
communication, or voluntarily withdrew from the trial (personal communication with
trial author)
Funding Funding for the trial was provided from the following sources:
1. The Society for Adolescent Medicine/APA/Centers for Disease Control and
Prevention Adolescent Special Immunization Projects Award, 2001;
2. The Maternal and Child Health Bureau, Health Resources and Services
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Administration, Department of Health and Human Services (Project 1T71 MC00022-
01).
GlaxoSmithKline donated all doses of the Engerix vaccine used in the trial
Notes *Details regarding the formulation of the vaccine were obtained from a 2001 Summary of
Product Characteristics for Engerix B (manufactured by SmithKline Beecham Biologicals
(now known as GlaxoSmithKline), Rixensart, Belgium) (SKB 2001).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors describe a random com-
ponent in the sequence generation process
(use of a random numbers table)
Allocation concealment (selection bias) High risk No allocation concealment procedure was
used in the trial (personal communication
with trial authors)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk There was no blinding of the trial partici-
pants and personnel. However, we judged
that the trial outcomes were not likely to be
influenced by lack of blinding (see Risk of
bias in included studies for an explanation
of this judgement).
Blinding of outcome assessment (detection
bias)
Immunogenicity outcomes
Low risk The laboratory technician who analysed
the blood samples was unaware of what
needle group (25 mm or 38 mm) the sam-
ples were from (personal communication
with trial authors)
Incomplete outcome data (attrition bias)
Immunogenicity outcomes
Unclear risk Missing outcome data were balanced in
numbers across the 2 needle size groups
with similar reasons for missing data across
groups. However, there was a notable dis-
parity between the number of participants
randomised (n = 65) and analysed (n = 24)
, and we considered that there was some
uncertainty over the potential for bias
Selective reporting (reporting bias) Unclear risk We considered that there was insufficient
information to permit a judgement of low
risk or high risk (see Risk of bias in included
studies for an explanation of this judge-
ment).
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Other bias Low risk There was an imbalance in the ages of the
trial participants in the 2 study groups,
which resulted in differences between the
groups in the dose of the vaccine adminis-
tered. However, we judged that this was un-
likely to have materially influenced the trial
results (see Risk of bias in included studies
for an explanation of this judgement).
Ag: antigen
anti-HBs: hepatitis B surface antibodies
BMI: body mass index
DTwP: diphtheria, tetanus and whole-cell pertussis
DTwP-Hib: diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b
DTwP-Hib-Hep B: diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae type b, and hepatitis B
ELISA: enzyme-linked immunosorbent assay
HBV: hepatitis B virus
MBPS: Modified Behavioural Pain Scale
MenC: meningococcal C
NHS: National Health Service (UK)
SBA: serum bactericidal activity
SD: standard deviation
VAS: visual analogue scale
WHO: World Health Organization
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Ipp 1989 Not a randomised controlled trial. The trial participants were assigned sequentially to the study groups
Additional notes: children aged 18 months (n = 246) who were receiving a combined diphtheria, tetanus, whole-
cell pertussis, and inactivated polio vaccine (DTwP-IPV) were assigned sequentially to 1 of 3 groups: intramuscular
injection into the deltoid region with a 25 G 16 mm needle; intramuscular injection into the anterolateral thigh
with a 25 G 25 mm needle; intramuscular injection into the anterolateral thigh with a 25 G 16 mm needle
Shaw 1989 Trial participants were not children and adolescents. The mean ages in years of the participants in the 3 comparison
groups of the trial were 37.4 (SD 11.0), 35.5 (SD 9.9), and 38.4 (SD 11.7)
Additional notes: a parallel-group randomised trial with 3 groups involving healthy adult healthcare workers.
Participants (n = 634) were randomly allocated to receive a plasma-derived hepatitis B vaccine (Heptavax-B, MSD)
administered with: 1) a 25 mm needle into the deltoid region of the upper arm; 2) a 25 mm needle into the upper
lateral quadrant of the buttock; 3) a 50 mm needle into the buttock.*
*Administering hepatitis B vaccine into the buttock is no longer recommended for infants, children, adolescents, and
adults. The Centers for Disease Control and Prevention have recommended that: “hepatitis B vaccine administered
by any route or site other than intramuscularly in the deltoid muscle should not be counted as valid and should be
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repeated unless serologic testing indicates that an adequate response has been achieved” (CDC 2005; CDC 2006a).
Johnsen 1995 Not a randomised controlled trial and did not involve children or adolescents as defined in this review
Additional notes: in 1992, approximately 1600 employees of the Massachusetts Department of Correction (DOC)
and 200 healthcare workers in 21 DOC correctional facilities received 3 doses of a hepatitis B vaccine (Engerix-B)
administered into the deltoid muscle. It was subsequently discovered that the vaccines had been administered with
needles of different lengths (16, 25, and 38 mm) in different facilities. 225 staff had blood drawn for hepatitis B
surface antibody titre determinations, and the immune response was analysed according to needle length. Facilities
were classified based on the shortest needle used when more than 1 needle length had been used at a facility. The
facility from where blood had been drawn could be identified for only 174 individuals
Cook 2005 Different injection techniques were used in the comparison groups
Additional notes: children aged 2, 4, 6, and 18 months (n = 375) were randomly allocated to receive an acellular
pertussis-containing and Haemophilus influenzae type b vaccine administered intramuscularly into the anterolateral
thigh using 3 injection techniques: 1) the Australian technique with a 23 G 25 mm needle; 2) the US technique
with a 23 G 25 mm needle; or 3) the WHO technique with a 25 G 16 mm needle. The trial authors describe these
techniques as follows
1. Australian technique: “the needle was inserted at the junction of the upper and middle thirds of the vastus
lateralis with the needle angled at 45°- 60° to the skin and pointing down towards the knee”
2. US technique: “The needle was inserted into the upper lateral quadrant of the thigh at an angle of 45° to the
long axis of the femur and posteriorly at an angle of 45° to the table top, with the baby supine. The thigh muscle
was bunched at the injection site to increase muscle mass and to minimise the chance of striking bone”
3. WHO technique: “The needle was inserted into the anterolateral thigh at an angle of 90° to the long axis of
the femur with the skin compressed between the index finger and the thumb”
Jackson 2008 Not a randomised controlled trial
Additional notes: Children (n = 1498; median age 4.5 years) participating in a postlicensure assessment of the
safety of the fifth consecutive dose of a combined diphtheria, tetanus, and acellular pertussis vaccine (DTaP) were
vaccinated at a large health maintenance organisation in Washington state by clinical staff “according to their usual
practice.” Of the 1315 children included in the final analysis, 1174 were vaccinated in the upper arm (381 with a
16 mm needle; 793 with a 25 mm needle), and 141 were vaccinated in the thigh (49 with a 16 mm needle and 92
with a 25 mm needle)
Ozdemir 2012 Precise methods used to allocate participants to study groups could not be definitively determined, and insufficient
details were available regarding outcome data
Additional notes: full-term, healthy macrosomic infants (n = 65) with a birth weight > 4000 g born at a maternity
teaching hospital in Turkey between February and April 2011 were vaccinated with 3 doses (0.5 mL) of a recombinant
hepatitis B vaccine administered on a 0 (first dose, shortly after birth), 1 month (second dose), 6 month (third
dose) schedule. For the first dose of the vaccine, either a 26 G 25 mm needle (n = 32) or a 26 G 16 mm needle
(n = 33) was used to administer the vaccine. All subsequent vaccinations (at 1 and 6 months) in both groups were
administered using a 26 G 25 mm needle
All infants were vaccinated at birth (first dose) by the same nurse in the hospital. All vaccinations at 1 and 6 months
(i.e. second and third doses) were performed by the same nurse at an outpatient clinic. Vaccines were administered
into the quadriceps muscle of the anterolateral thigh using the ’pinching technique’ described by Groswasser 1997
which “requires bunching the thigh muscle at the injection site to increase muscle mass and to minimize the chance
of striking bone.”
The needle was inserted at a 90° angle to the skin and up to the needle hub (i.e. no needle visible between the skin
and hub)
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Fateh 2014 Different types of syringe were used in the comparison groups
Additional notes: the trial participants were children (n = 1000) attending 4 primary healthcare centres for either
the first dose (due at age 2 months), second (due at age 4 months), third (due at 6 months), fourth (booster 1, due
at 18 months), or fifth (booster 2, due at 6 years) doses of a DTwP vaccine. The children were randomly allocated
to be vaccinated with either:
1. 1 mL syringe with a 24 G 25 mm needle; or
2. 0.5 mL auto-disable syringe with a 23 G 25 mm needle.
The trial authors do not describe the injection technique used to administer the vaccine. The first to the fourth
doses of the vaccine were injected into the thigh. The fifth dose was injected into the deltoid
DTwP: diphtheria, tetanus, and whole-cell pertussis
SD: standard deviation
WHO: World Health Organization
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D A T A A N D A N A L Y S E S
Comparison 1. Comparisons between needles with different lengths and different gauges




participants Statistical method Effect size
1 Individual local reactions:
swelling, tenderness, and
redness on the day after
vaccination with the third dose
of a DTwP-Hib vaccine
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Swelling 2 528 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.36, 0.93]
1.2 Tenderness 2 528 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.40, 1.00]
1.3 Redness 2 528 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.36, 1.01]
Analysis 1.1. Comparison 1 Comparisons between needles with different lengths and different gauges,
Outcome 1 Individual local reactions: swelling, tenderness, and redness on the day after vaccination with the
third dose of a DTwP-Hib vaccine.
Review: Needle size for vaccination procedures in children and adolescents
Comparison: 1 Comparisons between needles with different lengths and different gauges
Outcome: 1 Individual local reactions: swelling, tenderness, and redness on the day after vaccination with the third dose of a DTwP-Hib vaccine









Diggle 2000a 15/53 36/57 48.2 % 0.45 [ 0.28, 0.72 ]
Diggle 2006 30/215 39/203 51.8 % 0.73 [ 0.47, 1.12 ]
Subtotal (95% CI) 268 260 100.0 % 0.58 [ 0.36, 0.93 ]
Total events: 45 (23 G 25 mm), 75 (25 G 16 mm)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.20, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Tenderness
Diggle 2000a 4/53 8/57 16.5 % 0.54 [ 0.17, 1.68 ]
Diggle 2006 22/215 32/203 83.5 % 0.65 [ 0.39, 1.08 ]
Subtotal (95% CI) 268 260 100.0 % 0.63 [ 0.40, 1.00 ]
Total events: 26 (23 G 25 mm), 40 (25 G 16 mm)
0.01 0.1 1 10 100
Favours 23 G 25 mm Favours 25 G 16 mm
(Continued . . . )
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Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
3 Redness
Diggle 2000a 15/53 36/57 42.5 % 0.45 [ 0.28, 0.72 ]
Diggle 2006 70/215 87/203 57.5 % 0.76 [ 0.59, 0.97 ]
Subtotal (95% CI) 268 260 100.0 % 0.61 [ 0.36, 1.01 ]
Total events: 85 (23 G 25 mm), 123 (25 G 16 mm)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.76, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.97), I2 =0.0%
0.01 0.1 1 10 100
Favours 23 G 25 mm Favours 25 G 16 mm
A P P E N D I C E S
Appendix 1. Needle size recommendations for administering vaccines via the intramuscular route
made by National Immunization Technical Advisory Groups (NITAGs) in 4 countries
Needle size recommendations made by NITAGs in 4 countries for administering intramuscular vaccine injections at preferred
injection sites in children and adolescents








Preterm or very small in-
fants
A-L thigh NS 16 mm
Infants < 1 year A-L thigh 23 G or 25 G 25 mm
Older children and
adults
Deltoid 23 G or 25 G 25 mm
Ireland/NIAC
(NIAC 2016)
Infants < 2.5/3 kg A-L thigh NS 16 mm
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Birth to < 12 months A-L thigh 23 G to 25 G 25 mm
12 to < 36 months A-L thigh or deltoid 23 G to 25 G 25 mm
3 years and older1 Deltoid 23 G to 25 G 25 mm
US/ACIP2
(Kroger 2017)
Neonates (first 28 days of
life)
A-L thigh 22 G to 25 G 16 mm3
Infants 1 to 12 months A-L thigh 22 G to 25 G 25 mm
Toddlers 1 to 2 years A-L thigh 22 G to 25 G 25 to 32 mm
Children 3 to 18 years Deltoid 22 G to 25 G 16 mm3 to 25 mm
Australia/ATAGI
(ATAGI 2016)
Preterm babies (< 37
weeks’ gestation) up to
age 2 months; or very
small infants
A-L thigh 23 G or 25 G4 16 mm
Infants < 12 months A-L thigh 23 G or 25 G4 25 mm
Children ≥ 12 months,
adolescents, and adults5
Deltoid 23 G or 25 G4 25 mm
ACIP: Advisory Committee on Immunization Practices; ATAGI: Australian Technical Advisory Group on Immunisations; JCVI:
Joint Committee on Vaccines and Immunisation; NIAC: National Immunisation Advisory Committee. A-L: anterolateral; NS: gauge
not explicitly specified
1A 40 mm needle is recommended in women > 90 kg and men > 118 kg (gauge not specified)
2The guidance states that “The needle gauge for intramuscular injection is 22-25 gauge. A decision on needle length and site of
injection must be made for each person on the basis of the size of the muscle, the thickness of adipose tissue at the injection site, the
volume of the material to be administered, injection technique, and the depth below the muscle surface into which the material is to
be injected” (Kroger 2017).
316 mm is deemed to be adequate if the skin is stretched tightly and subcutaneous tissues are not bunched
4If using a narrow 25 G needle for an intramuscular vaccination, it is recommended that the vaccine is injected slowly over a count
of 5 seconds to avoid injection pain and muscle trauma (ATAGI 2016).
5A 23 G or 25 G 38 mm needle is recommended for a very large or obese person
The precise reasons for some of the disparities in needle size recommendations between different countries are unclear. One contrib-
utory factor may be the use of different research evidence to inform the recommendations (see Appendix 9).
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Appendix 2. Pain assessment tools with established validity and reliability
For the purposes of this review, we will use the same definition of “established validity and reliability” specified in the protocol for
a Cochrane Review of psychological interventions for needle-related procedural pain (Uman 2005), namely “prior publication in at
least one scientific paper from a peer-reviewed journal.” These validated and reliable pain assessment tools will include, but may not be
limited to, the tools recommended by the Brighton Collaboration for assessing immunisation site pain (Gidudu 2012), the tools listed
in the Royal College of Nursing’s clinical practice guideline on the recognition and assessment of pain in children (RCN 2009), and
the tools specified in the protocols for Cochrane Reviews that have evaluated the effects of interventions for needle-related procedural
pain or procedural pain (Lander 2002; Uman 2005; Pillai Riddell 2006; Harrison 2010; Kassab 2010; Hogan 2012). The names of
these tools are provided in the tables below.
Table A: Pain assessment tools recommended by the Brighton Collaboration for assessment of acute and delayed pain following
immunisation (Gidudu 2012)
Age Assessment methods for acute pain fol-
lowing immunisation: assessor and tool
Assessment methods for delayed pain
following immunisation: assessor and
tool
Pre-verbal child
≤ 18 months Clinician: MBPS
Parent: NRS
Parent: NRS (for pre-verbal children ≤ 3
years)
> 18 months Clinician: FLACC
Parent: NRS
Verbal child
≥ 3 to 6 years Child: Poker Chip Child: Poker Chip
≥ 4 years Child: FPS-R Child: FPS-R
≥ 9 years Child: NRS Child: NRS
FLACC: Face Legs Activity Crying Consolability scale (Merkel 1997); FPS-R: Faces Pain Scale Revised (Hicks 2001); MBPS: Modified
Behavioural Pain Scale (Taddio 1995); NRS: Numerical Rating Scale (Miró 2009; von Baeyer 2009; Bailey 2010); Poker Chip: Poker
Chip tool (Hester 1979).
NOTE: the references cited above are those specified by the Brighton Collaboration (Gidudu 2012).
The following tables summarise pain scales described by the Royal College of Nursing as valid and reliable tools for assessing pain
intensity in neonates and non-verbal children with cognitive impairment (Table B) and infants and verbal children without cognitive
impairments (Table C) (RCN 2009). References for all scales mentioned in the tables are provided in RCN 2009.
Table B: Pain scales for assessing pain intensity in neonates and non-verbal children with cognitive impairment
Pain scales for neonates Pain scales for non-verbal children with cognitive impairment
Tool name Features Tool name Features
95Needle size for vaccination procedures in children and adolescents (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
COMFORT OR; T; PM Face, Legs, Activity, Cry, Consolability
(FLACC)
OR
CRIES OR; T; PM Paediatric Pain Profile (PPP) OR
Neonatal Facial Coding System
(NFCS)
OR; T Non-Communicating Children’s Pain
Checklist - Revised (NCCPC-R)
OR
Nepean NICU Pain Assessment
Tool (NNICUPAT)
OR; T NCCPC-PV (Non-Communicating
Children’s Pain Checklist - Post-operative
Version)
OR
Neonatal Infant Pain Scale
(NIPS)
OR; T -
Objective Pain Scale (OPS) OR; T; PM
Pain Assessment Tool (PAT) OR; T; PM
Premature Infant Pain Profile
(PIPP)
OR; T; PM
OR: observer rated; PM: tool includes physiological measures; T: requires training
Table C: Pain scales for infants and verbal children
Tool name Features
Alder Hey Triage Pain Scale (AHTPS) OR; T
Cardiac Analgesic Assessment Tool (CAAT) OR; T
Chedoke-McMaster Paediatric Pain Management Sheet OR; T; SR
Colour Analogue Scale T; SR
Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS) OR
COMFORT OR; T; PM
Derbyshire Children’s Hospital Pain Tool (DCHPT) OR; T
FACES scale (Wong-Baker) OR; T
FACES scale (a six-graded faces scale by Tree Takarn) SR; T
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Faces Pain Scale (FPS; by Bieri) SR; T
Face, Legs, Arms, Cry, Consolability (FLACC) OR; T




Poker Chip Tool SR; T
Post-operative Pain Score (POPS) OR; T
Pain Rating Scale OR; T
Sheffield Children’s Hospital Facial Expression Scale SR; T
Toddler Preschool Post-operative Pain Scale (TPPPS) OR; T
University of Wisconsin Pain Scale OR; T
Visual Analogue Scale (self rated) SR; T
Visual Analogue Scale (observer rated) OR; T
Verbal Rating Scale SR; T
Word Descriptor Scale SR; T
Word Graphic Rating Scale SR; T
OR: observer rated; PM: tool includes physiological measures; SR: self report tool; T: requires training
Tools not mentioned in Tables A to C (above) but that are cited in protocols for Cochrane Reviews that have evaluated the effects of
interventions for needle-related procedural pain or procedural pain include the following:
1. Douleur Aiguë du Noveau-né pain scale (DAN) (cited in protocol by Hogan 2012);
2. Riley Infant Pain Scale (RIPS); Infant Body Coding System (IBCS); E’chelle Bouleur Inconfort Nouveau-Ne’ (EDIN) (cited in
protocol by Kassab 2010);
3. Baby Facial Action Coding System; Maximally Discriminative Facial Movement Coding System; Children’s and Infants
postoperative Pain Scale; Clinical Scoring System; Modified Postoperative Comfort Score; Liverpool Infant Distress Scale; Neonatal
Pain, Agitation and Sedation Scale (N-PASS); Scale for Use in Newborns (SUN); Pain Assessment in Neonates Scale (PAIN); Bernese
Pain Scale (cited in protocol by Pillai Riddell 2006).
References for all of these tools are provided in the protocols by Pillai Riddell 2006; Kassab 2010; and Hogan 2012.
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Appendix 3. Quantitative correlates and surrogates of protection after vaccination
Table A: Thresholds of vaccine-induced correlates and surrogates of protection for selected vaccines (adapted from Plotkin
2010; Thakur 2012)
Vaccine Test Threshold of
protection
Serum IgG Mucosal IgG Mucosal IgA T cells
Diphtheria Toxin neutralisa-
tion
0.01 to 0.1 IU/
mL
++
Hepatitis A ELISA 10 mIU/mL ++
Hepatitis B ELISA 10 mIU/mL ++
Hib polysaccha-
rides
ELISA 1 µg/mL ++ +
Hib conjugate ELISA 0.15 µg/mL ++ ++
Hib polysaccha-
rides
ELISA 1.0 µg/mL ++ ++
Japanese
encephalitis
Neutralisation 1:10 titre ++
Measles Microneutralisa-
tion
120 to 200 mIU/
mL
++ +(CD8+)





















≥ 1:64 titre; ≥ 5
IU/mL
++ +(CD4+)
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Yellow fever Neutralisation 0.7 LNI ++
ELISA: enzyme-linked immunosorbent assay; FAMA: fluorescent antibody-to-membrane-antibody; Hib: Haemophilus influenzae
type b; Ig: immunoglobulin; LNI: log neutralisation index.
Appendix 4. Glossary of selected terms used within the review
Adjuvant: a vaccine component that is intended to modify or augment the effects of a vaccine by stimulating the immune system to
respond more vigorously to the vaccine antigen. Aluminium salts are most often used as adjuvants in contemporary vaccines.
Anaphylaxis: “a sudden and severe allergic reaction, which results in a serious fall in blood pressure and/or respiratory obstruction and
may cause unconsciousness and death if not treated immediately” (ATAGI 2013: p 489).
Brachial neuritis: “Pain in the arm, causing persisting weakness of the limb on the side of vaccination” (ATAGI 2013: p 489).
Brighton Collaboration: an international voluntary collaboration that facilitates the development, evaluation, and dissemination of
high-quality information about the safety of human vaccines (Bonhoeffer 2002). The Brighton Collaboration “develops standardized
case definitions [for adverse events following immunisation] and guidelines for data collection, analysis and presentation via participation
of more than 500 experts from 57 countries from public health, clinical care, academic, regulatory organizations and industry” (Kohl
2005).
Cellulitis: “diffuse and especially subcutaneous inflammation of connective tissue” (Merriam-Webster 2013).
Correlate of vaccine protection: in this Cochrane Review, a correlate of protection is defined in accordance with the definition proposed
by Plotkin 2008b: “A specific immune response to a vaccine that is closely related to protection against infection, disease or other
defined end point”. Correlates of protective immunity usually entail vaccine-induced immune responses. Historically these responses
have been defined in terms of antibody titres, although current technology also allows consideration of cell-mediated, mucosal and
memory-based immune responses (Hudgens 2004). Widely accepted immunological correlates of protection exist for certain antigens
and consist of “defined humoral antibody responses above which there is a high likelihood of protection in the absence of any host
factors that might increase susceptibility to the infectious agent” (EMA 2005).
Febrile: “related to a fever, as in febrile illness and febrile convulsions” (ATAGI 2013: p 491).
Geometric mean: the average of logarithmic values, converted back to the base. It is less sensitive than the arithmetic mean to one or a
few extreme values (CDC 2006b). The geometric mean is the measure of choice for variables measured on an exponential or logarithmic
scale, such as dilutional titres of assays, and it is a standard statistic used to summarise immunogenicity values. If the observations are
titres, the geometric mean titre (GMT) is used. If the observations are concentrations, the geometric mean concentration (GMC) is
used (Nauta 2011). Both GMC and GMT are commonly used immune response endpoints in vaccine efficacy trials (Horne 2001).
Geometric mean fold increase (GMFI): refers to the postvaccination antibody level divided by the prevaccination antibody level.
Haematoma: “a mass of usually clotted blood that forms in a tissue, organ, or body space as a result of a broken blood vessel”
(Merriam-Webster 2013).
Hypotonic-hyporesponsive episode (shock, collapse): “the sudden onset of pallor or cyanosis, limpness (muscle hypotonia), and
reduced responsiveness or unresponsiveness occurring after vaccination, where no other cause is evident, such as a vasovagal episode or
anaphylaxis. The episode usually occurs 1 to 48 hours after vaccination and resolves spontaneously” (ATAGI 2013: p 491).
Immunobiologic: “Antigenic substances (e.g., vaccines and toxoids) or antibody-containing preparations (e.g., globulins and antitoxins)
from human or animal donors. These products are used for active or passive immunization or therapy. Examples of immunobiologics
include antitoxin, immune globulin and hyperimmune globulin, monoclonal antibodies, toxoids, and vaccines” (CDC 2011).
Immunogenicity: the ability of a vaccine to induce a humoral-mediated or a cell-mediated (or both) immune response. The ideal
endpoint for evaluating the immune response to an administered vaccine is the incidence of the disease the vaccine is designed to
prevent. However, commonly used endpoints in vaccine clinical trials include the geometric mean concentration (GMC) or geometric
mean titre (GMT) of antibodies elicited by the vaccine and the ’proportion of seroprotected vaccine recipients’ (see Glossary entry
below for an explanation of this term).
Jet injectors: these are “needle-free devices that pressurize liquid medication, forcing it through a nozzle orifice into a narrow stream
capable of penetrating skin to deliver a drug or vaccine into intradermal, subcutaneous, or intramuscular tissue” (CDC 2011).
Morphological: “of, relating to or concerned with form or structure” (Merriam-Webster 2013).
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Necrosis: “Death of living tissue; specifically: death of a portion of tissue differentially affected by local injury” (Merriam-Webster
2013).
Needle size: in this Cochrane review, the term ’needle size’ is used to refer to two dimensions of needle geometry, namely gauge and
length.
National Immunization Technical Advisory Groups (NITAGs): these groups are “Expert advisory committees that provide rec-
ommendations to guide a country’s national immunization programmes and policies. They consist of independent experts with the
technical capacity to evaluate new and existing immunization interventions. The premise of these groups is to facilitate a system-
atic, transparent process for developing immunization policies by making evidence-based technical recommendations to the national
government” (Bryson 2010). One global survey of these advisory groups reported the existence of NITAGs in 89 countries (Bryson
2010). Details of the NITAGs in different countries can be obtained from the SIVAC initiative’s (Supporting National Independent
Immunization and Vaccine Advisory Committees) NITAG Resource Center (AMP 2012a; AMP 2012b).
Paraesthesia: “a sensation of pricking, tingling, or creeping on the skin having no objective cause and usually associated with injury or
irritation of a sensory nerve or nerve root” (Merriam-Webster 2013).
Proportion of seroprotected vaccine recipients: this refers to the proportion of vaccine recipients who respond in a prescribed manner
to the vaccine administered. This endpoint in vaccine clinical trials is particularly meaningful “if there is a particular threshold level of
immune response that is believed to be important. For example, for Haemophilus influenzae type b (Hib), proportion of recipients with
a postvaccination concentration of anti-polyribosyl ribitol phosphate antibody that is ≥0.15µg/mL and ≥1.00µg/mL have been used
to evaluate the immune response to the Hib component” (Horne 2001).
Reactogenicity: in accordance with other Cochrane Reviews (e.g. Bar-On 2012), the term reactogenicity is used in this Cochrane
Review to refer to adverse events following the administration of a vaccine. Common reactogenicity events that occur following
vaccination include pain, redness, swelling, induration and tenderness at the injection site, local hypersensitivity reactions, and systemic
adverse reactions that include fever, malaise, myalgia, irritability, headache, and loss of appetite (DoH UK 2012b).
Serious adverse event: for the purposes of this review, this term refers to any untoward medical occurrence after vaccine administration
that at any dose results in death, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or
significant disability/incapacity, or is life-threatening (WHO 2013b).
Substitute immunogenicity endpoint: in this Cochrane Review the term ’substitute endpoint’ is a general term that includes both
correlates and surrogates of vaccine protection, or ’intermediate endpoints’, i.e. immune response quantities that may be measured
instead of the clinical endpoint (i.e. disease) of ultimate interest. The term ’substitute endpoint’ has been used in recent World Health
Organization publications in recognition of the fact that the terms ’correlates’ and ’surrogates’ of protection are defined and used
inconsistently in the international literature (WHO 2013a).
Surrogate of vaccine protection: in this Cochrane Review, a surrogate is defined in accordance with the definition proposed by Plotkin
2008b: “a quantified specific immune response to a vaccine that is not in itself protective but that substitutes for the true (perhaps
unknown) correlate.”
Syncope (faint): “episode of pallor and unresponsiveness or reduced responsiveness or feeling light-headed AND occurring while
vaccine is being administered or shortly after (usually within 5 minutes) AND bradycardia AND resolution of symptoms with a change
in position (supine position or head between knees or limbs elevated)” (ATAGI 2013: p 493).
Vaccine antigen: “the active component of a vaccine is known as the vaccine ”antigen“. This is a modified or partial form of the virus,
bacteria or the toxin that causes the disease against which the vaccine protects. The vaccine antigen is altered from its original form so
it no longer causes disease, but it can produce an immune response” (NCIRS 2013: p 1).
Vaccination and immunisation: although the terms ’vaccination’ and ’immunisation’ are frequently used interchangeably in the
international literature, they are not strictly synonymous “because the administration of an immunobiologic cannot be equated
automatically with development of adequate immunity” (CDC 2011). In this Cochrane Review, the term ’vaccination’ is used to refer
to the physical act of administering any vaccine or toxoid. The term ’immunisation’ is used to refer to the process of inducing or
providing immunity by administering an immunobiological (CDC 2011). The only exception to this occurs in the context of the
phrases ’adverse events following immunisation (AEFI)’ and ’immunisation schedules’, which are established terms that are widely
used in the international literature. Within the context of these phrases, the word ’immunisation’ should be understood as referring to
vaccine administration rather than the process of inducing immunity.
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Appendix 5. Search strategies for CENTRAL (the Cochrane Library), MEDLINE and MEDLINE in
Progress (Ovid), Embase (Ovid), and CINAHL (EBSCO)
CENTRAL
#1 MeSH descriptor: [Immunization] explode all trees
#2 MeSH descriptor: [Immunization Programs] explode all trees
#3 MeSH descriptor: [Injections] explode all trees
#4 (immuni* or vaccin* or inject*):ti,ab,kw (Word variations have been searched)
#5 #1 or #2 or #3 or #4
#6 needle*:ti,ab,kw (Word variations have been searched)
#7 MeSH descriptor: [Needles] this term only
#8 #6 or #7
#9 #5 and #8
MEDLINE (Ovid)
1 exp Immunization/
2 exp Immunization Programs/
3 exp Injections/





9 5 and 8
10 randomized controlled trial.pt.







18 exp animals/ not humans.sh.
19 17 not 18
20 9 and 19
Embase (Ovid)
1. exp Immunization/
2. exp Immunization Programs/
3. exp Injections/












16. (doubl$ adj blind$).tw.
17. (singl$ adj blind$).tw.
18. assign$.tw.
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23. Randomized Controlled Trial/
24. Single Blind Procedure/
25. or/10-24
26. (animal/ or nonhuman/) not human/
27. 25 not 26
28. 9 and 27
CINAHL (EBSCO)
S19 S9 AND S18
S18 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17
S17 (allocat* random*)




S12 (MH “Random Assignment”)
S11 (Randomi?ed control* trial*)
S10 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S9 S5 AND S8
S8 S6 OR S7
S7 needle*
S6 (MH “Needles”)
S5 (S1 OR S2 OR S3 OR S4)
S4 (immuni* or vaccin* or inject*)
S3 (MH “Injections+”)
S2 (MH “Immunization Programs”)
S1 (MH “Immunization+”)
Appendix 6. Details of the number of records identified through database searching and via other
sources for review update
Databases searched Number of records identified
The Cochrane Central Register of Controlled Trials (CENTRAL)
via the Cochrane Register of Studies Online (CRSO) (24 October
2017)
688
MEDLINE and MEDLINE in Progress via Ovid (November
2014 to 23 October 2017)
768
Embase via Ovid (November 2014 to 2017 week 43) 524
CINAHL via EBSCOhost (November 2014 to October 2017) 17
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WHO International Clinical Trials Registry Platform (ICTRP) 319
Total 2885
Total after removal of duplicates 2151
Details of the records identified in the original review are available in Appendix 6 in Beirne 2015.
Appendix 7. Sensitivity analyses
1. Meta-analyses performed with random-effects and fixed-effect models
In the Effects of interventions section of the review, we presented the results of a random-effects meta-analysis of the trial data from
Diggle 2000a and Diggle 2006 for the outcomes of swelling, tenderness, and redness at 24 hours (day 1) after vaccination with the third
dose of a diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b (DTwP-Hib) vaccine. We repeated the analysis
using a fixed-effect model to determine if our overall interpretation of the evidence was robust to decisions about meta-analysis model.
The table below compares the pooled effect measures for each outcome at day 1 postvaccination using both fixed-effect and random-
effects meta-analyses.
Sensitivity analysis: comparison between the results of random-effects and fixed-effect
meta-analyses of the trial data from Diggle 2000a and Diggle 2006 at day 1 post-vaccination
Population: infants aged 4 months undergoing vaccination with the third dose of a DTwP-Hib vaccine
Intervention and comparison: 23 G 25 mm vs 25 G 16 mm needles
Outcomes: swelling, tenderness, and redness
Outcomes and time points Risk ratio (95% CI)
Random-effects
Risk ratio (95% CI)
Fixed-effect
Pooled results for swelling at day 1 0.58 (0.36 to 0.93) 0.60 (0.43 to 0.82)
Pooled results for tenderness at day 1 0.63 (0.40 to 1.00) 0.63 (0.39 to 1.00)
Pooled results for redness at day 1 0.61 (0.36 to 1.01) 0.67 (0.54 to 0.84)
CI: confidence interval; DTwP-Hib: diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b.
The point estimates for the pooled risk ratios for each outcome were similar for fixed-effect and random-effects meta-analyses. The
only material difference between the analyses was that the non-significant pooled estimate for redness at day 1 postvaccination with
the random-effects model was rendered statistically significant with the use of the fixed-effect model. We consider that our overall
interpretation of the evidence (that 23 G 25 mm needles probably reduce local reactions compared with 25 G 16 mm needles) was
robust to variations in decisions about meta-analysis model.
103Needle size for vaccination procedures in children and adolescents (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Meta-analyses performed with random-effects and fixed-effect models and at 4 time points postvaccination (6 hours, day 1,
day 2, day 3)
In the Effects of interventions section of the review, we presented the results of a random-effects meta-analysis of the trial data from
Diggle 2000a and Diggle 2006 for the outcomes of swelling, tenderness, and redness at 24 hours (day 1) after vaccination with the
third dose of a DTwP-Hib vaccine. As explained in the Unit of analysis issues section of the review, we believe that the 24-hour time
point was an appropriate time point at which to present the results of local reaction analyses. Nevertheless, we conducted a sensitivity
analysis to determine if our overall interpretation of the evidence was robust to decisions about time point selection and meta-analysis
model. The table below compares the pooled effect measures for each outcome at each time point (6 hours, day 1, day 2, and day 3)
using both fixed-effect and random-effects meta-analyses.
Sensitivity analysis: comparison between the results of random-effects and fixed-effect meta-analyses of the trial data from (Diggle
2000a; Diggle 2006) at 6 hours and on days 1, 2 and 3 post-vaccination
Population: infants aged 4 months undergoing vaccination with the third dose of a DTwP-Hib vaccine
Intervention and comparison: 23 G 25 mm vs. 25 G 16 mm needles
Outcomes: swelling, tenderness, and redness
Outcomes and time points Risk ratio (95% CI)
Random-effects
Risk ratio (95% CI)
Fixed-effect
Pooled results for swelling at 6 hours 0.55 (0.30 to 1.03) 0.59 (0.43 to 0.82)
Pooled results for swelling at day 1 0.58 (0.36 to 0.93) 0.60 (0.43 to 0.82)
Pooled results for swelling at day 2 0.44 (0.29 to 0.68) 0.45 (0.29 to 0.68)
Pooled results for swelling at day 3 0.32 (0.17 to 0.59) 0.31 (0.17 to 0.59)
Pooled results for tenderness at 6 hours 0.79 (0.58 to 1.06) 0.78 (0.58 to 1.05)
Pooled results for tenderness at day 1 0.63 (0.40 to 1.00) 0.63 (0.39 to 1.00)
Pooled results for tenderness at day 2 0.64 (0.22 to 1.87) 0.65 (0.30 to 1.40)
Pooled results for tenderness at day 3 0.99 (0.33 to 2.96) 0.96 (0.33 to 2.83)
Pooled results for redness at 6 hours 0.81 (0.61 to 1.06) 0.83 (0.69 to 1.01)
Pooled results for redness at day 1 0.61 (0.36 to 1.01) 0.67 (0.54 to 0.84)
Pooled results for redness at day 2 0.50 (0.14 to 1.82) 0.70 (0.50 to 0.97)
Pooled results for redness at day 3 0.30 (0.08 to 1.07) 0.34 (0.18 to 0.64)
CI: confidence interval.
In general, the confidence intervals around the effect estimates were narrower with the fixed-effect than with the random-effects meta-
analyses, and some non-statistically significant analyses using the random-effects model were rendered statistically significant with the
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use of the fixed-effect model. Effect sizes were larger for swelling and redness for the analyses at later time points compared with earlier
time points. The event rates for tenderness in both needle size groups in the two trials were very low at days two and three, and hence
the confidence intervals around the pooled risk ratio estimates were very wide.
Although the magnitude of the effect varied at different time points, the direction of effect was consistent across all time points and
indicative of a reduced incidence of local reactions following vaccination with the 23 G 25 mm needle compared with the 25 G 16
mm needle. We therefore consider that our overall conclusion (that 23 G 25 mm needles probably reduce local reactions compared to
25 G 16 mm needles) was reasonably robust to variations in decisions about meta-analysis model and the time points for analyses.
3. Comparison of effect sizes at different time points (6 hours, day 1, day 2, day 3, and at any time point postvaccination) for
the composite outcome in the Diggle 2006 trial
In the Effects of interventions section of the review and in the ’Summary of findings’ tables, we presented the results for the effects of
needle size on a composite local reaction outcome (any swelling, tenderness, redness, or hardness) at 24 hours (day 1) after vaccination
with the first, second, and third doses of a DTwP-Hib vaccine in the Diggle 2006 trial. As explained in the Unit of analysis issues
section of the review, we believe that the 24-hour time point was an appropriate time point at which to present the results of local
reaction analyses. Nevertheless, we conducted a sensitivity analysis to determine if our overall interpretation of the evidence for each of
the three main comparisons made in the review was robust to time point selection for this composite outcome.
Comparison 1:
The table below compares the effect measures for comparison 1: 25 G 25 mm versus 25 G 16 mm needles for the composite local
reaction outcome at each time point (6 hours, day 1, day 2, and day 3) after each dose of the DTwP-Hib vaccine in the Diggle 2006
trial.
Sensitivity analysis: comparison of risk ratio effect estimates for the composite outcome of ’any local reaction’ in the Diggle 2006
trial at various time points
Population: infants aged 2 to 4 months undergoing DTwP-Hib vaccination
Interventions: 25 G 25 mm vs 25 G 16 mm needles
Outcomes: any local reaction (any swelling, redness, tenderness, or hardness)
Time points and vaccine dose Risk ratio
(95% CI)
6 hours after first dose 0.78 (0.68 to 0.90)
Day 1 after first dose 0.64 (0.52 to 0.79)
Day 2 after first dose 0.49 (0.35 to 0.70)
Day 3 after first dose 0.57 (0.34 to 0.95)
At any time point after first dose 0.80 (0.70 to 0.90)
6 hours after second dose 0.86 (0.72 to 1.03)
Day 1 after second dose 0.67 (0.54 to 0.83)
Day 2 after second dose 0.51 (0.38 to 0.69)
Day 3 after second dose 0.39 (0.24 to 0.64)
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(Continued)
At any time point after second dose 0.84 (0.72 to 0.97)
6 hours after third dose 0.77 (0.64 to 0.93)
Day 1 after third dose 0.65 (0.52 to 0.80)
Day 2 after third dose 0.51 (0.37 to 0.71)
Day 3 after third dose 0.44 (0.26 to 0.73)
At any time point after third dose 0.75 (0.64 to 0.89)
CI: confidence interval.
The magnitude of the intervention effect varied depending on time point selection, with larger effects sizes for analyses at days 2 and 3
compared with day 1. The effect sizes were smaller for the analyses conducted at 6 hours and across all time points compared with the
day 1 analysis. However, the direction of effect was entirely consistent for all analyses irrespective of time point, and the differences in
effect sizes at different time points were between small and large beneficial effects in favour of the longer needle. Thus, although our
estimates of the magnitude of the intervention effect would have varied depending on time point selection, our overall conclusion that
the 25 G 25 mm needle probably reduces the incidence of local reactions would not have materially altered according to time point
selection.
Comparison 2:
The table below compares the effect measures for comparison 2: 25 G 25 mm versus 23 G 25 mm needles for the composite local
reaction outcome at each time point (6 hours, day 1, day 2, day 3, and at any time point) after each dose of the DTwP-Hib vaccine in
the Diggle 2006 trial.
Sensitivity analysis: comparison of risk ratio effect estimates for the composite outcome of ’any local reaction’ in the Diggle 2006
trial at various time points
Population: infants aged 2 to 4 months undergoing DTwP-Hib vaccination
Interventions: 25 G 25 mm vs 23 G 25 mm needles
Outcomes: any local reaction (any swelling, redness, tenderness, or hardness)
Time points and vaccine dose Risk ratio
(95% CI)
6 hours after first dose 0.88 (0.76 to 1.02)
Day 1 after first dose 0.92 (0.73 to 1.17)
Day 2 after first dose 0.92 (0.62 to 1.38)
Day 3 after first dose 1.23 (0.66 to 2.29)
At any time point after first dose 0.90 (0.79 to 1.03)
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6 hours after second dose 0.90 (0.76 to 1.08)
Day 1 after second dose 0.89 (0.70 to 1.12)
Day 2 after second dose 0.78 (0.56 to 1.10)
Day 3 after second dose 0.66 (0.38 to 1.14)
At any time point after second dose 0.92 (0.79 to 1.08)
6 hours after third dose 0.84 (0.70 to 1.02)
Day 1 after third dose 0.84 (0.66 to 1.06)
Day 2 after third dose 0.67 (0.47 to 0.95)
Day 3 after third dose 0.81 (0.46 to 1.43)
At any time point after third dose 0.79 (0.67 to 0.94)
CI: confidence interval.
The direction of effect was consistently in favour of the narrower gauge needle at all time points, with the exception of the analysis
conducted at day 3 after the first vaccine dose. The only material alteration to our assessment of the evidence would have occurred if we
had chosen to present the results of analyses across all time points rather than at day 1 postvaccination. Taking into account the width of
the confidence intervals around the effect estimates at day 1, we downgraded for imprecision because the confidence intervals included
the suggested GRADE threshold for imprecision (a relative risk reduction or relative risk increase of 25%). However, this downgrading
would not have occurred for the effect estimates calculated across all time points as the confidence intervals were narrower. Our rating
of the quality of evidence would therefore have been raised from ’low’ to ’moderate’ quality if we had presented the results of analyses
across all time points rather than at the 24-hour time point. The alteration in rating would have resulted in a change in the qualitative
emphasis of our conclusions: instead of stating that the 25 G needle may reduce local reactions compared to the 23 G needle, we would
have stated that the 25 G needle probably reduces local reactions. Nevertheless, we consider that the more conservative conclusion (may
reduce) is reasonable taking into account the fact that the analyses at any time point after the first and second doses of the vaccine were
not statistically significant and precluded making confident statements about the precise magnitude of the effect.
Comparison 3:
The table below compares the effect measures for comparison 3: 23 G 25 mm versus 25 G 16 mm needles for the composite local
reaction outcome at each time point (6 hours, day 1, day 2, day 3, and at any time point) after each dose of the DTwP-Hib vaccine in
the Diggle 2006 trial.
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Sensitivity analysis: comparison of risk ratio effect estimates for the composite outcome of ’any local reaction’ in the Diggle 2006
trial at various time points
Population: infants aged 2 to 4 months undergoing DTwP-Hib vaccination
Interventions: 23 G 25 mm vs 25 G 16 mm needles
Outcomes: any local reaction (any swelling, redness, tenderness, or hardness)
Time points and vaccine dose Risk ratio
(95% CI)
6 hours after first dose 0.89 (0.78 to 1.00)
Day 1 after first dose 0.69 (0.57 to 0.84)
Day 2 after first dose 0.53 (0.38 to 0.74)
Day 3 after first dose 0.46 (0.27 to 0.80)
At any time point after first dose 0.88 (0.79 to 0.99)
6 hours after second dose 0.95 (0.81 to 1.12)
Day 1 after second dose 0.76 (0.62 to 0.92)
Day 2 after second dose 0.65 (0.50 to 0.85)
Day 3 after second dose 0.59 (0.39 to 0.90)
At any time point after second dose 0.91 (0.79 to 1.04)
6 hours after third dose 0.92 (0.78 to 1.09)
Day 1 after third dose 0.77 (0.64 to 0.94)
Day 2 after third dose 0.76 (0.57 to 1.00)
Day 3 after third dose 0.54 (0.34 to 0.86)
At any time point after third dose 0.95 (0.83 to 1.09)
CI: confidence interval.
The magnitude of the intervention effect varied depending on time point selection. The effect sizes were larger for the analyses at days
2 and 3 compared with day 1. The effect sizes were smaller for the analyses conducted at 6 hours and across all time points compared
with the day 1 analysis. In addition, the analyses at six hours and across all time points were not statistically significant. Nevertheless,
the direction of effect was entirely consistent for all analyses irrespective of time point, and the differences in effect sizes at different
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time points were between small and large beneficial effects in favour of the longer needle. In addition, although the analyses at six hours
and across all time points were not statistically significant, this would not have resulted in a downgrading of the quality of evidence for
imprecision, as the confidence intervals did not include the suggested GRADE threshold for downgrading (a relative risk reduction or
relative risk increase of 25%). We also factored into our interpretation of the evidence the meta-analyses of the results of the Diggle
2006 and Diggle 2000a trial pertaining to individual components of the composite (redness, swelling, and tenderness) after the third
dose of a DTwP-Hib vaccine. The results of these meta-analyses strengthened the evidence in favour of a reduced rate of local reactions
associated with the 23 G 25 mm needle compared with the 25 G 16 mm needle.
Thus, although our estimates of the magnitude of the intervention effect would have varied depending on time point selection, our
overall conclusion that the 23 G 25 mm needle probably reduces the incidence of local reactions compared to the 25 G 16 mm needle
would not have materially altered according to time point selection.
4. Comparison of effect sizes for the composite outcome in the Diggle 2006 trial with the effect sizes for the individual
components of the composite
The use of a composite outcome in the ’Summary of findings’ tables for a systematic review inevitably results in a ’loss of information’
due to the combination of several separate outcomes into a single outcome measure. Of particular concern is that users of a review may
assume that the intervention effect applies equally to all components of the composite, whereas in reality the intervention effect may
vary across individual components of the composite that have different clinical importance. In such a scenario the use of a composite
outcome could be potentially misleading.
The composite outcome in the Diggle 2006 trial arguably included individual components with differing clinical importance. For
example, redness and hardness at the injection site may not be regarded by clinicians, patients (consumers), parents, and policymakers
as having the same importance as tenderness or swelling. We therefore conducted sensitivity analyses to investigate if there were
disparities between the estimates of intervention effect on the composite outcome (any redness, swelling, tenderness, or hardness) and
the estimates of intervention effect on individual components of the composite in this trial. The results of the sensitivity analyses are
presented in the tables below. The analyses indicate that there were some variations in the magnitude of the intervention effect on
individual components of the composite for all of the main comparisons made in the review. However, the direction of effect was
generally consistent across individual components, particularly for the comparisons between the 25 mm and 16 mm needles, and this
direction of effect was accurately reflected in the effect size for the composite outcome. On balance, we consider that the decision to
present composite rather than individual local reaction outcomes in the ’Summary of findings’ tables was appropriate and that it was
an efficient way to summarise the effects of needle size on vaccine reactogenicity without overwhelming the reader with information
on intervention effects on individual local reaction outcomes.
Sensitivity analysis: comparison of risk ratio effect estimates for the composite outcome of ’any local reaction’ in the Diggle 2006
trial at day 1 vs effect estimates for the individual components of the composite
Population: infants aged 2 to 4 months undergoing DTwP-Hib vaccination
Intervention and comparison: 25 G 25 mm vs 25 G 16 mm needles
Outcomes: composite outcome; individual outcomes
Outcome and vaccine dose Risk ratio
(95% CI)
Composite day 1 after first dose 0.64 (0.52 to 0.79)
Swelling day 1 after first dose 0.59 (0.38 to 0.92)
Tenderness day 1 after first dose 0.61 (0.40 to 0.91)
Redness day 1 after first dose 0.68 (0.47 to 0.98)
Hardness day 1 after first dose 0.56 (0.42 to 0.77)
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Composite day 1 after second dose 0.67 (0.54 to 0.83)
Swelling day 1 after second dose 0.66 (0.42 to 1.02)
Tenderness day 1 after second dose 0.70 (0.41 to 1.18)
Redness day 1 after second dose 0.65 (0.48 to 0.88)
Hardness day 1 after second dose 0.53 (0.40 to 0.71)
Composite day 1 after third dose 0.65 (0.52 to 0.80)
Swelling day 1 after third dose 0.40 (0.23 to 0.69)
Tenderness day 1 after third dose 0.76 (0.46 to 1.23)
Redness day 1 after third dose 0.64 (0.49 to 0.84)
Hardness day 1 after third dose 0.55 (0.40 to 0.76)
CI: confidence interval.
Sensitivity analysis: comparison of risk ratio effect estimates for the composite outcome of ’any local reaction’ in the Diggle 2006
trial at day 1 vs effect estimates for the individual components of the composite
Population: infants aged 2 to 4 months undergoing DTwP-Hib vaccination
Intervention and comparison: 25 G 25 mm vs 23 G 25 mm needles
Outcomes: composite outcome; individual outcomes
Outcome and vaccine dose Risk ratio
(95% CI)
Composite day 1 after first dose 0.92 (0.73 to 1.17)
Swelling day 1 after first dose 1.24 (0.72 to 2.12)
Tenderness day 1 after first dose 1.02 (0.64 to 1.61)
Redness day 1 after first dose 1.08 (0.71 to 1.63)
Hardness day 1 after first dose 0.90 (0.64 to 1.26)
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Composite day 1 after second dose 0.89 (0.70 to 1.12)
Swelling day 1 after second dose 0.88 (0.55 to 1.41)
Tenderness day 1 after second dose 0.64 (0.38 to 1.07)
Redness day 1 after second dose 0.86 (0.62 to 1.18)
Hardness day 1 after second dose 0.81 (0.58 to 1.12)
Composite day 1 after third dose 0.84 (0.66 to 1.06)
Swelling day 1 after third dose 0.55 (0.31 to 0.97)
Tenderness day 1 after third dose 1.16 (0.68 to 2.00)
Redness day 1 after third dose 0.85 (0.63 to 1.14)
Hardness day 1 after third dose 0.73 (0.52 to 1.03)
CI: confidence interval.
5. Choice of minimum important differences for differences in seroprotection rates between needle size groups
For differences in seroprotection rates between needle size groups, we used as a minimum important difference (MID) a risk difference
(RD) of 10% based on the recommended non-inferiority protection rate for vaccines specified by the Committee for Proprietary
Medicinal Products (CPMP 1999). However, we accept that this choice of MID is debatable, and a case could reasonably be made for
a lower value. For example, we identified a small number of non-inferiority trials of combination vaccines that have specified a 5%
MID in seroprotection rates (e.g. Collins 2004; de Menezes Martins 2008). We therefore conducted a sensitivity analysis to investigate
if our interpretation of the evidence from the Diggle 2006 trial pertaining to the effects of needle size on the immune response to the
diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b (DTwP-Hib) vaccine would have altered depending on the
choice of MID. The tables below indicate that the choice of an MID of 5% rather than 10% would not have resulted in a material
alteration to our conclusion that there is probably little or no difference in immune response between 25 G 25 mm, 23 G 25 mm, and
25 G 16 mm needle sizes.
Sensitivity analysis: effects of needle size on the immune response to the DTwP-Hib vaccine. Does the interpretation of results from
the Diggle 2006 trial vary depending on the choice of MIDs (10% or 5%) between needle size groups?
Comparison 1: comparisons between needles with different lengths and the same gauges
Needle sizes compared MID Interpretation of results
25 G 25 mm
vs




The CIs around the effect estimates indicate
that the immune response to the diphtheria
and tetanus vaccine antigen components is
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probably equivalent between the needle size
groups. The longer needle may result in a supe-
rior immune response to the Hib component
of the vaccine (RD 8%, 95% CI 1% to 15%),
but the results are inconclusive as the CI crosses
the threshold for an important effect (10%),
but the lower boundary of the CI is close to
the ’null value’
5% difference Interpretation same as above
Comparison 2: comparisons between needles with different gauges but with the same length
25 G 25 mm
vs




The CIs around the effect estimates indicate
that the immune response to the diphtheria,
tetanus, and Hib vaccine antigen components
is probably equivalent between the needle size
groups
5% difference Interpretation same as above for diphtheria and
tetanus. The narrower gauge needle may re-
sult in a superior immune response to the Hib
component of the vaccine (RD 3%, 95% CI -
4% to 9%), but the results are inconclusive
Comparison 3: comparisons between needles with different gauges and different lengths
23 G 25 mm
vs




The CIs around the effect estimates indicate
that the immune response to the diphtheria
and tetanus vaccine antigen components is
probably equivalent between the needle size
groups. The longer needle may result in a supe-
rior immune response to the Hib component
of the vaccine (RD 5%, 95% CI -2% to 13%)
, but the results are inconclusive
5% difference Interpretation same as above
CI: confidence interval; DTwP-Hib: diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b; Hib: Haemophilus
influenzae type b; RD: risk difference.
6. Choice of antibody titre level threshold of protection against Haemophilus influenzae type b disease
For seroprotection against Haemophilus influenzae type b (Hib) disease, we chose an antibody titre level threshold of 1.0 µg/mL or
greater and presented the results of analyses based on this threshold in the ’Summary of findings’ tables and in the Effects of interventions
section of the review. However, some population level studies suggest that an antibody concentration of 0.15 µg/mL or greater provides
adequate short-term protection against invasive Hib disease, but that a concentration of 1.0 µg/mL or greater is necessary for long-
term protection (Chandran 2013). We therefore performed a sensitivity analysis to investigate if our interpretation of the evidence
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pertaining to the effects of needle size on the immune response to the Hib component of the vaccine would have varied depending on
the choice of threshold.
Sensitivity analysis: effects of needle size on vaccine immunogenicity. Does the interpretation of results vary depending on the choice
of cut-off antibody titre level threshold (≥ 1.0 µg/mL or ≥ 0.15 µg/mL) for seroprotection against Haemophilus influenzae type b
disease?
Comparison 1: comparisons between needles with different lengths and the same gauges





(based on an MID of 10%)
25 G 25 mm
vs
25 G 16 mm
≥ 1.0 µg/mL 8%
(1% to 15%)
The longer needle may result in a superior
immune response to the Hib component of
the vaccine, but the results are inconclusive
(the CI crosses the threshold for an impor-
tant effect (10%), but the lower boundary
of the CI is close to the ‘null value’)
≥ 0.15 µg/mL 4%
(1% to 8%)
Immune response probably equivalent be-
tween groups
Comparison 2: comparisons between needles with different gauges but with the same length
25 G 25 mm
vs
23 G 25 mm
≥ 1.0 µg/mL 3%
(-4% to 9%)
Immune response probably equivalent be-
tween groups
≥ 0.15 µg/mL 5%
(1% to 9%)
Immune response probably equivalent be-
tween groups
Comparison 3: comparisons between needles with different gauges and different lengths
23 G 25 mm
vs
25 G 16 mm
≥ 1.0 µg/mL 5%
(-2% to 12%)
The longer needle may result in a superior
immune response to the Hib component of
the vaccine, but the results are inconclusive
≥ 0.15 µg/mL -1%
(-6% to 4%)
Immune response probably equivalent be-
tween groups
CI: confidence interval; Hib: Haemophilus influenzae type b; MID: minimum important difference; RD: risk difference
Using a cut-off point of 1.0 µg/mL or greater, we were unable to exclude the possibility that the longer needles (25 G 25 mm, 23 G
25 mm) may result in a superior immune response to the Hib component of the DTwP-Hib vaccine compared with the 25 G 16 mm
needle (the confidence intervals for the effect estimates crossed the threshold for an important effect (MID of 10%)). However, the
trial results were inconclusive, as the confidence intervals were also compatible with little or no difference between the groups. Had we
used a cut-off point of 0.15 µg/mL or greater and the same MID, we would have concluded that the immune response was equivalent
between the needle size groups for all comparisons (1, 2, and 3) because the 95% confidence intervals accompanying all effect estimates
excluded the MID value of 10%. The choice of cut-off point would not have influenced our GRADE rating. Our overall conclusion
that there is probably little or no difference in immune response between using 23 G 25 mm, 25 G 25 mm, and 25 G 16 mm needles
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to administer a series of three doses of a DTwP-Hib vaccine would thus not have materially altered depending on the choice of cut-off
point for seroprotection against Hib disease.
Appendix 8. Results of ’imaging studies’ measuring subcutaneous tissue and muscle thickness at the
anterolateral thigh vaccination site
Results of 6 studies measuring the thickness of subcutaneous tissue and muscle at the anterolateral thigh vaccination site in infants



























Ultrasound1 4 months (n =
24)
13 M, 11 F
Details not pro-
vided
14 ± 2.4 (M)
13 ± 2.8 (F)
Details not pro-
vided
32 ± 4.5 (M)





a hospital in New
Delhi, India
Ultrasound2 6 to 12 weeks
(n = 52)
4.6 ± 1.09 10.3 ± 2.3 8.3 ± 1.7 18.7 ± 3.5
13 to 18 weeks
(n = 58)
6.06 ± 0.98 10.4 ± 2.1 11.3 ± 2.8 21.7 ± 3.8
19 to 24 weeks
(n = 63)



















8 (± 0.3) (R)
8.1 (± 0.3) (L)
9.2 (± 0.3) (R)
9.3 (± 0.3) (L)
17.3 (± 0.5) (R)















(range 6 to 15.1)
10.5 ± 2.4
(range 6.2 to 14.
3)
Not provided
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(range 6.5 to 13.
5)
12.2 ± 2.0
(range 9.6 to 15.
3)
Not provided













people at a large
children’s hospi-
tal in the mid-
western US who
had an MRI or
CT scan of their
normal thigh be-
tween the ages of
2 months and 6
years
MRI or CT scan
5





10.9 ± 2.77 (M)
14.6 ± 3.76 (F)
15.3 ± 2.39 (M)




























5 to < 6 kg
(n = 20)
6 to < 7 kg
(n = 6)
7 to < 8 kg
(n = 2)





5 to < 6 kg
(n = 9)
6 to < 7 kg
(n = 18)
7 to < 8 kg
(n = 3)
8 to < 9 kg
(n = 2)







6 to < 7 kg
(n = 17)
7 to < 8 kg
(n = 9)
8 to < 9 kg
(n = 2)
Not provided Not provided 26.6*
(95% CI 25.35,
28.31)
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5 to < 6 kg
(n = 3)
6 to < 7 kg
(n = 9)
7 to < 8 kg
(n = 12)
8 to < 9 kg
(n = 4)
9 to < 10 kg
(n = 1)
Not provided Not provided 27.3*




6 to < 7 kg
(n = 7)
7 to < 8 kg
(n = 15)
8 to < 9 kg
(n = 7)
9 to < 10 kg
(n = 1)
Not provided Not provided 27.8*
(95% CI 25.98,
29.87)
CI: confidence interval; CT: computed tomography; F: female; M: male; MRI: magnetic resonance imaging; SCT: subcutaneous
tissue; SD: standard deviation
*Only the 95% CIs were provided in the published report of the study. The means were estimated from the graphs published in the
papers using a web-based plot digitizer (Rohatgi 2017).
1Hick 1989: measurements were performed using a 10-millihertz frequency ultrasound with a theoretical axial resolution of 0.5 mm
(Diasonics, Inc., Milpitas, CA). Measurements were obtained at a point equidistant from the right anterior iliac crest and the superior
border of the right patella, in the mid-line. The ultrasound transducer was lightly applied to the skin to avoid tissue compression.
Skin-to-muscle measurements were obtained in longitudinal plane and skin-to-bone measurements were obtained in the transverse
plane. Two measurements were taken in each plane and the mean calculated. Details of the ultrasound operator(s) and any training
or calibration exercises to ensure intra- and interoperator consistency were not provided
2Chugh 1993: measurements were performed using high-resolution real-time linear 7.5-millihertz ultrasound (ALOKA SSD). On
the anterolateral aspect of the middle one-third of the left thigh, the transducer of the ultrasound machine was lightly applied so as
to ensure that tissues under the transducer were not compressed. Details of the ultrasound operator(s) and any training or calibration
exercises to ensure intra and interoperator consistency were not provided
3Groswasser 1997: measurements were performed using high-frequency real-time ultrasonography (ALOKA 2000 SSD) with a 6-
centimetre-long 7.5-hertz transducer. For the quadriceps, the anterolateral aspect of the thigh at the junction of the upper third and
lower two-thirds of the muscle was examined at a 45° angle to the horizontal plane. The transducer was applied lightly to the skin
to avoid tissue compression. Two concordant measurements were performed, at a 90° angle both to the skin and to the long axis of
the leg or arm; an image take at each point provided an automatic measurement in millimetres of the morphometric parameters.
Two operators performed the experiments, each doing approximately half of the measurements. Details of any training or calibration
exercises to ensure intra- and interoperator consistency were not provided
4Cook 2002: measurements were performed using a high-resolution real-time ultrasonography with a 4-centimetre footprint and 7-
millihertz linear transducer. Anterolateral thigh measurements were made at the junction of the upper third and lower middle thirds
of the muscle mass, with the ultrasound probe applied at 45° to the vertical at right angles to the skin’s plane and parallel to the
long axis of the leg, with the child gently restrained with his or her pelvis flat on the examination couch. The transducer was applied
lightly to the skin to avoid tissue compression. Measurements were made on both thighs and data pooled for analysis due to lack of
significant difference between thigh measurements. Details of the ultrasound operator(s) and any training or calibration exercises to
ensure intra and interoperator consistency were not provided
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(Continued)
5Lippert 2008: the thickness of the subcutaneous fat and muscle was measured from the CT or MRI scan of the thigh in the middle
third of the vastus lateralis (anterlateral thigh area) at a 90° angle to the skin. Picture Archiving and Communications System software
(GE Healthcare, Piscataway, NJ) was used to make these measurements to a scale of 1:1 to maximise the accuracy. Details of the
person(s) who conducted the measurements and any training or calibration exercises to ensure intra- and interoperator consistency
were not provided
6Nakayama 2016: the researchers state that “ultrasonic echograms were performed on the middle of the [....] centro-lateral thigh using
Viamo SSA-640A with the linear probe PLT-740AT (Toshiba Medical Systems, Japan), Aplio 400/500 with th linear probe PLT-
704SBT (Toshiba Medical Systems, Japan) and Prosound SSD-α10 with the linear probe UST-5411 (Hitachi Aloka-Medical, Japan)
.” The skin was stretched flat during measurement. Details of the ultrasound operator(s) and any training or calibration exercises to
ensure intra- and interoperator consistency were not provided
Appendix 9. Evidence used to support needle size recommendations for administering vaccines
intramuscularly made by National Immunization Technical Advisory Groups in 4 countries
Table A: Evidence used to inform needle size recommendations for intramuscular injections made by National Immunization
Technical Advisory Groups (NITAGs) in 4 countries
Country/NITAG Evidence/publications cited to support needle size recommendations





















0 - - 5 guidelines
(CDC 2011; DoH UK
2012a; ATAGI 2013;






















1 guideline (CDC 2011)
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(Continued)
ACIP: Advisory Committee on Immunization Practices; ATAGI: Australian Technical Advisory Group on Immunisations; CCT:
Controlled Clinical Trial; JCVI: Joint Committee on Vaccines and Immunisation; RCT: Randomised Controlled Trial
NIAC: National Immunisation Advisory Committee.
aSee the section of the guidance entitled “Choice of needle size” (pp 29-30)
bSee the bibliography of Chapter 2 of the guidance entitled “General Immunisation Procedures”. No references are cited in the main
text of Chapter 2, therefore it is impossible to state precisely which of the publications listed in the bibliography have been used to
support specific needle size recommendations
cSee Section 6 of the guidance entitled “Vaccine administration” (pp 82-107)
dSee Section 2.2.5 of the guidance entitled “Vaccine injection techniques” and Table 2.2.2
W H A T ’ S N E W
Last assessed as up-to-date: 24 October 2017.
Date Event Description
2 February 2018 New citation required but conclusions have not changed The updated search identified no new trials that met the
selection criteria for the review
2 February 2018 New search has been performed We have updated this review to include the results of a
new search on 24 October 2017
C O N T R I B U T I O N S O F A U T H O R S
PB co-ordinated the review team, searched for trials, and screened titles and abstracts of retrieved records for the original and updated
review. He also entered citations into Review Manager 5, selected trials for inclusion that met the prespecified selection criteria,
developed and piloted the data extraction form, wrote to authors of papers for additional information, assessed the risk of bias in
included trials, extracted trial data using the data extraction form, entered data into Review Manager 5, decided which analyses to
conduct in consultation with the review team statistician (TF) and all other members of the review team, interpreted the analysis, and
drafted the final review. He will co-ordinate future review updates.
SH searched for trials and screened titles and abstracts of retrieved records for the original and updated review. She also selected trials
for inclusion that met the prespecified selection criteria, piloted the data extraction form, assessed the risk of bias in included trials,
extracted trial data using the data extraction form, checked all data entered into Review Manager 5 by PB, approved the analyses to
be conducted in consultation with other members of the review team, assisted with interpreting the analysis, and assisted with editing
and proofreading of the final review.
SC piloted the data extraction form, assessed the risk of bias in included trials, extracted trial data using the data extraction form,
checked all data entered into Review Manager 5 by PB, approved the analyses to be conducted in consultation with other members of
the review team, assisted with interpreting the analysis, and assisted with editing and proofreading of the final review.
FS searched for trials and screened titles and abstracts of retrieved records for the original review. She also selected trials for inclusion
that met the prespecified selection criteria, and assisted with editing and proofreading of the final review.
TF provided statistical advice with regard to data analyses. He assisted with interpreting analyses and with the drafting of aspects of the
final review that required statistical input.
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FML assisted with interpreting analyses by providing a clinical perspective, assisted with editing and proofreading of the final review,
and obtained information on needle sizes supplied with vaccines included in routine immunisation schedules in Ireland.
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• University College Cork (UCC), Ireland.
All review authors are employees of UCC and receive support from the University in the form of a salary.
External sources
• No sources of support supplied
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In the review protocol, we did not specify what measures of treatment effect we would use in instances were continuous data were
summarised using geometric means. In accordance with guidance proposed by the Cochrane Infectious Diseases Group (Donegan
2010), we reported geometric mean ratios as effect measures and included this information in the Measures of treatment effect section.
In the review protocol, we included a table in Appendix 3 outlining thresholds of vaccine-induced correlates and surrogates of protection
for selected vaccines. We omitted a threshold for protection against meningitis C based on rabbit complement. We have rectified this
omission in the review (see Appendix 3).
We included some outcomes in the ’Summary of findings’ tables that were not prespecified in the protocol. We have explained our
rationale for the entries in the ’Summary of findings’ tables in the Data collection and analysis section, under the heading ’Summary of
findings’ tables. In the Effects of interventions section of the review we have presented the results for each outcome in the same order as
they appear in the ’Summary of findings’ tables.
In the review protocol, we did not explain how we would apply the GRADE system to assess the quality of evidence. In the review, we
have explained the methods used in the Data collection and analysis section under the heading Methods used to assess the quality of the
evidence for outcomes included in ’Summary of finding’ tables.
In the review protocol, we did not identify appropriate minimum important differences (MIDs) for the review outcomes. In the
review, we have explained our selection of MIDs for specific outcomes in the Data collection and analysis section under the heading
Identification and definitions of minimum important differences.
In the review protocol, we did not specify a specific time point at which we would analyse trial data pertaining to local reaction outcomes.
In the review, we selected a 24-hour time point (or the nearest approximation to this time point) and have explained the reasons for
this decision in the Unit of analysis issues section.
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An additional review team member was recruited (SC) who was not involved in the protocol stage of the review. The tasks fulfilled by
all members of the review team are described in the Contributions of authors.
The original text in the protocol describing the types of interventions that would be considered in the review was edited for the final
review to enhance clarity and coherence. There was no alteration to the prespecified selection criteria.
We conducted several sensitivity analyses that were not prespecified in our protocol. These analyses and the rationale for the analyses
are presented in Appendix 7.
During the review process, we were unable to implement all of the methods outlined in the protocol. In accordance with the advice
specified in the Cochrane Handbook for Systematic Reviews of Interventions, we have outlined (below) the methods that were not
implemented, and this will serve as a protocol for future updates of the review.
Imputing missing data
In our review protocol (Beirne 2013), we described the methods that we would use in our review to impute missing data in instances
where missing outcomes could not reasonably be assumed to be missing at random. In our review, we did not deem it necessary or
appropriate to employ any imputation methods to deal with missing data (see Dealing with missing data and the entries for attrition
bias in the ’Risk of bias’ tables for each included trial). In future updates of this review, if there are instances where missing outcome
data cannot be assumed to be missing at random and where the nature of the outcome renders it reasonable to do so, we will impute the
missing data with replacement values and conduct sensitivity analyses to investigate how sensitive results are to changes in assumptions
regarding the replacement values. We will use both best-case and worst-case imputation scenarios for dichotomous outcome data. For
continuous outcome data, we will consider using the last observation carried forward (LOCF) approach if the nature of the outcome
renders it reasonable to do so and if individual participant data are available from trial authors. In the Discussion section of future
review updates, we will discuss the potential impact of missing data and our analysis strategies for dealing with missing data on the
findings of the review.
Meta-analyses of continuous data
In our review protocol (Beirne 2013), we described the methods that we would use to perform meta-analyses of continuous data.
We did not perform any such meta-analyses due to the small number of trials that reported continuous outcomes. If additional trials
reporting continuous outcomes are included in future updates of the review, we will use the mean difference as the summary statistic in
meta-analyses of continuous data when outcome measurements in trials are all made on the same scale. We will pool mean differences
using the random-effects inverse variance method. In instances where the included trials assess the same continuous outcome (e.g. pain)
but do so in a variety of ways (e.g. using different pain scales), we will use the standardised mean difference (SMD) as the summary
statistic in meta-analyses and pool SMDs using the random-effects inverse variance method.
Subgroup analyses
We did not conduct the subgroup analyses prespecified in the review protocol (Beirne 2013), as there was an insufficient number
of trials included in our review. In future updates of this review, if sufficient trials are available and if there is evidence of statistical
heterogeneity, we will investigate the following characteristics of trials for their possible influence on the magnitude of the intervention
effect:
1. participant characteristics: age, weight (kilograms) or body mass index (BMI), gender;
2. vaccine characteristics: type of vaccine, formulation of vaccine (including vaccine viscosity);
3. site of vaccine administration: deltoid, anterolateral thigh, other;
4. co-interventions administered during trial: e.g. multiple vaccines administered to trial participants;
5. technique of vaccine administration: ’bunching’ or ’stretching’ of skin before needle insertion, angle of needle insertion;
6. person administering the vaccine: doctor, nurse, other healthcare professional.
Sensitivity analyses
In our review protocol (Beirne 2013), we planned to conduct the following sensitivity analyses to investigate if our conclusions were
robust to decisions made during the review process:
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1. in instances where missing outcome data have been imputed with replacement values and included in a meta-analysis, we
planned to repeat our analyses using different assumptions about the replacement values (see Dealing with missing data);
2. we planned to repeat meta-analyses including and excluding trials that were judged to have unclear or inadequate allocation
concealment;
3. we planned to repeat meta-analyses including and excluding trials that were judged to have unclear or inadequate blinding of
outcome assessors.
We did not undertake these analyses due to the small number of trials (two) included in the meta-analyses performed in our review. We
will conduct these sensitivity analyses if sufficient trials are available in future updates of our review. However, some of these analyses
will not be required if authors of future trials implement appropriate allocation concealment methods and adopt strategies to ensure
blinding of outcome assessors.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Needles [adverse effects]; Crying; Equipment Design; Immunization [∗instrumentation; methods]; Injections, Intramuscular [in-
strumentation; methods]; Pain [prevention & control]; Randomized Controlled Trials as Topic; Vaccines [administration & dosage;
immunology]
MeSH check words
Adolescent; Child; Child, Preschool; Humans; Infant; Young Adult
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